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The strict regulations of the pharmaceutical industry are aimed at ensuring that only safe, 
effective and high quality drugs reach the market. Regulators are under increasing pressure 
to balance the desire for rapid market access to new drugs with the need for having an 
acceptable knowledge of the benefits and risks of new drugs at time of approval. (1) A 
productivity decline in the pharmaceutical industry has been observed where increased 
investment in pharmaceutical research and development did not result in an increased 
number of new active substances approved each year. (2) This development is in part caused 
by what has been called "the cautious regulator problem"; where regulators continue to 
lower their risk tolerance in response to safety issues or scandals, raising the bar for 
introduction of new drugs which increases development costs. (3) This development is of 
concern as new drugs might become too expensive to develop or unaffordable to pay for by 
consumers or insurers. (4) 
While there are still diseases for which no pharmaceutical treatments are available, or 
considered inadequate, the new drugs coming to the market usually do not target these 
unmet medical needs. (5,6) In fact, many of the new drugs have only limited added value to 
what is already available. Pharmaceutical companies might prefer to avoid risks and focus on 
areas they are familiar with and that have higher probability of success. The industries view 
may be understandable, as the success rate for drugs entering phase Ill clinical trials is 
estimated at 64%. (7) In 2009, only 60% of new drug applications received a positive opinion 
by the European Medicines Agency's Committee for Medicinal Products for Human Use 
(CHMP). (8) Drugs for which industry sought scientific advice from the EMA were more 
successful than those for which this was not the case. Some of these failures might have 
been prevented by improving the dialogue during drug development and by better 
adherence of the industry to the scientific advice given by regulators. (9) 
In this context Tl-Pharma initiated the Escher project. It aims at improving science-driven 
drug regulation and innovative research throughout phased drug development. Top Institute 
Pharma is a public private partnership where universities and partners from the 
pharmaceutical industry work together on multidisciplinary research. The Escher project also 
involves co-operation from the Dutch Medicines Evaluation Board with the aim "to evaluate 
and remove regulatory bottlenecks hampering the efficiency in pharmaceutical innovation 
and stimulate factors helping innovation". (10) The research presented in this thesis was 
performed within this project. 
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Regulatory procedures to help meet unmet medical need 
For many diseases with unmet medical need, new therapeutic options are essential. For 
those cases, the regulators have established special registration procedures that either 
accelerate the approval procedure (e.g. Accelerated Approval procedure in the USA) or 
reduce the requirements for the amount of data to be presented at registration (e.g. the 
Exceptional Circumstances (EC) or Conditional Approval (CA) procedures in Europe). (11-13) 
Regulatory mechanisms for continuous safety ascertainment 
When a drug is approved, a new phase of its life cycle begins. The population using the drug 
is no longer the limited trial population from the clinical development, but includes also 
patients that might not have been included in the trials. (1,14) To meet the challenges of 
continuous safety ascertainment, regulatory agencies have moved from a reactive system 
monitoring, mostly spontaneous ADRs, to a proactive system of Risk Management Plans 
which is a mandatory part of the marketing application since 2005. (15) An important part of 
risk management and risk minimization is timely and accurate risk communication of serious 
safety concerns identified post marketing. (16) In Europe the risk communication can have 
the form of a Direct Healthcare Professional Communication (DHPC), a letter sent out by the 
marketing authorisation holder, in collaboration with the regulators, to physicians, 
pharmacists and other healthcare professionals involved in the use of the particular drug. 
Safety related market withdrawal and DHPCs are regarded as safety related regulatory 
actions. (17) 
Regulatory learning and drug class effects 
Adverse drug reactions that were discovered post-marketing have sometimes triggered 
recalling drugs from the market. (18,19) Review of registration dossiers showed that some 
adverse events could have been predicted at time of approval. (20) Adverse drug reactions 
(ADRs) related to the drug's mechanism of action can potentially be identified pre-approval 
while ADRs that are due to off-target (unexpected) pharmacological effects are often 
unpredictable and are likely only identified post-approval. Thus, for certain drug classes 
safety issues may be relevant for subsequent new drugs in the same class. These should be 
monitored in the clinical development program and, where necessary, long term, using 
appropriate methods. (21) Determining ADRs for novel drugs as compared to next-in-class 
(or 'me-too') drugs seems more difficult as there is no class experience. This is acknowledged 
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in the new European pharmacovigilance legislation which stipulates that first-in-class or 
novel drugs could be subject to additional monitoring post-marketing or will be subject to 
restricted medical prescription. (22) This raises the question whether more DHPCs are being 
issued for drugs that lack safety knowledge at time of approval and should be subject to 
additional monitoring post marketing. 
Patient involvement in regulatory decision making 
Today, the importance to take the patients' perspective into account in health care is 
acknowledged as the most important next step in developing quality of health care. In 
management of chronic diseases, patient self-management and participation in treatment 
decisions is an integral part. (23) Active patient involvement in monitoring and reporting of 
side effects is also increasing and is becoming an important source for detection of ADRs. 
(24,25) Also regulating agencies also recognize this development as illustrated by the 
increasing interest in patient reported outcomes. (26) Regulators have accepted that 
patients are not only important in reporting of ADRs, but can also contribute to work within 
the regulatory agencies. As a platform for patient co-operation the European Medicines 
Agency has set up a framework for collaboration with qualified patient organisations with 
the Patients' and Consumers' Working Party (PCWP) and the US Food and Drug 
Administration has established the Patient Representative Program. (27,28) 
Throughout the years, patient involvement in the European Medicines Agency has been of 
an advisory nature. Patient organisations do have representatives in the Committee for 
Orphan Medicinal Products and the Paediatric Committee, where they are active 
participants in the discussions and decisions made. However, these representatives are 
assigned by patient organisations and are not necessarily patients themselves. The CHMP 
decides on whether a drug should be granted market authorisation and occasionally invites 
patient representatives for consultation. The input of patients or their representatives to the 
CHMP is purely of an advisory nature and they are not allowed to participate in scientific 
deliberations. As patients are now more involved in the activities of the European Medicines 
Agency, the Agency believes their scientific committees are encouraged to reflect about the 
real-life implications of regulatory decisions. (27) However, whether that is the case has not 
yet been established and it is unclear whether regulators share the same values of benefits 
and risks as patients or healthcare professionals. Additionally, formal assessment of patient 
10 
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or healthcare professional preferences has to date not been a part of the regulatory decision 
making. 
Research aim and outline of the thesis 
In line with the general aim of the Escher project, this thesis aims at evaluating the balance 
of benefit and risk ascertainment, as seen in the regulatory system. This thesis focuses on 
two issues that the regulatory system is grappling with, the uptake of knowledge about 
safety issues when deciding on market approval (part I), and the agreement on decision 
criteria between regulators and the decision makers in daily life about actual use of drugs 
(part II). 
Part I of this theses focuses on timely uptake of safety issues. Here we look at whether the 
regulatory system provides sufficient tools to evaluate drug safety at time of approval. 
Chapter 2 explores whether safety issues arising for HIV drugs result in changes in the 
development and assessment of other HIV drugs that arrive later to the market. The 
question will be addressed of whether regulators considered class experience sufficiently. 
Chapter 3 evaluates whether market registration of drugs using procedures that allow less 
data to be submitted, results in an increased probability of safety issues. The question will be 
addressed on whether regulatory systems to approve drugs for unmet medical need are 
sufficiently robust to ensure that safe (and effective) drugs reach the market. 
Chapter 4 assesses the association of highly innovative drugs with the probability of safety 
issues arising post marketing. Innovative drugs may need more monitoring post-approval as 
there is no class experience and we hypothesize that this may lead to more detection of 
safety issues post-marketing. 
Part II focuses on the perception of stakeholders in diabetes care regarding benefits and 
risks of drugs and their preferences for benefit-risk balance. Diabetes is one of the most 
important health problems today, in terms of its prevalence and in terms of availability of 
pharmacotherapy options. 
Global prevalence of diabetes is high and is still increasing. In the year 2000 it was estimated 
that between 154 and 171 million persons had diabetes with estimates up to over 360 
million for the year 2030. (29,30} Among patients with diabetes, the annual mortality is 2.9%, 
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mostly related to cardiovascular disease. In fact having diabetes is an independent risk factor 
for a number of cardiovascular disease (CVD) and once a diabetes patient develops CVD 
survival prognosis diminishes significantly. (31,32) 
Several drug groups are available for the treatment of type 2 diabetes, each with their own 
ADR profile. Some of the more common side effects associated with diabetes drugs include 
gastro-intestinal upset and hypoglycaemias. (33) However, more serious ADRs have also 
been associated with these drugs. Rosiglitazone, for example, has been shown to increase 
the very risk it was intended to decrease; the risk of myocardial infarction, and pioglitazone 
seems associated with an increased risk of bladder cancer. (34,35) 
Although diabetes is a disease for which multiple treatment options are available, regulators 
acknowledge the need for new drugs with improved benefits and risks. Still many patients 
are not adequately controlled with currently available treatments, that are also associated 
with several important ADRs. (35-37) It is unknown whether regulators are in agreement 
with patients and doctors in their value of benefits versus risks and the field of diabetes 
seems appropriate to assess the (dis)agreement between the groups. 
Chapter 5 describes the method used to compile a list of drug effects to use in creating 
choice sets for measurement of preferences. 
Chapter 6 assesses the preferences of benefit-risk balance of patients with type 2 diabetes. 
We sought to evaluate the importance of short term glucose regulation and long term 
cardiovascular benefits of oral anti-diabetes drugs relative to symptomatic ADRs and serious 
ADRs when choosing a drug. 
Chapter 7 compares the benefit-risk preferences of assessors working at the Dutch 
medicines evaluation board with doctors and patients with type 2 diabetes. Regulators make 
their decisions on a population level and doctors and patients on an individual level and 
some regulatory decisions have been criticised as the conclusion on a drug's benefit/risk 
balance are not always shared by doctors, patients or society at large. The question is 
addressed whether the difference between regulators on one hand and doctors and patients 
on the other is just the result of making decisions at a different, more population oriented 
level, instead of the individual patient level, or whether regulators genuinely value benefits 
and risks of drugs differently from other stakeholders. 
Chapter 8 is a summary of the results presented in this thesis and a discussion on their 
implication in regulatory policy and practice, as well as perspectives for future research. 
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Part I 
Uptake of safety knowledge 




Does safety information on newer HIV drugs benefit from experience with older HIV drugs? 
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Drug Safety 2011;34(11):1101-1114. 
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Background: Knowledge on the safety of new medicines is limited at the time of market 
entry. Nearly half of all drugs used to treat HIV registered in the EU required at least one 
Direct Healthcare Professional Communication {DHPC) in the past 10 years for safety issues 
identified post-approval. 
Objective: The aim was to evaluate the extent to which regulators and industry have 
addressed the risk of safety issues for HIV drugs based on prior experience with other drugs 
in the same class and whether doing so impacts development time of these drugs. 
Methods: HIV drugs receiving �1 DHPC in the Netherlands between January 1999 and 
December 2008 were identified. Each drug with a DHPC { ' index ' drug) was paired with 
subsequently approved HIV drug{s) in the same class {Anatomical Therapeutic Chemical [ATC] 
4th level) [ 'follow-on' drugs]. Characteristics of safety issues were extracted from the DHPCs 
of the 'index' drugs. European Public Assessment Reports {EPARs) were reviewed regarding 
whether the safety issues had been considered during development and approval. 
Consideration of previously identified safety issues in 'follow-on' drug applications was 
assessed regarding attention paid to adverse drug reaction {ADR) symptoms in pre­
marketing studies, Summary of Product Characteristics (SmPC) and postmarketing 
commitments, and whether size of the safety population was in accordance with Regulatory 
guidelines. 'Index' drugs were also paired with drugs in the same class already on the market 
('older' drugs). For 'older' drugs, we identified whether the safety issue led to appropriate 
changes in the current SmPC {January 2011) compared with the SmPC at the time of 
marketing authorization. 
Clinical development time was assessed using time from first patent application to market 
authorization as proxy, and comparison was made between 'index' and 'follow-on' drugs. 
Results: For 9 {43%) of the 21 centrally authorized HIV drugs, 11 serious safety issues that 
required a DHPC were identified. Two drugs were excluded from our analysis (DHPCs related 
to contamination/medication error). Six 'index' drugs were paired, each with one to six 
'follow-on' drugs. Three concerned drug-drug interactions {DOis); the other three were 
intracranial haemorrhage, neuromuscular weakness and severe skin/hepatic reactions. All 
but one 'follow-on' drug had information in the EPAR on that specific ADR {i.e. attention was 
paid to the ADR). The DOis were addressed in pre-marketing studies and/or the SmPC. Two 
of the other AD Rs were addressed by post-marketing surveillance commitments; intracranial 
haemorrhage was not addressed. Three safety issues for two safety issues could not be 
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paired with a 'follow-on' drug as no drug in the same class was approved after the 
corresponding DHPCs were issued. 
Five of the nine safety issues were added to at least one of the current SmPCs for the 'older' 
drugs already on the market at the time of DHPC issue. Two safety issues were already in the 
Sm PC of the 'older' drugs at time of market approval and two were not introduced into the 
SmPC of 'older' drugs. 
Population size to assess short-term safety complied with the guidelines for four 'index', 
seven 'follow-on' and three 'older' drugs; population size to assess long-term safety 
complied for one, three and two drugs, respectively. For five drugs, EPARs did not provide 
adequate information on population size. No statistically significant difference in 
development time between 'index' and 'follow-on' drugs was found. 
Conclusion: Generally, safety issues were taken into account in the approval process of 
other drugs in the class. The approaches were different and determined by the nature of the 
ADR. Taking safety issues into account in the approval process did not seem to impact on the 




As new drugs enter the market, their full safety profile is usually not fully established. (1-4) 
Clinical trials on which marketing applications are based are primarily designed to assess 
efficacy, have a relative short duration, include sometimes low-risk patients with narrowly 
defined co-morbidities, and generally do not include enough patients to identify safety 
issues that are relatively rare (incidence less than 1 : 1000). (5) Thus, it seems almost 
inevitable that new safety issues emerge post-approval. Serious safety issues requiring 
regulatory action are identified in approximately 10% of all marketed drugs, with higher 
rates for specific classes of drugs, such as drugs to treat HIV (referred to hereafter as HIV 
drugs). (6) 
Most (serious) adverse drug reactions (ADRs) related to the drug's mechanism of action can 
be predicted and identified pre-approval. In contrast, the ADRs identified post-approval are 
often unpredictable (idiosyncratic) or due to off-target (unexpected) pharmacological effects. 
It is, therefore, important that for pharmacologically related new drugs (similar drug class or 
molecule) coming to the market, the risk of ADRs that could be class-related are thoroughly 
evaluated in the drug development programme, in particular during the market 
authorization process. (7) 
The evaluation of idiosyncratic ADRs may be particularly challenging in therapeutic areas 
with a large unmet medical need and the accompanying pressure to prevent unnecessary 
delay in access to new drugs. HIV/AIDS is still considered a disease with such high unmet 
medical need by the European Medicines Agency (EMA). Prolongation of the development 
phase for HIV drugs to evaluate a potential but rare risk might negatively affect public health 
by delaying access to potentially beneficial drugs. (8) Also, additional study requirements will 
add to the costs that are associated with development of new drugs, further hampering their 
development. (9) Therefore, for HIV drugs, 'accelerated approval' in Europe is possible 
through approval procedures under Exceptional Circumstances or Conditional Approval, 
allowing drugs to be approved with more limited clinical data packages. (10-12) 
However, a considerable number of new serious ADRs have been identified with these HIV 
drugs post-approval. The EMA has acknowledged this risk and stipulated that safety issues 
based on class experience may be relevant for subsequent new HIV drugs and should be 
monitored long term using appropriate methods. (7,13) 
In this study, we aim to evaluate the extent to which regulators and industry have addressed 
the risk of safety issues for HIV drugs based on experience with other drugs in the same class. 
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In a separate exploratory analysis we assessed the impact of (increasing) regulatory 
requirements on development times for new HIV drugs. 
METHODS 
Study Drugs 
All HIV drugs approved by the EMA from the start of the EMA Central Procedure on 1 
January 1995 until 31 December 2008 were reviewed. We identified those HIV drugs with 
new important safety issues that required a Direct Healthcare Professional Communication 
(DHPC) in the period 1 January 1999 to 31 December 2008, referred to as 'index' drugs. 
DHPCs are paper-based letters sent by the Marketing Authorization Holder (MAH), in 
cooperation with the regulatory authorities, to relevant healthcare professionals. In the US, 
the equivalent of DHPCs are Dear Healthcare Professional Letters. (14) We excluded those 
DHPCs with safety issues that were related to the production process, route of 
administration or to the device. First, HIV drugs from the same drug class (Anatomical 
Therapeutic Chemical [ATC] 4th level). (13) that received marketing approval after the initial 
safety issue with the 'index' drug were studied (referred to as 'follow-on' drugs) [figure 1]. 
Same ATC 
level 4 
'O lder' d rug  
MA approva l  
' Fo l low-on '  d rug  
M A  approval 
(e.g. RitonaYir, J05AE03) ( e.g. Darunm·it-, J05AEJ 0) 
' I ndex ' d rug  
DHPC 
(e.g. Atazanavir. J05AE08) 
Time  
Figure 1 Definition of 'index', 'follow-on' and 'older' drugs. ' Index' HIV drugs are defined by 
a Direct Healthcare Professional Communication (DHPC) issued for a new drug 
safety issue. 'Follow-on' drugs are HIV drugs in the same class (Anatomical 
Therapeutic Chemical [ATC] 4th level) as the 'index' drug that were granted 
marketing authorization after the date of the DHPC. 'Older' drugs were HIV drugs 
in the same ATC-4 class as the 'index' drug that were granted Marketing 
Authorization (MA) before the DHPC was issued. 
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Second, we studied those HIV drugs that were already approved at the time the 'index' drug 
received a DHPC (referred to as 'older' drugs). 
Characteristics of Safety Issues 
DHPCs were retrieved from the Dutch Medicines Evaluation Board (MEB) website. (15) The 
data extracted from DH PCs was as follows: (6) 
• type of ADR; 
• incidence rate of the ADR; 
• the research method by which the safety issue was identified (e.g. clinical trials, 
spontaneous ADR reports or epidemiological studies); 
• precursory symptoms or markers identified. 
Review Procedure 
European Public Assessment Reports (EPARs), which contain publicly available summary 
reports of the clinical dossier that was the basis for the marketing authorization, were 
retrieved from the EMA website. (16) Two reviewers (AHA and PGMM) evaluated the clinical 
studies, as presented in the EPARs, and independently extracted the data. Discrepancies 
were resolved by consensus. This was done for both the HIV drugs for which the safety issue 
was initially communicated postmarketing ('index' drugs) and for the HIV drugs of the same 
class (ATC 4th level) [ 'follow-on' drugs] (13) that received a marketing authorization after the 
safety issue was communicated by the DHPC. 
Data Extracted 
The EPARs were reviewed to establish if an earlier-identified safety issue had been critically 
addressed in the pre-clinical (animal) studies, pharmacokinetic studies and clinical trials. This 
was done for both 'index' and 'follow-on' drugs. Each issue was scored on pre-specified 
criteria regarding the identification of the ADR of interest, in line with the EMA guideline for 
clinical development of HIV drugs. (7) The score ranged from - (insufficient) to +++ (excellent) 
with respect to the effort put in establishing and describing these ADRs pre-approval [table 
1]. 
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We compared the size of the study population of the 'index' drugs with their respective 
'follow-on' drugs, as well as for 'older' drugs. Both short- and long-term safety populations 
were identified for which minimal requirements were set by the EMA as being 1500 subjects 
exposed and 100 patients treated for at least 1 year, respectively. (7,17,18) 
We recorded whether the safety issue identified was also reflected in the initial Summary of 
Product Characteristics (SmPC) of each product at the time of marketing authorization, as 
retrieved from the European Commission website. (19) The SmPC is a document that 
includes information for the health professional on how to use the drug effectively and 
safely. For the 'older' drugs we identified whether the safety issue led to a change in the 
current SmPC (January 2011) compared with the SmPC at the time of marketing 
authorization that was approved before the safety issue in the 'index' drug had occurred. 
Finally, it was recorded whether the drugs obtained a marketing authorization through the 
Exceptional Circumstances or Conditional Approval procedure. (20,21) 
Table 1 Scoring system of European Public Assessment Reports 
Grade 
- ( insufficient) 
+ 
++ 
+++ (excel lent) 
Markers/symptoms 






ADR = adverse drug reaction. 
Clinical Development Time 
Markers/symptoms 
l inked to the possibi l ity 





Investigation or discussion 
on the presence or absence 





A patent search in the Newport Horizon Global™ database (22) was performed. The clinical 
development time was defined as the time from the date of first patent application until the 
date of marketing authorization. Patent time was used as proxy for clinical development 
time as developers of drugs generally apply for a patent when the development process of 
the drug has not reached the point of clinical trials. (23) 
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Regression analysis was used to probe for a possible trend in clinical development time, and 
the Mann-Whitney U test was used to probe for a difference in clinical development time 
between the 'older', 'index' and their 'follow-on' drugs. 
RESULTS 
Characteristics of Safety Issues 
For 9 (43%} of the 21 centrally authorized HIV drugs, 11 serious safety issues that required a 
DHPC were identified [figure 2]. We excluded two safety issues since they did not concern an 
ADR related to the pharmacology of the drug. Three of nine safety issues were drug-drug 
interactions (DOis), which resulted in subtherapeutic plasma levels of the antiviral drug or 
loss of virological response due to mutation of the virus. Another three safety issues were 
idiosyncratic ADRs, including intracranial haemorrhage, neuromuscular weakness and severe 
skin/liver reaction. Assessment of incidence rate was only possible for two of the 
safety issues. Three safety issues could not be paired with a 'follow-on' drug as no drug in 
the same class was approved after the corresponding DHPCs were issued; these concerned 
drug hypersensitivity, myocardial infarction {Ml) and renal disorder [table 2]. 
Evaluation of Identified Safety Issues for Class-Related Drugs 
The impact of six safety issues could be evaluated in the EPARs of one to six 'follow-on' drugs 
per safety issue [table 3]. 
In the case of a drug-drug interaction with St John's wort by indinavir, described in table 2, 
all 'follow-on' drugs underwent non-clinical (in vitro) and/or clinical pharmacokinetic 
investigations to assess the metabolism of the active compounds [table 3] . All these drugs 
were determined to be cytochrome P450 (CYP) 3A4 substrates as well as inhibitors or 
inducers of the isoenzyme and received a contraindication for concomitant use with St 
John's wort at the time of market authorization. (33-38) All three of the 'older' drugs did not 
mention an interaction with St John's wort in their original SmPC (39-41) but received a 
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Figure 2: Timeline of approvals and safety risk communication (Direct Healthcare Professional Communication [DHPC]) of HIV 
drugs. EC = Exceptional Circumstances market authorization; CA = Conditional Approval market authorization; Arrows 
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Atazanavir's pH-dependent absorption, leading to lower plasma levels when co-administered 
with proton pump inhibitors (PPls), was studied in appropriate pharmacokinetic interaction 
studies for the 'follow-on' drugs, i.e. tipranavir and darunavir. No discernable interaction 
was observed for concomitant administration of darunavir with a PPI and, as a consequence, 
no contraindication was included in the SmPC. An interaction study with an antacid but not 
with a PPI was performed for tipranavir. Based on the lowered plasma levels of tipranavir, a 
warning was included in the SmPC (37) to separate intake of antacids and tipranavir by 2 
hours. Four of the seven 'older' drugs had a comment on acid-reducing agents but no 
comment on PPls in the 'interactions' section of their original SmPC. (33,36,41,45) In the 
current January 2011 version of the SmPC, all drugs, except indinavir, had a comment on 
either acid-reducing agents or PPls in their 'interactions' section. (42-44,46-48) 
lntracranial haemorrhage was reported as a serious ADR of tipranavir. The 'follow-on' drug, 
darunavir, showed some effects on platelets in rats. It was claimed that this effect did not 
lead to bleeding and no further specific investigation of bleeding or the occurrence of 
intracranial haemorrhage was performed in clinical trials. For the eight 'older' drugs, none 
had any mention of haemorrhage or bleeding, except in patients with haemophilia, in 
neither the original Sm PC (33-36,39-41,45) nor the version valid in January 2011. (42-44,46-
50) 
Regarding neuromuscular weakness that occurred with stavudine, a discussion on lactic 
acidosis (a precursory symptom) in clinical trials was present in the EPARs for both 'follow­
on' drugs, tenofovir and emtricitabine, and a warning was included in their SmPCs. (51,52) 
Lamivudine, one of two 'older' drugs, had no mention of lactic acidosis or neuromuscular 
weakness in its original SmPC. (53) The original SmPC for abacavir was not available on the 
European Commission website, but there was a mention of lactic acidosis in its original 
patient information leaflet. (54) Both drugs have a discussion of lactic acidosis in the SmPC 
valid in January 2011. (55,56) 
For tenofovir, where a pharmacodynamic interaction with lamivudine/abacavir or 
lamivudine/didonasine was observed, the 'follow-on' drug, emtricitabine, was tested in vitro 
for resistance of the known mutation type virus but only for lamivudine alone and not for 
the combination of lamivudine with abacavir or didonasine. The SmPC mentions that 
combination therapy with lamivudine cannot be recommended as specific interaction 
studies have not been performed. (52) For the three 'older' drugs, there was no mention of 
the mutated virus strain in the Sm PC of stavudine and lamivudine, (53,57) while it could not 
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(Mar  2004} 
Nelfinavir 




(i} Jun 2007a 
( i i }  Ju l  2007 a 
Lopinavir/ritonavir ( i }  Sep 2006 a 
(Mar  2001} ( i i }  Aug 2007 a 
ADR 
DDI with St John's wort 
DOI with omeprazole 
( i  + i i }  Therapeutic 
product contamination 
( i  + i i }  I nformation 
capable of leading to 
medication error 
Symptoms and/or 
mechanism of ADR 
Plasma levels of indinavir 
lowered significantly 
I nteraction is via the CYP 
metabolic pathway 
Plasma levels of atazanavir 
lowered significantly 
U ptake of atazanavir is 
inh ib ited by the change in 
acid ity 
Other PPls and preparations 
that increase gastric pH are 
l ikely to have a s imi lar effect 
Excluded from ana lysis 
Excluded from ana lysis 
a These DHPCs were excluded from the assessment of European Publ ic Assessment Reports. 
Discovery of ADR as 
presented in DHPC 
ADR was d iscovered in a 
post-approval cl inica l  tria l  
(DD I  study} 
ADR was d iscovered in a 
post-approva l c l inica l  trial 
(DD I  study} 
Comment 
Not related to 
pharmacology 
Not related to 
pharmacology 
c.a . = approximately; CYP = cytochrome P450; DOI = drug-drug interaction; DHPC = Direct Hea lthcare Professional Communication; M l = 
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Table 2 (con't.): Characteristics of the study d rugs a nd  a dverse drug reaction s  (AD Rs) 
Drug DHPC date ADR Symptoms and/or Discovery of ADR as Comment 
(approval date) mechanism of ADR presented in DHPC 
Abacavir Mar 2008 Drug hypersensitivity HLA-B*S701 genotypes a re The PREDICT-1 double-bl ind No subsequent 
(Ju l  1999) sensitive to this ADR only. Patients clinical tria l demonstrated that drug approved 
should be genoptyped before this a l ready known ADR 0 CD 
i n itiating abacavir treatment occurred in 48-61% of HLA-
Ill 




Apr 2008 Myocardial infarction No established MoA, but Ml had ADR was confirmed in a No subsequent o' 3 
been identified as a possible risk in postmarketing cohort study.l241 drug approved 
the pre-approval programme. The a bsolute M l  rate was er ::s 
Cardiovascular risk factors such as 6.1/1000 patient years 0 ::s 
hypertension, dysl ip idaemia 
::s 
CD 
and/or diabetes should be � 
monitored :c < 
Tenofovir (i) Jul 2003 ( i + ii + i i i )  Decreased Mutation in  the virus resulted in ADR was d iscovered in a post- � 
C 
(Feb 2002} ( i i )  Oct 2003 efficacy: resistance and lack of virological approva l cl in ical trial (IQ 
( i i i )  Mar  2005 pharmacodynamics (combination tria ls) .  80 cases 
tr 
response CD ::s 
i nteraction with Seems to be related to the same (c.a. 50%} of patients a lso using 
lamivudine + abacavir types of mutations in the virus, lamivudine + abacavir 
0 
combination and and genotyping of the viral load combination and 22 cases (c.a. 3 
CD 
l amivudine + was advised 90%) of patients a lso using 
didanosine lamivudine + didanosine � 
i;" 
combination combination suffered virologica l ::s 
CD 
non-response ! 
( iv) Mar 2006 (iv + vi ) Renal Creatinine clearance and serum ADR was discovered with No subsequent :::J" 0 
(v) Apr 2008a d isorder; (acute) renal sodium phosphate should be postmarketing data survei l lance drug approved ii: 
fa i lure, nephrogenic monitored (spontaneous ADR reporting) :c 
diabetes insipidus < � 




c.a. = approximately; CYP = cytochrome P450; DD I  = drug-drug i nteraction; DHPC = Direct Healthcare Professional Communication; M l  = . ..., 
myocardia l  infarction; MoA = Mechanism of Action; PPI  = proton pump inhibitor. 
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be determined for abacavir since the original SmPC was not available. The mutated virus 
strain is discussed in the January 2011 version of the Sm PC for lamivudine and abacavir, but 
not stavudine. (55,56,58) 
Following the severe skin and/or hepatic reaction of nevirapine, rash was reported in clinical 
trials of the 'follow-on' drug, etravirine, and hepatic events were slightly more frequent than 
for placebo. Rash was included as a common adverse effect in the SmPC. (59) For efavirenz, 
the single 'older' drug, a rash was listed as a possible adverse effect in both the original and 
January 2011 versions of the Sm PC. (60,61) 
Three safety issues could not be paired to a 'follow-on' drug and were only assessed for 
'older' drugs, already on the market when the DHPC was issued. All three safety issues were 
for nucleoside and nucleotide reverse transcriptase inhibitors. 
For the drug hypersensitivity associated with abacavir and described in table 2, all four 
'older' drugs did have a contraindication for the use of the drug when the patient was known 
to have hypersensitivity to the drug in both the original and January 2011 versions of their 
SmPC. (51-55,57,58,62,63} 
For the Ml associated with abacavir, and described in table 2, none of the four 'older' drugs 
had any discussion on M l  or precursory symptoms in either the original or January 2011 
version of their Sm PC. (51-55,57,58,62,63} 
For the renal disorder associated with tenofovir and described in table 2, three of the 'older' 
drugs had no mention of renal disorders in the 'undesired effect' section of either the 
original or January 2011 version of their Sm PC. (52,53,55,57,58,63) For abacavir, the original 
SmPC could not be accessed and its patient information leaflet had no mention of renal 
disorders in the 'adverse effect' section. (54) Abacavir did have renal failure listed as a 
possible undesired affect in the SmPC valid in January 2011. (56) 
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Table 3 Evaluation of identified adverse drug reactions (ADRs) for study drugs in drug 
development and product information 
Protease inhibitors 







Atazanavir (DOI  with omeprazole) 
tipranavir 
darunavir 
























Nucleoside and nucleotide reverse transcriptase inhibitors 




Tenofovir (DOI  with lamivudine/abacavir ++ 
or lamivudine/didanosine) 
emtricitabine +++ 
Non-nucleoside reverse transcriptase inhibitor 
Nevirapine ( l iver/skin reaction)  + 
etravirine + 
a Source: EPARs. 
+ 
NA 
b EPAR has shown that a warning in SmPC is not required. 



































DOI = drug-drug interaction; EPAR = European Publ ic Assessment Report; NA = not appl icable; RCTs = 
randomized controlled tria ls; SmPC = Summary of Product Characteristics; - indicates not mentioned 
in the EPAR or SmPC; + indicates evidence is present, but d iscussion is poor or fol low up on  the 
evidence is not performed; ++ indicates d iscussion present on evidence of the ADR or evidence that 
suggests the ADR is not l ikely; +++ ind icates a good discussion on the ADR, e ither that the ADR is 
possib le or not at all l ikely. 
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Table 4 Eva luat ion of popu l at ion exposed to study d rugs a n d  t he  duration of d rug 
deve lopment 
Drug Population Time from Approval Year of 
long-term safety patent to type approva l 
popu lationa populationb MA (y) 
Protease inhibitors 
Ritonavir (O) Inadequate 374 2.7 EC 1996 
i nformationc 
Saquinavir (O) >180 574 5.8 EC 1996 
l ndinavi r ( I )  ~100 ~2000 3.4 Regular  1996 
Nelfinavir (0) 24 819 3.3 EC 1998 
Amprenavir (F)  >lOOd >1000 7 .1 EC 2000 
Lopinavir/ritonavir ( F) Inadequate 2000 7.2 EC 2001 
i nformationc 
Atazanavir ( I )  >200 2244 6.9 EC 2004 
Fosamprenavir ( F) >470 >1000 6.3 Regular 2004 
Tipranavir ( I )  57 3 195 10.5 EC 2005 
Darunavir (F)  1056 1783 13.5 CA 2007 
Nucleoside and nucleotide reverse transcriptase inhibitors 
Stavudine ( I )  >lOOd >13 000 8.4 Regu lar 1996 
Lamivudine (O) I nadequate 18 889 6.5 Regu lar 1996 
i nformationc 
Abacavir (O) 147 4400 10.0 Regu lar 1999 
Tenofovir ( I )  75 1050 15.8 EC 2002 
Emtricitabine (F)  1348 2136 12.8 Regu lar 2003 
Non-nucleoside reverse transcriptase inhibitor 
Nevi rapine ( I )  ~450 906 7.6 EC 1998 
Efavirenz (O) 408 2437 5.8 Regular 1999 
Etravirine ( F) 279 1041 8.8 CA 2008 
a Number of patients exposed to the drug for at least one year. 
b N umber of patients a nd healthy volunteers exposed to the drug. 
C EPAR did not provide sufficient i nformation to estimate the population. 
d I nformation in EPAR is unclear and the population was est imated .  
CA = Conditional  Approval; EC = Exceptiona l  C ircumstances; EPAR = European Publ ic Assessment 
Report; F = 'fol low-on' drug; I = ' index' d rug; 0 = 'older' drug; MA = Marketing Authorization. 
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Size of Safety Population 
Less than 1500 subjects (patients and healthy volunteers) were included in the clinical 
development programme of six (two 'index', one 'follow-on' and three 'older') HIV drugs in 
our study. The programme of two 'follow-on' drugs (amprenavir and fosamprenavir) 
included more than 1000 subjects, but for these two we could not assess properly whether 
the number exceeded 1500 subjects [table 4]. Two of the 'index' drugs did not have the 
required long-term population of 100 patients treated for at least 48 weeks. Both drugs 
were licensed under exceptional circumstances. For one 'follow-on' drug the information in 
the EPAR was not sufficient to assess the number of the long-term participants. One 'older' 
drug did not have the required long-term population of 100 patients treated for at least 48 
weeks and for two 'older' drugs the information in the EPAR was not sufficient to assess the 
number of the long-term participants. For the remaining 12 drugs, the EPARs indicated that 
at least 100 patients were treated for 48 weeks with the new HIV drug. 
Eleven (61%) of the 18 HIV drugs were approved under Exceptional Circumstances or 
Conditional Approval; four were 'index', four were 'follow-on' and three were 'older' drugs. 
These drugs were more likely (81.8%) than the regularly approved drugs (28.6%; p = 0.024) 
to be non-compliant with the guidelines on safety population and long-term population 
[table 4]. 
Clinical Development Times 
The median time from patent application to marketing authorization approval for all study 
drugs was 8.4 years, ranging from 2.7 to 15.8 years. No significant difference was shown in 
the median time from patent application to marketing authorization approval between the 
'older' drugs and 'index' drugs (median 6.7 years, interquartile range [IQR] 4.6-9.2) and their 
'follow-on' drugs (median 8.8 years, IQR 7.1-12.8; p = 0.689). Clinical development time 
(years) did significantly increase over time for the studied HIV drugs per year of market 




Our study shows that in the clinical development for the majority of new HIV drugs, 
attention is paid to previously identified ADRs of drugs approved earlier in the same 
pharmacological class without significantly affecting drug development time. The ADRs are 
discussed in the EPARs and, if appropriate, relevant information is included in the SmPC. For 
drugs already on the market, the occurrence of a safety issue for a drug of the same drug 
class seems to result in a re-evaluation of the safety information in the Sm PC for most of the 
'older' drugs. 
In our study, we show that EMA guidelines for development of HIV drugs, requiring that 
ADRs that have been observed for earlier-approved drugs are evaluated in clinical 
development programmes of new HIV drugs, were followed. (7,17,18) Pre-marketing clinical 
trials are generally considered insufficient to establish the full safety profile of a drug. 
Furthermore, when ADRs have been identified they are not translated into clear warnings or 
usable knowledge for the healthcare professional. (5) However, we find the latter is not the 
case for the class-related safety issues we studied. All but one of these ADRs were generally 
carefully evaluated pre-approval and resulted in appropriate warnings in the SmPC. (7) In the 
case of intracranial haemorrhage, identified with tipranavir, this issue was not discussed in 
the EPAR of darunavir, the only subsequently approved protease inhibitor in our study. (25) 
We cannot rule out that evaluation of class-related safety issues was triggered by something 
other than the DHPC. A general effect of acid-reducing agents was described for four of 
seven 'older' protease inhibitors, but none specifically mentioned PP ls. Most of the SmPCs 
valid in January 2011 do mention PP ls specifically as is the issue evaluated in 
pharmacokinetics programmes of the 'follow-on' drugs. 
Most SmPCs of 'older' drugs did change to include class-related safety issues at sometime 
between approval and January 2011. This suggests that a re-evaluation of the safety of 
'older' drugs is performed and SmPCs change as a result. However, there were exceptions. 
No change to the SmPC of indinavir was made, despite evidence that the absorption of 
indinavir is also dependent on the pH. (26) Since all other protease inhibitors do have a 
comment on possible interaction with acid-reducing agents, this seems clearly a class­
related safety issue. On the other hand, no 'older' drug had a comment on intracranial 
haemorrhage in their January 2011 SmPC, and since the 'follow-on' drug did not have 
investigation on intracranial haemorrhage in its EPAR this suggests that the safety issue is 
regarded as idiosyncratic rather than class-related. The Ml associated with abacavir could 
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also be regarded as idiosyncratic, (24) thus explaining the lack of SmPC changes for 'older' 
drugs. Where the safety issue is already included in the original SmPCs of 'older' drugs, e.g. 
in the case of hypersensitivity of abacavir, it could be that there is always a hypothetical 
possibility of the safety issue and the comment is added as routine. 
Development time of the 'follow-on' drugs - drugs sharing the same pharmacological class -
did not significantly increase compared with the 'index' drugs and 'older' drugs. There was 
one exception; indinavir had a shorter development time than all its 'follow-on' drugs, 
although slightly longer than the 'older' drug ritonavir. lndinavir and ritonavir were two of 
the first protease inhibitors to be approved. They opened up the route for new potent 
treatment combinations that became known as highly active antiretroviral therapy (HAART). 
(27) Thus, indinavir and ritonavir were regarded as an important breakthrough in the 
treatment of HIV and this may have led to their very short clinical development time. As for 
other drugs, development times over the studied years are observed to be increasing. (28) 
Our research showed that HIV drugs are likely to be licensed under Exceptional 
Circumstances or Conditional Approval and are more likely to receive a DHPC than other 
centrally approved drugs. (6,29) This finding suggests that because of the complex nature of 
the disease or the pressure put on regulators to approve the marketing applications quickly, 
(12,30,31) HIV drugs are more at risk of safety issues arising post-approval. The size of the 
safety population was, in the majority of the study drugs, in line with the regulatory 
guidelines. (18) Licensing under Exceptional Circumstances or Conditional Approval creates 
the possibility of including fewer subjects in clinical trials, and we found that the size of 
safety population did significantly correlate with the type of marketing authorization of HIV 
drugs. In general, drugs licensed under Exceptional Circumstances and Conditional Approval 
are less likely to fulfil the requirements of more than 1500 subjects exposed. However, in 
another study, we showed that for all centrally approved drugs in the EU, drugs approved 
through these procedures were no more likely to receive a DHPC than were drugs approved 
through the standard procedure. (32) Furthermore, in this study, we did not find a 
correlation between evaluation of safety issues for drugs approved through the Exceptional 
Circumstances/Conditional Approval versus standard procedure. 
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Limitations of the study 
We collected most of our data from EPARs that do not provide access to confidential data. 
However, one may assume that all relevant clinical efficacy and safety data are present in 
the EPARs; the available data should therefore be sufficient to draw conclusions. The use of 
patent application dates is a weak proxy for clinical development time. The time from patent 
application to the beginning of pre-clinical or clinical research can vary depending on several 
issues, but generally companies do apply for patents before requesting ethics approval of 
their clinical trials. (23) We are not aware of a central database of clinical trial applications 
covering our study period; therefore, time from first patent application to marketing 
authorization was the best available proxy for clinical development time. The study 
evaluated only HIV drugs and cannot be extrapolated to other types of drugs. However, we 
could expect comparable results for other drug classes. Regulatory guidelines for clinical 
development of various drug classes or disease areas acknowledge class-related adverse 
effects. Finally, we only had access to DHPCs issued after 1 January 1999 (6) and cannot 
evaluate if any DHPCs were issued for HIV drugs between 1995 and 1998 and how this was 
followed up. 
CONCLUSION 
We found that in the case of HIV drugs, knowledge on ADRs gained from earlier-approved 
drugs has been used in the development of new drugs in the same class. We were not able 
to demonstrate that this affects clinical development times. 
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Aims: Regulatory requirements for new drugs have increased. Special approval procedures 
with priority assessment are possible for drugs with clear 'unmet medical need'. We 
question whether these Exceptional Circumstances (EC) or Conditional Approval (CA) 
procedures have led to a higher probability of serious safety issues. 
Methods: A retrospective cohort study was performed of new drugs approved in Europe 
between 1999 and 2009. The determinant was EC/CA versus standard procedure approval. 
Outcome variables were frequency and timing of a first Direct Healthcare Professional 
Communication (DHPC). An association between approval procedure and the time from 
market approval to DHPC was assessed using Kaplan-Meyer survival analysis and Cox­
regression to correct for covariates. 
Results: In total 289 new drugs were approved. Forty-six {16.4%) were approved under EC or 
CA of which seven received a DHPC (15%). This was similar to the standard approval drugs 
(243) of which 33 received one or more DHPC {14%, p=0.77). The probability of acquiring a 
DHPC for standard approval drugs versus EC/CA drugs during 11 years follow-up is 22% 
{95%CI: 14% ; 29%) and 26% {95%CI: 8% ; 44%) respectively (Log-Rank p=0.726). This 
difference remained not significant in the Cox-regression model: hazard ratio 0.94 {95%CI: 
0.40 ; 2.20). Only drug type was identified as a confounding covariate. 
Conclusion: The EC/CA procedure is not associated with a higher probability of DHPCs 
despite limited clinical development data. These data do not support the view that early 
drug approval increases the risk of serious safety issues emerging after market approval. 
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INTRODUCTION 
Increasingly, society has become aware that drugs not only cure or prevent diseases but also 
can lead to considerable patient harm. Adverse drug events, whether or not due to 
(in)correct use of drugs, have been estimated to be a leading cause of unplanned hospital 
admission. (1,2) New drugs are allowed to the market based on relatively limited knowledge 
of their benefit-risk profile due to inherent and well known limitations in pre-approval 
clinical trials. (3) Those trials are typically performed in carefully selected patient populations 
not fully representing 'real world' patients, are of relatively short duration, and are primarily 
developed to determine efficacy. (4) They are not powered to detect rare adverse events, 
adverse events with a high background incidence or those related to the disease. (5) It is 
therefore not surprising that both in Europe and the USA for approximately 10% of all 
marketed drugs, serious adverse drug events were identified post approval that had to be 
communicated to healthcare professionals or patients. (6,7) Consistently, cardiovascular 
adverse events including QT prolongation and hepatotoxicity were leading causes for safety 
withdrawals of drugs. (6,7) Acknowledging this situation regulatory authorities have 
increased their pre-approval requirements over time. For example, thorough QT studies 
have become part of many new drug applications since QT prolongation and associated life­
threatening arrhythmias have led to several drugs being withdrawn from the market. (8,9) 
More recently, the debate on rosiglitazone has led FDA to step up its pre-approval 
requirements for new drugs for diabetes, to demonstrate absence of an excess risk of 
cardiovascular events. (10) The negative consequences are that drug development times 
may increase, as do costs that are estimated upward of 800 million USD for the development 
of a new drug, limiting development of all but the most lucrative drugs. (11) 
This development may not be in the interests of patients with a shortage of available 
treatment options for their disease, such as HIV/AIDS, cancer and many orphan diseases 
with unmet medical need. This is why the Food and Drug Administration (FDA) introduced 
the Accelerated Approval (AA) procedure in the USA and the European Medicines Agency 
(EMA) the Exceptional Circumstances (EC) or Conditional Approval (CA) procedures in 
Europe to approve drugs based on more limited clinical data sets. In Europe, the EC and CA 
procedures do not shorten the approval procedure itself, as is a common misconception. In 
the case of AA and CA procedures companies are required to perform confirmatory studies 
post approval, whereas in case of EC approval this is sometimes considered not realistic, e.g. 
43 
Chapter 3 
due to the (extreme) rarity of the disease. {12,13) However, an earlier effort by the FDA to 
streamline the regulatory process, the Prescription Drug User Fee Act (PDUFA) that 
restricted review times of new drugs, was criticised as it may have lead to unsafe drugs being 
approved. (14) Since the EC procedure has been used since 1995 and the CA procedure since 
2007, it seems opportune to evaluate whether these special approval procedures have led to 
more safety issues identified after the drugs were marketed. 
Our study evaluates whether the early approval under exceptional circumstances or 
conditional approval has led to a higher probability of new serious safety issues post 
approval than for drugs approved with the standard procedure of the EMA. 
METHODS 
Study design & study population 
A retrospective cohort study was performed including all new active substances approved 
under the European Centralised Procedure (CP) from 1 January 1999 to 31 December 2009, 
using a limited definition of new active substances, by excluding biosimilars as defined by 
Eichler et al.. (15,16) The determinant was whether the drug product was approved using 
EC/CA or the standard procedure. Regulatory and scientific information on drugs was 
obtained from the European Public Assessment Report (EPAR) which is a summary report of 
the application. EPARs are issued for drugs that have received a marketing authorisation 
under the European Centralised Procedure (CP). EPARs are publicly available and can be 
retrieved from the EMA website. (17) 
Outcome 
The primary outcome was the identification of a first serious safety issue post approval. A 
serious safety issue was defined as an issue requiring regulatory risk communication in the 
form of a Direct Healthcare Professional Communication (DHPC) or a safety-related 
withdrawal of the marketing authorisation. 
A DHPC contains information aimed at ensuring safe and effective use of medicinal products. 
It is delivered directly to individual healthcare professionals by a Marketing Authorisation 
Holder, or by a Competent Authority. DHPCs issued for drugs approved with the European 
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CP were retrieved from the Dutch Medicines Evaluation Board website. (18) We included 
European DHPCs issued from 1 January 1999 to 31 December 2009 and excluded DHPCs, 
where the safety issues were related to the administration of the drug, the pharmaceutical 
quality of the product or to malfunctioning in a device for the administration of the drug. 
Time to DHPC or safety related market withdrawal, defined as the time in months from the 
date of market approval to the date of a first DHPC or withdrawal, was assessed. Whether a 
withdrawal was safety-related or not, was determined from the EMA press release regarding 
each drug withdrawal, as retrieved from the EMA website. 
Covariates 
Covariates were defined that could be considered as potential confounders. These were 
related to the drug, procedural issues and the clinical development and were obtained from 
the EPAR. The factors related to the drug were drug class (on anatomical therapeutic and 
chemical (ATC) code. (19) ATC-2 level, where more than 5 drugs were approved through the 
EC or CA procedure), whether it was first in class (y/n) and the type of drug (small molecule 
or biological including vaccines) as these might influence the likelihood of receiving EC or CA 
marketing authorisation as well as potentially increase the risk of serious safety issues post 
approval. The procedural issue was orphan drug status (y/n), because orphan drugs could be 
more prone to receiving EC or CA market approval and might be less prone to issuance of 
DHPCs. Another potentially important factor in the marketing authorisation application 
dossier related to the clinical development process was the size of safety population (less 
than 1500 subjects, y/n). EC/CA drugs can more often be approved with less than 1500 
subjects exposed and drugs with smaller exposure in patients / healthy volunteers before 
approval may lead to more adverse drug reactions only being identified after approval. This 
number of 1500 has been specified by the El document published by the Internal 
Conference on Harmonisation (ICH) - agreement between USA, European and Japanese 
regulators - as a minimum number of subjects/patients that are expected to be exposed pre­
approval to any new drug product. (20) 
Analysis 
Differences between baseline characteristics were analysed using chi-square and are 
presented in table 1. The probability for EC/CA and drugs approved with standard procedure 
to receive a DHPC or to be withdrawn for safety reasons was evaluated by Kaplan Meyer 
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analysis correcting for follow-up duration and by the Log-rank test. A follow-up duration of 
11 years was deemed appropriate, as 73% of DHPCs are issued in the first ten years after 
market approval. (7) 
Our study had 80% power at a 5% alfa-level to detect a difference of 10% between EC/CA 
and drugs approved with standard procedure of identifying safety-related issues requiring a 
DHPC during the 11-years follow-up. This is considering that 280 new drugs obtained 
marketing authorisation during the study period and had a 20% baseline chance for 
acquiring a DHPC, which is approximately in between the estimation for biologicals (29%) (21) 
and for all drugs (10%) (6) during 10 years follow-up. 
A multivariable Cox proportional hazard model (HR and 95% Cl) was used to evaluate the 
association between approval type and time to first DHPC, correcting for confounding 
covariates (p<0.1 in the chi-square analyses). A sensitivity analysis was also performed 
including all covariates in the Cox model. 
As the research did not involve any patient data or other confidential material, no ethics 
approval was necessary for the performing of the study. 
RESULTS 
Of the 289 new drugs that obtained a marketing authorisation between 1 January 1999 and 
31 December 2009, 46 (16%) were approved under EC/CA of which 38 with EC approval and 
8 with CA. In the study period two to ten EC/CA drugs were approved annually, without any 
obvious pattern [Figure 1]. Sixteen drugs were withdrawn from the market for commercial 
reasons, all approved with standard procedure. The medium follow up of those withdrawn 
drugs was 45 months. 
In total 74 DH PCs were issued for 49 drugs of the 289 drugs included, with 16 drugs receiving 
more than one DHPC. Five drugs, all approved with standard procedure, were withdrawn 
because of safety concerns; inhaled insulin, efalizumab, r imonabant, valdecoxib and a 
combination vaccine (Hexavac™). Eleven DHPCs for nine drugs were excluded; for five drugs 
the safety issues were related to the administration of the drug, for three drugs to the 
pharmaceutical quality of the product and for one drug to a malfunction in a device for the 
administration of the drug. A list of all DH PCs is presented in the appendix. Of the 46 drugs 
with EC/CA approval seven received a DHPC (15%) in comparison to 33 of 243 standard 
46 
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Table 1: Approval procedures and issuance of a DHPC for new active substances approved between 1 January 1999 and 31 
December 2009 and drug, procedural issues and clinical development characteristics. 
Approval DHPC 
AII NAS 
EC/CA Standard Yes No 
N (%)* N (%)* N {%)* p** N {%)* N (%)* p** HR {95% Cl)*** 
Total 289 (100) 46 (100} 243 {100} 40 {100} 249 {100} 0.94 (0.40 ; 2,20) 
Drug 
Drug classes (ATC-2 levelc) <0.001 0.01 
Alimentary tract and 
metabolism - other {A16) 13 (5) 7 {15) 6 {3} 1 {3) 12 (5) 0.57 (O.Q7 ; 4.43) 
Direct acting antivirals (J05} 19 (7) 8 (17) 11  (5) 7 {18} 12 (5) 3.07 { 1.28 ; 7.37) 
Antineoplastics {L01} 38 {13} 11  (24) 27 (11) 7 {18} 31 {12) 1.62 (0.69 ; 3 .83)  
Other drug classes # 219 (76} 20 (44} 199 {82} 25 {63) 194 {78} reference 
F irst in class (y) 37 {13} 5 (11) 32 (13) 0.669 6 {15) 31 {12) 0.65 
Biologicals (y) 109 {38} 14 (30} 95 {39} 0.266 13 {33} 96 {39} 0.46 
Procedural issues 
Orphan drugs (y) 55 {19} 20 (44) 35 {14) <0.001 7 {18} 48 {19} 0.79 
Clinical development 
Safety population <1500 (y)¥ 157 {56} 38 (83} 119 {51) <0.001 23 {59} 134 {56} 0.69 
NAS New Active Substance; DHPC Direct Hea lthcare Professional Communication (as proxy for safety issues) after excluding non-safety related 
DHPCs; EC Exceptional Circumstances; CA Conditional Approval; * Percentages are expressed within  NAS, approval type and DHPC (column); 
* *  p-va lue of Chi square; * **  Cox-proportional  Hazard Ratio corrected for covariates presented; § Drug classes a re selected to over-represent 
EC/CA procedure (2:5 drugs registered through EC/CM procedure); # All d rugs that a re not categorized on ATC-2 level as A16, J05 or LOl; c 
Variable is categorical and ratio of values adds up to 100%; (y) Variable is d ichotomous and va lue represents the "yes"; ¥ EPARs were not 






































1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Total 
Year 
■ EC/CA registered drugs that did not receive a DHPC □ EC/CA registered drugs that did receive a DHPC 
■ Regular registered drugs that did not receive a DHPC □ Regular registered drugs that did receive a DHPC 
Figure 1: Proportion of new active substances that obtained a marketing authorisation 
between 1999 and 2009 under exceptional circumstances / conditional approval or 
standard marketing authorisations with or without a DHPC. (Labels represent the 
absolute numbers.) 
approvals (14%, p=0.77). DH PCs for three EC approved drugs (drotecogin alfa, atazanavir and 
tenofovir) regarded lack of efficacy concerns in certain subpopulations. All other DHPCs 
concerned safety issues. 
The mean follow-up duration, from the date of approval to a first DHPC, withdrawal or end 
of study period, for EC/CA and standard approved drugs was 52 months {95% Cl: 42 ; 62) and 
55 months (95% Cl: 50 ; 60), respectively. The Kaplan Meyer derived probability for drugs 
receiving a DHPC was similar for both types of approval processes [Figure 2, log-rank 
p=0.726]. At 3 years follow-up drugs under EC/CA approval had a 7% {95% Cl: 0% ; 15%) risk 
of receiving a DHPC, while standard approvals had a 10% (95% Cl: 6% ; 14%) risk of receiving 
a DHPC. At 11 years follow up this risk was 26% (95% Cl: 8% ; 44%) for EC/CA approved drugs 
and 22% (95% Cl: 14% ; 29%) for standard approved drugs. 
The unadjusted hazard ratio (HR) for EC/CA drugs to receive a DHPC during the follow-up 
was 1.16 (95% Cl: 0.51 ; 2.62). When correcting for confounders the EC/CA drugs had a 0.94 
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(95% Cl: 0.40 ; 2.20) hazard ratio (HR) to receive a DHPC during the follow-up in the Cox 
proportional hazards model. From the confounders hypothesised to be present, the 
distribution of 'drug classes' (ATC-2 level) was significantly different between drugs 
approved under EC/CA and standard conditions (p<0.001), as the drug classes were 
specifically selected to have more than five drugs licensed under EC/CA. As could be 
expected EC/CA drugs were more likely to be orphan drugs (44%) than the drugs approved 
with standard procedure (14%, p<0.001) and more EC/CA drugs (83%) had safety 
populations that did not meet the ICH threshold of 1500 patients exposed to a new drug 
before approval than drugs approved with standard procedure (51%, p<0.001). For nine 
drugs we were unable to retrieve the variable 'size of the safety population' as scientific 
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Follow-up time [months] 
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EC/CA Exceptional circumstances and conditional approval marketing authorisations 
Figure 2: Proportion of new active substances authorised under exceptional 
circumstances/conditional approval (EC/CA) or standard conditions with a 
subsequent Direct Healthcare Provider Communication. 
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been withdrawn from the market. However, only drug class was associated with the 
issuance of a DHPC (p=0.014) and was subsequently included in the Cox model as a potential 
confounder [Table 1]. In the sensitivity analysis that incorporated all covariates the results 
were similar. The approval procedure did however not affect the issuance of DHPCs, for 
example 38% (3 of 8) EC/CA and 36% (4 of 11) HIV AIDS drugs approved with standard 
procedure received a DHPC. HIV/AIDS drugs had an increased risk of a DHPC, HR 3.07 (95% 
Cl: 1.28 ; 7.37) independent of the approval procedure. 
DISCUSSION 
In the EU drugs receiving approval through the Exceptional Circumstances or Conditional 
Approval procedure have a similar probability of a first serious safety issue requiring a DHPC 
as drugs approved with standard procedure in our 11 year follow-up study; 26% and 22% 
respectively. None of the EC/CA, but five of the drugs approved with standard procedure 
were withdrawn from the market because of safety concerns. 
In this direct comparison of approval procedures no association could be found between 
approval procedure and identification of serious safety issues post approval. Recent 
examples have shown the need for continuous monitoring of the benefit risk balance during 
the lifecycle of a drug. (7) This has led to a more proactive approach of pharmacovigilance 
through risk management plans. In the risk management plan, based on the knowledge of 
the drug's characteristics at the time of the approval gaps in data are identified, companies 
are required to obtain additional data on benefits and risks of the drug in daily practice or in 
post-marketing trial settings. (22,23) Since the EC/CA drugs have been approved on 
preliminary evidence, regulators usually require even stricter risk management plans. 
(12,13,24) This close follow-up is expected to be more sensitive in picking up important 
safety issues than routinely collecting spontaneous adverse drug reactions, which is the 
usual approach for drugs approved with standard procedure. 
Balancing this effect of close follow-up is that EC/CA drugs are generally intended to treat 
rare diseases and not all European countries reimburse conditionally approved drugs. 
Therefore, the population exposed to these drugs post-approval may still not be sufficiently 
large to detect less common adverse drug reactions. Heemstra et al. consider this a likely 
explanation for their observation of orphan drugs having fewer safety issues post approval 
so 
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than biologicals or [all] new drugs in cross study comparisons. (24) Supportive for their 
explanation is that they observed an association of safety-related regulatory action for drug 
classes with the highest expected use, those orphan drugs used within oncology and 
gastroenterology and metabolic indications (ATC classes L01/L02 and A respectively). In our 
study these drug classes and drugs to treat HIV/AIDS (ATC class JOS) were also over­
represented in the EC/CA group. Moreover, drug classes and specifically those involving the 
HIV/AIDS drugs, were shown to truly confound the results - for which we corrected in the 
Cox-proportional hazard model - as they also more frequently led to a DHPC. HIV/AIDS drugs 
are the most commonly used EC/CA drugs, which may indeed explain that rare but serious 
safety issues are picked up relatively early. Our data, however, also showed that for both 
HIV/AIDS and anti-cancer [data not shown] drugs the approval procedure did not predict 
whether serious safety issues were identified more readily post-approval. Unfortunately, 
data on drug usage could not be obtained. Many of the EC and CA licensed drugs are used in 
hospital setting and hospital drug consumption data is not readily available in the 
Netherlands or for the EU as a whole. Also, reimbursement is different across EU countries 
and associated prescription data difficult to obtain. This needs further study, perhaps in a 
setting where comprehensive total drug usage is available. Our results are in line with Richey 
et al. (25) who concluded that anti-cancer drugs approved with the accelerated approval 
were safe because none was withdrawn. They also confirm the more limited analyses by 
Boon et al.. (26) However, Boon et al. included in their assessment all withdrawals, not 
discriminating between withdrawals due to safety issues and withdrawals for commercial 
reasons. 
Our finding that EC/CA drugs that were approved with more limited clinical data sets are as 
safe as drugs approved with standard procedure seems at odds with the current societal 
demand for more pre-approval ascertainment of harms and benefits of new drugs. 
(10,11,27,28) This finding has important societal implications. The request for large-scale 
outcome studies for e.g. new drugs for diabetes may already be prohibitive even in a field 
with a large target population. Therefore, it is reassuring to learn that EC/CA registration 
with limited clinical data sets seems to have been safe in the past decade for drugs with high 
unmet medical need. 
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Reassuringly, only 3 DHPCs were issued because of efficacy concerns from confirmatory 
trials, indicating that the objective to allow early access of potentially effective drugs meets 
its expectations. 
Although we showed in an earlier study that approximately 10% of all marketed drugs 
throughout their life-cycle required safety-related regulatory action (7), we found in this 
study that for more recently approved drugs within 11 years after that approval the 
probability of requiring a DHPC is 26%. This is higher than reported earlier by Lasser et.al, (6) 
but in line with Giezen et al who reported similar probabilities for biologicals. (21) Lasser 
included all drugs on the market in the USA from 1975 to 1999, while the study done by 
Giezen was more recent and included only biological drugs approved in Europe and the USA 
between 1995 and 2007. Our finding is consistent with the increasing trend of regulatory risk 
communications (DHPCs) per year that we observed in our earlier study. (7) The difference 
between our results and Giezen et al.'s on one hand, and those of Lasser on the other, could 
be due to increasing risk awareness, or to the implementation of more sensitive 
pharmacovigilance tools 
With this apparent growing risk-awareness, it was remarkable that 51% of all drugs 
with regular authorisation did not meet the ICH guideline of at least 1500 subjects exposed 
to the drug in pre-approval trials (safety population), in particular because this ratio is rather 
constant throughout the study period [data not shown]. It would be a topic of future 
research to explore why the safety population is so limited in the marketing authorisation 
procedure. However, one must keep in mind that the safety requirements in the EU and ICH 
guidelines are merely a guide. A complete cure for a rapidly fatal disease would require 
relatively few patients, while, to establish clinical benefit, and an absence of harm, for a new 
surrogate endpoint may take many thousand patient years. 
Limitations of the study 
DHPCs might not be the most sensitive proxy for safety issues and could be handled or 
perceived differently for EC/CA drugs addressing 'unmet medical needs'. The acceptability of 
serious safety issues in the overall benefit/risk balance may be higher and could have a 
higher threshold for issuing a DHPC resulting in less strong safety-related regulatory action 
such as a change in the Summary of Product Characteristics. However, this does not become 
apparent when the observed safety issues reported for EC/CA are considered versus those 
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for regularly approved drugs. [Appendix] Furthermore, The DHPC is recommended as risk 
communication tool to guarantee continued safe use of a drug. (29) Other studies have used 
the DHPC as the most important proxy of serious safety issues. (6,21,24) It is the best we 
have as an overall measure that is going through a careful evaluation procedure at the EU 
level. 
We cannot be completely sure that drugs withdrawn from the market for commercial 
reasons do not also have a safety issue prompting the company's decision to withdraw the 
drug. However, in the reported cases the EMA press releases explicitly mentioned either that 
safety concerns were not the reason for withdrawal or that commercial reasons prompted 
the withdrawal. 
As mentioned, EC/CA drugs are used in relatively small patient populations, which reduces 
the chance of finding rare adverse events. Therefore, our conclusion for the EC/CA 
procedure does not imply that this procedure would be appropriate for all drugs. 
Conclusion 
Our study showed that the risk of receiving a DHPC is similar for those drugs licensed using 
Exceptional Circumstances and Conditional Approval and the drugs that were licensed using 
the standard procedure in the past 11 years in the EU. 
The use of Exceptional Circumstances and Conditional Approval should be continued, as it is 
valuable in allowing earlier entry to the market for eligible drugs that are mostly intended 
for rare diseases, without an apparent increased risk of unexpected serious side effects. 
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Background: The knowledge at the time of approval for more innovative drugs that are 
often first-in-class and have a new mechanism of action might not be as extensive as 
compared to less innovative drugs. Since pre-approval programs are inherently limited in 
establishing the full safety profile of any new drug, the more innovative drugs might have 
even more serious safety issues that are identified only post approval. 
Objective: To compare the frequency and timing of serious safety issues identified during 
the early and later stages post-approval for more innovative drugs versus less innovative 
drugs. 
Methods: A retrospective cohort study was performed that included all new active 
substances approved under the European Centralized Procedure (CP) and for which serious 
safety issues were identified post-approval from 1 January 1999 to 31 December 2011. 
Serious safety issues were defined as issues requiring a Direct Healthcare Professional 
Communication (DHPC) to alert individual healthcare professionals of a new serious safety 
issue, or a safety-related drug withdrawal. Data were retrieved from publicly available 
websites of the Dutch Medicines Evaluation Board and the European Medicines Agency. The 
level of innovation was scored using a validated algorithm, grading drugs as important (A), 
moderate (B) or modest (C) innovations or as pharmacological or technological (pharm/tech) 
innovations. The data were analyzed using appropriate descriptive statistics and Kaplan­
Meier analysis, with a Mantel-Cox log-rank test, and Cox-regression models correcting for 
follow-up duration, to identify a possible trend in serious safety issues with an increasing 
level of innovation. 
Results: A total of 279 new drugs were approved in our review period; 59 (21%) were graded 
A, 63 (23%) B, 34 (12%) C, and 123 (44%) as pharm/tech. Nine drugs were withdrawn from 
the market, and 53 drugs received one or more DHPC. Serious safety issues were identified 
for 15 (25%) drugs graded A, 13 (21%) graded B, 8 (24%) graded C, and 19 (15%) for the 
drugs graded as pharm/tech [p=0.12, linear-by-linear test]. The Kaplan Meyer derived 
probability for having a first serious safety issue was not statistically significant, log-rank 
(Mantel-Cox) p=0.067. In the final adjusted Cox proportional hazard model there was no 
statistically significant difference in occurrence of a first serious safety issue for the more 
innovative (A, B, and C) drugs when compared to the pharm/tech [reference] drugs; hazard 
ratios 1.63 (95%CI: 0.77; 3.43), 1.48 (95%CI: 0.71; 3.08)], and 1.16 (95%CI: 0.48; 2.82), 
respectively. 
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Conclusion: Slightly more than half of all new drugs approved in Europe can be considered 
as at least modest innovations that add value to the available drug armamentarium. A higher 
level of innovation was not clearly related to an increased risk of serious safety issues that 




It is estimated that a third of all drugs being approved in Europe can be considered 
important drug innovations. (1) These important drug innovations target diseases 
demonstrating major benefits on clinical endpoints or established surrogate endpoints for 
diseases where treatment is not available, at least not for important subgroups of patients. 
(1,2) They are often first-in-class and act through a new mechanism of action. As a result 
knowledge for these drugs at the time of approval might not be as extensive as compared to 
less innovative drugs, for which there are already more comparable substances approved. 
Any pre-approval clinical development program is limited in size, targets a specific 
population, and is primarily focused on establishing efficacy. (3) Especially for the innovative 
drugs the complete benefit-risk will only be fully established post-approval. Yet, innovative 
drugs are eagerly awaited by society with often high pressure to speed up development with 
rapid approval. As these drugs offer a potential therapeutic advantage to existing alternative 
treatment forms they may be rapidly taken up in clinical practice early after approval. 
Although serious safety issues can occur at any time throughout the lifecycle of a drug,(4) 
these innovative drugs may thus be at a higher risk of identification of serious safety issues 
early post-approval. New safety issues may be identified earlier in part due to their relative 
quick uptake,(S) but also because they are channelled to patient groups that are more 
difficult to treat, such as patients unresponsive to already available drug therapy or who 
cannot tolerate available therapy. These patients may be more vulnerable and experience 
more drug-related problems. (6) As experience grows with these drugs they will find their 
way to a more general patient population and any potential difference in susceptibility due 
to the treated population will disappear. (7) Previously, Tavassoli and Montastruc studied 
the relation between level of drug innovation and safety alerts as issued by the French Drug 
Agency, using the French National Authority for Health classification for the level of 
innovation, i.e. 'improvement in actual benefit'. They found an association with these alerts 
and the more innovative drugs and recommended to monitor these drugs more actively 
after approval. However, their study had a cross-sectional design and it is therefore unclear 
whether this observation applies to the early stages post-approval only. (S) 
The aim of this study is to compare the frequency and timing of serious safety issues 
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A retrospective cohort study was performed that included all new active substances 
approved under the European Centralized Procedure (CP} and associated serious safety 
issues that were identified post approval from 1 January 1999 to 31 December 2011. New 
active substances were defined according the limited definition of Eichler et al; i.e. excluding 
biosimilars. (8} In this paper the term drugs is used for new active substances. The level of 
innovativeness of drugs was determined using the algorithm developed by Motola by which 
drugs were graded as A} important, B} moderate, or C} modest innovations or as 
'Pharmacological' / 'Technological' innovations [See figure 1] . (1,2} In this paper we grouped 
the latter, i.e. pharmacological and technological (pharm/tech) innovations, resulting in four 
levels of innovation (A, B, C and pharm/tech}. For grading, drugs were first divided into three 
groups, depending on the availability of alternative treatment possibilities; group A}, drugs 
for diseases without available therapy, group B} drugs for subsets of patients unresponsive 
to available therapy, and group C} drugs with effective alternative therapy available. In the 
latter group class Cl drugs are more effective and/or safe than available alternatives, class 
C2 drugs only pharmacologically different (pharmacokinetics or mechanism of action}, and 
class C3 drugs that are only technologically different. Secondly, drugs were graded according 
to their demonstrated treatment effect; group A} with a major benefit on clinical endpoint, 
group B} with a partial benefit on disease or less robust demonstration of major benefit, and 
group C} with minor or temporary benefit on some aspects of the disease. The algorithm of 
Motola does not allow classification of vaccines and diagnostics, which for that reason were 
excluded from the analyses. 
Drugs approved up to 2004 have previously been classified by Motola and his group 
according to their own classification. (2} Drugs approved after 2004 were each classified 
independently by two assessors of the Dutch Medicines Evaluation Board and/or co-authors 
of this paper [PM, PV, PdG, AHA, DM]. The level of agreement in classifying the level of 
innovation was evaluated for a random subset of 20 drugs and was found to be adequate 
(kappa = 0.57). Therefore, in cases with disagreement all classifications were resolved in a 
consensus meeting with a minimum of three assessors. 
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Scientific and regulatory information on drugs was obtained from the European Public 
Assessment Report (EPAR). The EPAR is published at the EMA website 
(http://www.emea.europa.eu) and contains a summary report of the marketing application 
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Figure 1 Classification of drugs 
Algorithm used to assign the overa l l  score for innovation. Ava i lable treatments: A = drugs for 
d iseases without recognized standard treatment; B = d rugs for d iseases where subsets of patients are 
less responsive to marketed drugs and/or other medical i nterventions, C = drugs for d iseases 
responsive to marketed drugs or other medical interventions (Cl= more effective or safer than 
existing drugs; C2= mere pharmacological i nnovation, i .e .  drugs with better kinetics or new 
mechanism of action; C3= mere technologica l i nnovation, i .e .  a new chemica l or biotechnologica l 
product with therapeutic role simi lar to a l ready existing ones). Therapeutic effect: A = major benefit 
on c l in ica l end-points (e.g. increased surviva l rate and/or qua l ity of life) or va l idated surrogate end­
points; B = partial benefit on the disease (on c l in ica l or va l idated surrogate end-points) or l imited 
evidence of a major benefit ( inconsistent resu lts); C = m inor  or temporary benefit on some aspects of 
the d isease (e.g. only partial symptomatic re l ief of a serious disease) .  
[Figure reproduced with permission from Motola in Brit J C l in  PharP 2005(2)] 
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Outcome 
The primary endpoint was the identification of a first serious safety issue post approval. 
Serious safety issues were defined as issues requiring a Direct Healthcare Professional 
Communication (DHPC} to alert individual healthcare professionals to a new serious safety 
issue, or a safety-related drug withdrawal. DHPCs issued between 1 January 1999 and 1 
January 2012 were retrieved from the Dutch Medicines Evaluation Board website. 
(http://www.cbg-meb.nl) Only safety-related DHPCs were included; any DHPC related to 
administration of the drug, the pharmaceutical quality and /or the malfunctioning of a 
device (used to administer the drug) were excluded. In addition, DHPCs issued to inform 
healthcare professionals on the lack of efficacy of a drug were excluded. Whether a drug 
withdrawal was safety-related was determined from the related press release and the EPAR 
section 'Procedural steps taken and scientific information after approval' as retrieved from 
the EMA website. 
Time to the primary endpoint was defined as the time in months from the date of market 
approval to the date of a first DHPC or safety-related withdrawal, whichever came first. 
Key characteristics 
Drug and procedural characteristics that could be possible confounders in our analysis were 
retrieved. These key characteristics were chosen based on literature data that suggested an 
increased risk of drug safety issues that are identified post-approval; e.g. drug class,(4) and 
biological drugs. (9) A larger patient population exposed to a drug before or after approval, 
could be hypothesized to decrease respectively increase the likelihood of identifying new 
serious safety issues after approval. (l0)[Duijnhoven, in press] The 'channelling' 
phenomenon may be different for drugs that are used by highly specialized prescribers for 
rare diseases (orphan drugs), for drugs approved under 'exceptional circumstances (EC}' or 
with 'conditional approval (CA)'. (11) As of November 2005 Risk Management Plans (RMP) 
have become a requirement for new drug applications in Europe. This more pro-active 
approach in risk management could potentially result in identifying new safety issues earlier 
or more frequently. 
This resulted in the extraction of the following drug characteristics. Drug class was classified 
using the anatomical main group of the Anatomical Therapeutic and Chemical code (ATC-1 
level). Three classes (A, J and L) comprise more than 50% of all drugs and are separately 
presented, the rest of drugs are grouped in the 'other' category. Second, the type of 
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molecule, was categorised as either a biological or a small molecule, identified from the 
EPARs. Third, the number of drug users, determined from the Drug Information System of 
the Health Care Insurance Board. This database comprises drug dispensing data for 
reimbursed drugs in the ambulatory care setting of 26 Dutch health care insurance 
companies, covering nearly all 16 million of the Dutch population. 
(http://www.gipdatabank.nl) The number of drug users was split into tertiles, according to 
the median number of users per year during the period 2007 to 2011. A separate group was 
created for the group of drugs not covered by the database as some drugs were not 
reimbursed, not marketed in the Netherlands, or used solely in the hospital setting. Fourth, 
the size of the study population; i.e. the total number of subjects exposed to the drug for 
any duration in the clinical development program before approval. [Duijnhoven, in press] 
Three procedural issues were identified; orphan drug status (y/n), registration type; i.e. 
under exceptional circumstances or receiving conditional approval, and whether the drug 
had been approved after Risk Management Programs (RMPs) had become a requirement. 
Analysis 
Descriptive statistics, chi-squares and Kruskal-Wallis were used to describe differences in 
baseline characteristics, across the four different levels of innovation and for drugs with and 
without a first DH PC/withdrawal. The probability of drugs at different levels of innovation to 
reach the primary endpoint (first DHPC/safety withdrawal) is evaluated using Kaplan Meyer 
analysis correcting for follow-up duration; p-value was determined using the log-rank test 
using a trend-analysis. In a multivariable Cox proportional hazard model (HR and 95% Cl) the 
association between level of innovation and the primary endpoint was determined, 
correcting for the key characteristics. Characteristics were included in the model (model 1) if 
they were unevenly distributed across the different levels of innovation or with respect to 
the occurrence of a serious safety issue (p<0.05). Using backward stepwise regression, only 
those characteristics were retained in the model that contributed to the model at p<0.2 
(model 2). 
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RESULTS 
A total of 633 drugs obtained a marketing authorization between 1 January 1999 and 31 
December 2011, of which 354 were excluded [figure 2]. Of the remaining 279 new drugs, 59 
(21%) were graded as important (grade A), 63 (23%} as moderate (B), 34 (12%) as modest (C), 
or as 123 (44%) 'pharmacological / technological innovations (pharm/tech)' [table 1]. The 
number of new drugs approved between 1999 and 2011 ranged between 12 and 26 per year 
[figure 3]. 
Total number of EU 
reg istrations: 633 
Excluded: 354 
309 contained no New Active Substance 
1 OB generics 
1 27 duplicates 




New Active Substances 
included: 279 
Figure 2 Flow chart of study drugs 
Number of registrations with the European Medicines Agency (EMA) through the Centra l ised 
Procedure from 1 January 1999 to 31  December 2011 .  Dupl icates a re drugs registered under 
d ifferent trade names, known substances a re d rugs approved earl ier either through national 
approva l procedures (e.g. Tobi Podhaler conta ining tobramycin) and/ or that were approved earlier 
for a different indication under a d ifferent registration number (e.g. si ldenafil as Viagra™ for erecti le 
dysfunction and subsequently as Revatio™ for pulmonary hypertension), combinations with at least 
one new active substances were included in our  study (e.g. Tredaptive™ for dysl ip idaemia that 
contained the new active substance laropiprant in addition to the known substance nicotinic acid), 
but not those contain ing only known active substances 
In total 114 DHPCs were issued of which 25 DHPCs for 15 drugs were excluded. Nine DHPCs 
concerned the administration of the drug, ten concerned the pharmaceutical quality of the 
drug product and two concerned the malfunctioning of a device for the administration of the 
drug. Four DHPCs for two highly innovative drugs (drotecogin alfa, and tenofovir [n=3]) 
regarded concerns of demonstrated lack of efficacy and were also excluded. This resulted in 
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the inclusion of 53 first and 36 repeated DHPCs. Nine drugs (3.2% of all drugs approved) 
were withdrawn for safety-related reasons. Clear safety-related withdrawals were 
efalizumab, sitaxentan (both grade B), rimonabant, rosigl itazone, and valdecoxib 
(pharm/tech). In four cases marketing was considered no longer commercially viable, 
because the target population had become too limited but without the regulatory 
authorities actively suspending their marketing authorisation; darbepoetin alfa, epoetin 
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Figure 3 Level of innovation of drugs approved in Europe (1999 - 2011) 
Drugs a re new active substances that are approved through the centra l ised procedure in Europe. 
Classification of innovation according to Motola (2); A) important, B) moderate, C) modest or as 
Pharm or Tech) merely pharmacological / technologica l innovations. 
Fifty-five first serious safety events were identified, 53 first DHPCs and two safety-related 
withdrawals without a prior DHPC (the epoetins). Serious safety issues were identified for 15 
(25%) drugs graded A, 13 {21%} graded B, 8 (24%) graded C, and 19 (15%) for the drugs 
graded as pharm/tech [ p=0.40, Chi-square test, p=0.12 linear-by-linear association, table 2]. 
The median follow-up was 7.8 years (IQR: 4.0-10.4) for drugs graded A, 4.6 years (IQR: 2.4-
6.9) graded B, 4.2 years ( IQR: 3.2-7.2) graded C, and 7.3 years (IQR: 2.9-10.4) for the drugs 
graded as pharm/tech [p=0.01, Kruskal-Wallis test]. The Kaplan Meyer derived probability 
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for having a first serious safety issue, correcting for duration of follow-up, did suggest a 
trend in safety issues with increasing level of innovation, but was not statistically significant, 
log-rank (Mantel-Cox) p=0.067. Except for the biologicals, all characteristics were unequally 
distributed across the various levels of innovation (p<0.05) and therefore included in the 
multivariable Cox-model. [table 1] The key characteristics were equally distributed across 
drugs with or without serious safety issues. For six drugs we were unable to retrieve the 
number of subjects studied before approval as the scientific discussion had been removed 
from the EMA website after withdrawal of the products from the market. For these drugs we 
imputed the study population based on drugs approved within the same ATC-class 
(interferon alfacon-1 (1197), valdecoxib (3550), dofetilide (3410), apomorphine (2764) and 
fomivirsen (1328). Except valdecoxib all withdrawals were for commercial reasons and thus 
not recorded as a primary outcome. 
In the adjusted Cox proportional hazards model {model 1) there was no statistical significant 
difference in occurrence of a first serious safety issue across the more innovative (A, B, and C) 
drugs when compared to the pharm/tech [reference] drugs [table 2, figure 4]. The results 
remained similar in model 2 that in addition to the level of innovation, incorporated as 
confounders drug class, study population size and post RMP approval; with for grade A [HR 
1.63 {95%CI: 0.77; 3.43)], grade B [HR 1.48 (95%CI: 0.71; 3.08)], or grade C 1.16 (95%CI: 0.48; 
2.82) drugs [table 2]. Antineoplastic and immunomodulating drugs (ATC-class L), as well as 






T a b l e  1 :  
K e y  c h a r a c t e r i s t i c s  a c r o s s  i n n o v a t i o n  l e v e l  o f  d r u g s  i n  E u r o p e  ( 1 9 9 9 - 2 0 1 1 )  
A l l  d r u g s  I n n o v a t i o n  l e v e l  o f  d r u g s  N { % ) *  
N ( % ) *  I m p o r t a n t  ( A )  M o d e r a t e  ( B )  M o d e s t  




T o t a l  
2 7 9  { 1 0 0 )  5 9  ( 1 0 0 )  6 3  ( 1 0 0 )  3 4  ( 1 0 0 )  1 2 3  ( 1 0 0 )  
D r u g  c h a r a c t e ris t i c s  
D r u g  c l a s s e s  ( A T C - 1  l e v e l )  
< 0 . 00 1  
A l i m e n t a r y  t r a c t  a n d  m e t a b o l i s m  ( A )  3 9  ( 1 4 )  7  ( 1 2 )  7  ( 1 1 )  4  ( 1 2 )  2 1  ( 1 7 )  
A n t i - i n f e c t i v e s  f o r  s y s t e m i c  u s e  ( J )  
3 8  ( 1 4 )  
2 1  ( 3 6 }  
7  ( 1 1 )  1 (3) 9  ( 7 )  
A n t i n e o p l a s t i c  a n d  i m m u n e  
m o d u l a t i n g  a g e n t s  ( L )  
7 5  ( 2 7 )  2 3  ( 3 9 )  1 9  { 3 0 )  1 6  ( 4 7 )  1 7  { 1 4 )  
O t h e r  d r u g  c l a s s e s  * * *  
1 2 7  ( 4 6 )  
8  ( 1 4 }  
3 0 ( 4 8 }  
1 3  ( 3 8 }  7 6  ( 6 2 }  
N u m b e r  o f  d r u g  u s e r s  p e r  y e a r  
�  
< 0 . 0 0 1  
H o s p i t a l  u s e  o n l y  
o r  n o t  r e i m b u r s e d  i n  N L  121 (43) 3 1  ( 5 3 )  3 3  ( 5 3 )  1 8  ( 5 3 )  3 9  ( 3 2 )  
5 2 2 8  
5 3  ( 1 8 }  
1 4  ( 2 4 )  
1 5  ( 2 4 )  
8  ( 2 4 )  1 6  ( 1 3 )  
>  2 2 8  a n d  5 2 . 1 1 7  
5 3  ( 1 9 )  
1 2  ( 2 0 )  
8  ( 1 3 )  
5  ( 1 5 )  2 8  ( 2 3 )  
> 2 . 1 1 7  
5 2  ( 1 9 )  
2 (3) 7  ( 1 1 )  3 (9) 4 0  ( 3 3 )  
B i o l o g i c a l s  ( y )  
8 3  ( 3 0 )  
2 0  ( 3 4 )  
1 7  ( 2 7 )  1 0 ( 2 9 )  3 6  ( 2 9 )  0 . 8 6 6  
S i z e  o f  s t u d y  p o p u l a t i o n ,  m e d i a n  ( I Q R ) '  1 2 2 7  9 0 0  1 0 4 1  
1 1 5 5  
1 7 8 9  0 . 0 0 1  
( 5 2 2 - 2 4 3 7 )  ( 5 1 1 - 1 7 1 2 )  ( 3 7 3 - 2 1 5 0 )  ( 3 9 7 - 2 9 4 9 )  
( 7 3 5 - 3 4 1 0 )  
P r o c e d u r a l  c h a ra c t e r i s t ic s  
O r p h a n  d r u g s  ( y )  
5 9  { 2 1 )  1 5  ( 2 5 )  2 2  ( 3 5 )  
1 3  { 3 8 )  9  ( 7 )  < 0 . 00 1  
E C  a n d  C A  r e g i s t r a t i o n s  ( y )  4 7  ( 1 7 )  1 9  ( 2 2 )  1 8  ( 2 9 )  
7  ( 2 1 )  2  ( 2 )  < 0 . 0 0 1  
P o s t  R M P  a p p r o v a l  ( y )  1 3 9  ( S O )  
23 (39) 4 2  ( 6 7 )  2 2  ( 6 5 )  5 2  ( 4 2 )  0 . 00 1  
*  P e r c e n t a g e s  a r e  e x p r e s s e d  w i t h i n  d r u g s ,  a n d  l e v e l  o f  i n n o v a t i o n  ( c o l u m n ) ;  * *  p - v a l u e  b a s e d  o n  C h i - s q u a r e  ( c a t e g o r i c a l  d a t a )  a n d  K r u s k a l - W a l l i s  ( c o n t i n u o u s  d a t a )  
t e s t ;  * * *  A l l  d r u g s  t h a t  a r e  n o t  c a t e g o r i z e d  o n  A T C - 1  l e v e l  a s  A ,  J  o r  L ;  &  M e d i a n  n u m b e r  o f  u s e r s  p e r  y e a r  i n  t h e  N e t h e r l a n d s  b a s e d  o n  2 0 0 7 - 2 0 1 1  r e i m b u r s e m e n t  d a t a  
f r o m  t h e  D r u g  I n f o r m a t i o n  S y s t e m  o f  t h e  H e a l t h  C a r e  I n s u r a n c e  B o a r d ,  ( y )  V a r i a b l e  i s  d i c h o t o m o u s  a n d  v a l u e  r e p r e s e n t s  t h e  " y e s " ;  I Q R  I n t e r q u a r t i l e  r a n g e  s h o w i n g  
2 5
t h  
a n d  7 5
t h  
p e r c e n t i l e s ;  ¥ E P A R s  w e r e  n o t  a v a i l a b l e  f o r  s i x  d r u g s  t h u s  t h e  s i z e  o f  t h e  s t u d y  p o p u l a t i o n  c o u l d  n o t  b e  e s t a b l i s h e d .  F o r  t h e  a n a l y s e s  v a l u e s  w e r e  i m p u t e d  
b a s e d  o n  t h e  m e a n  n u m b e r  o f  p a t i e n t s  s t u d i e d  f o r  d r u g s  w i t h  t h e  s a m e  A T C - 5  o r  n e x t  t h e  s a m e  A T C - 3  l e v e l .  O n l y  i n  t h e  c a s e  o f  v a l d e c o x i b  w a s  t h a t  w i t h d r a w a l  s a f e t y -
r e l a t e d ;  E C  E x c e p t i o n a l  C i r c u m s t a n c e s ;  C A  C o n d i t i o n a l  A p p r o v a l ;  R M P  R i s k  M a n a g e m e n t  P l a n ;  t h i s  v a r i a b l e  i n d i c a t e s  w h e t h e r  d r u g s  w e r e  a p p r o v e d  a f t e r  R M P s  
b e c a m e  a  r e q u i r e m e n t  f o r  n e w  d r u g  a p p l i c a t i o n s  i n  t h e  E u r o p e a n  U n i o n  ( N o v  2 0 0 5 )  
Table 2: Are serious safety issues and level of innovation associated (Cox-proportional hazards analyses) for centrally approved 
drugs in Europe (1999-2011) 
All drugs Serious Safety issue (N%) Cox-proportional hazards analyses 
N(%)* yes no P** Model 1 Model 2 
Total 279 (100) 55 (100) 224 (100) 
Level of Innovation 0.4 
Important (A) 59 (21) 15 (27) 44 (20) 1.93 (0.85;4.410) 1.63 (0.77;3.43) 
Moderate (B) 63 (23) 13 (23) 50 (22) 1.84 (0.85;3.97) 1.48 (O. 71;3.08) 
Modest (C) 34 (12) 8 (15) 26 (12) 1.37 (0.55;3.38) 1.16 (0.48;2.82} 
Merely phormocologlcal or 123 (44) 19 (35} 104 (46} Reference Reference 
technological (pharm/tech) 
Drug characteristics 
Drug classes (ATC-1 level) 0.23 
Alimentary tract and metabolism (A) 39 (14) 6 (11) 33 (15) 1.08 (0.42; 2.81) 0.95 (0.38;2.39) iil 
Anti-infectives for systemic use (J) 38 (14) 10 (18) 28 (13) 1.42 (0.57;3.49) 1.65 (0.71;3.85) 3 
Antineoplastic and immune 75 (27) 19 (34) 56 (25) 2.06 (1.01; 4.23) 2.13 (1.05;4.31) It) 
modulating agents (L) 
Ill 
Other drug classes ** • 127 (46) 20 (36) 107 (48) Reference Reference 
Number of drug users per year& 0.1 iii. 
Ill 
Hospital use only 121 (43) 20(36) 101 (45) 1.03 (0.44; 2.44) 
Ill 
or not reimbursed in NL C: 
S228 53 (18) 9 (16) 44 (20) 1.07 (0.39; 2.97) It) 
> 228 and Sl.117 53 (19) 17 {30) 36 (16) 1.82 (0.74; 4.48) 
iD' 
> 2.117 52 (19) 9 (16) 43 (19) Reference C. 
Biologicals (y) 83 (30) 18 (33) 65 (29) 0.59 
"C 
Size of study population, median (IQR)� 1227 1308 1218 0.15 1.00 (1.00;1.00) 1.00 (1.00;1.00) 
� 
Ill 
(522-2437) (878-2801) (460 - 2347) 
"C 
"C 
Procedural characteristics < 
Orphan drugs (y) 59 (21) 11 (20) 48 (21) 0.82 0.82 (0.36;1.86) � 
EC and CA registrations (y) 47 (17) 8 (15) 38 (17) 0.67 1.48 (0.65; 3.36) Q 
Post RMP approval (y) 139 (SO) 22 (40) 117 (52) 0.1 1.62 (0.84; 3.15) 1.65 (0.89;3.07) 5· 
* Percentages are expressed within drugs, and level of innovation (column); ** p-value based on Chi-square (categorical data) and Kruskal-Wallis (continuous data) test; * **  All drugs that are < 
Ill 
not categorized on ATC-1 level as A, J or L; & Median number of users per year in the Netherlands based on 2007-2011 reimbursement data from the Drug Information System of the Health <' Care Insurance Board, (y) Variable is dichotomous and value represents the "yes"; IQR Interquartile range showing 25th and 75th percentiles; ¥EPARs were not available for six drugs thus the It) 
size of the study population could not be established. For the analyses values were imputed based on the mean number of patients studied for drugs with the same ATC-5 or next the same ATC- C. 
3 level. Only in the case of valdecoxib was that withdrawal safety-related; EC Exceptional Circumstances; CA Conditional Approval; RMP Risk Management Plan; this variable indicates whether i: 
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Figure 4 Proportion of first serious safety issue according to level of innovation 
(Model 2* :  adjusted Cox-proportional hazards model). 
Model 2 HR of level of innovation are corrected for drug group, size of study population and post RMP 
approval 
DISCUSSION 
Our data indicate that of all new drug approvals 21% can be considered important 
innovations, while nearly half (44%) can be considered as 'me too' (pharmacological or 
technological) developments. While 19% (53/273) of all centrally approved drugs received 
one or more DHPCs for a serious safety issue, only nine (3%) drugs were withdrawn. In 
contrast to our hypothesis, the level of innovation of drugs is not clearly correlated with 
serious safety issues that are identified post approval. 
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Serious safety issues have been suggested to be more common with biological agents versus 
small molecules, (9) while fewer issues were identified with orphan drugs. (11) A review of 
Canadian drug approvals indicated that priority review may increase the risk of serious 
safety issues being identified only until after approval. (12) In contrast, we showed earlier 
that drugs approved through EC or CA procedures that are aimed to facilitate drug approval 
for the same type of drugs in Europe did not show an increased risk. (13) The difference may 
be that in Europe the review period for this type of drugs is not necessarily shorter, allowing 
a robust assessment procedure. Our current findings indicate that also the level of 
innovation is not clearly related to the identification of serious safety issues post-approval. 
Possibly, this could be explained by the observed lower use of the more innovative drugs in 
ambulatory care. Nevertheless, in our adjusted analyses the level of use in clinical practice 
did not affect the risk of identifying serious safety issues. Therefore, the rapid uptake seems 
a less likely driver of an increased risk of identifying serious safety issues post approval. Also, 
channeling may not have played an important role, as neither the ECCA procedure -approval 
under exceptional circumstances or conditionally approved- nor orphan drug designation 
affected the model. These drugs are less likely to be channeled to higher risk populations 
post-approval than the patient population they were evaluated in pre-approval, as they are 
often used and reimbursed for very specific patients in highly specialized treatment centers 
only. Although, we were not able to prove our hypothesis our data suggest a slight trend, 
based on trend analyses (linear-by-linear association, and Mantel-Cox log-rank test) and 
incremental hazard ratios in model 2. The numbers in our study were necessary limited, due 
to the total number of drugs approved in our study period. Repeating this study in e.g. five 
years from now could result in that trend becoming statistically significant. Therefore, 
grading of level of innovation could be considered as a possible additional tool to guide 
problem-based risk management for new drugs that is currently done on a case-by-case 
basis. 
Only two of the studied characteristics were true confounders in the association of 
innovative drugs and a serious safety event. Not surprising, for antineoplastic and 
immunomodulating drugs we observed a doubling of the risk of a serious safety issue post 
approval that was independent of the level of innovation. These drugs have been shown to 
be more commonly associated with safety-related regulatory actions. (4)(14) Still, 
accelerated approval of cancer drugs was considered safe, since only few drugs were 
withdrawn. (14} More surprising was that a larger size of the pre-approval study population 
73 
Chapter 4 
was associated with an increased risk of a serious safety issue. The numbers studied pre­
approval were larger for the drugs graded as pharm/tech innovations, with only small 
differences between the other levels. The 'me-too' products are developed to get a share of 
large drug markets and can therefore easily include more patients in the clinical 
development program without really contributing to new drug safety knowledge. Our 
finding suggests that increasing the number of study patients pre-approval should be done 
with clinical judgment and is not necessarily predictive for identifying important but rare 
adverse drug events. 
Over time there was no apparent pattern of more innovative drugs being approved, 
although it may be of some concern that the overall proportion of innovative drugs is lower 
than that reported in 2006. (1) This finding fits in the debate about the declining efficiency in 
drug development, drug approval success rates and lack of truly novel drug products and 
warrants further consideration. (8,15,16) Although, for approximately a fifth of all drugs a 
new serious safety issue was identified post-approval, this only resulted occasionally in the 
drug being withdrawn from the market. The lowest tolerance was possibly for the less 
innovative drugs that made up six of the nine withdrawals. 
Limitations 
Our study was limited to centralised products in Europa, which does not - especially in the 
earlier period - cover all important new drug approvals across the various European 
countries. This is however, unlikely to have affected our primary analysis as there seems to 
be a random variation in the level of innovation across the study years. We studied the 
duration from time of approval to the first serious safety issue. Therefore, as the total 
follow-up period, i.e. until the end of the study period, was similar (six to seven years) for 
both highly innovative and all other drugs this should allow for a proper analysis of time to 
event. The power of the study to detect differences may have been limited. However, we 
based our analysis on the total number of approved products in Europe, almost from the 
inception of the EMA in 1996. We argue that if a difference cannot be observed after 13 
years of follow-up this difference may be less relevant. 
Any assessment has an inherent level of subjectivity to it. The classification used by us is no 
exception. We performed independent assessments for each drug and resolved any 
discrepancies in consensus. A further shortcoming is the retrospective nature of assessing 
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the level of innovation. However, the EMA keeps the EPARs of the original market 
application at its website which we used for assessing innovativity at time of the initial 
approval. Whereas healthcare technology assessment agencies overseeing national 
reimbursement of drugs have their own grading system of a drug's innovativety or added 
value there is no system adopted by EMA or one European accepted classification procedure. 
It may be worthwhile to come to a single European procedure that may be useful for both 
problem-based risk management and as a comparative indicator for reimbursement 
decisions. Finally, we used a national drug use database, based on reimbursement claims, in 
ambulatory care as a proxy for exposure. This is not representative for the whole of Europa 
or for world-wide uptake. In addition, some drugs are limited to use in hospital, but their use 
may be considerable. 
Conclusion 
Although, our study showed that fewer drugs represent important drug innovations than in 
2006, more than half of all new drugs approved in Europe can be considered at least modest 
innovations that add value to the available drug armamentarium. Contrary to our hypothesis, 
a higher level of innovation was not clearly related to an increased risk of serious safety 
issues that are identified post marketing. Innovation does not go together a priori with an 
increased risk of serious safety issues identified post marketing. 
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APPENDIX TABLE: LIST OF DRUGS WITH OR WITHOUT SERIOUS SAFETY ISSUES AND CLASSIFICATION OF LEVEL OF INNOVATION 
Level of Innovation (grade) 
With serious safety issue 
Important (A) 
n=15 




Merely pharmacological or  
technological innovations 
n=19 




miglustat, voriconazole, atazanavir, tipranavir, abacavir, tenofovir, trastuzumab, a lemtuzumab, imatinib, 
sunitin ib, nata l izumab, etanercept, infl iximab, verteporfin, pal ifermin 
rimonabant, tigecycl ine, entecavir, telbivudine, etravi ri ne, bevacizumab, erlot in ib, bortezomib, efa l izumab, 
lenal idomide, ranibizumab, deferasirox, dexrazoxane 
methylna ltrexone, dabigatran, romiplostim, becaplermin, panitumumab, temsiro l imus, adal imumab, 
toci l izumab 
insul in human ( inhalation ), rosiglitazone, pioglitazone, eptifibatide, prasugrel, epoetin delta, darbepoetin 
a lfa, dronedarone, sitaxentan, daptomycin, s iro l imus, leflunomide, anakinra, valdecoxib, parecoxib, 
zoledronic acid, d ibotermin  alfa, strontium ranelate, a rip iprazole 
carglumic acid, agalsidase a lfa, protein C aga lsidase beta, a lglucosidase a lfa, sodium phenylbutyrate, 
n itisinone, drotrecogin a lfa, protein C, caspofungin, ribavirin, amprenavir, lopinavir /ritonavir, fosamprenavir, 
darunavir, te laprevir, boceprevir, adefovir, emtricitabine, efavirenz, r i lpivirine, 
emcitrabine/ri l pivi rine/tenovofir, enfuvirtide, raltegravir, maraviroc, pemetrexed, clofaribine, vinflunine, 
cabazitaxel, i pi l imumab, bexarotene, arsenic trioxide, eribul in, abiraterone, tumor necrosis factor a lfa-la 
(tasonermin), dacl izumab, belatacept, canakinumab, ri lonacept, pirfenidone, botul inum toxin type B, 
































A P P E N D I X  T A B L E  ( C o n t ) :  L I S T  O F  D R U G S  W I T H  O R  W I T H O U T  S E R I O U S  S A F E T Y  I S S U E S  A N D  C L A S S I F I C A T I O N  O F  L E V E L  O F  
I N N O V A T I O N  
L e v e l  o f  I n n o v a t i o n  ( g r a d e
)  
D r u g s  
M o d e r a t e  ( B )  
n = S O  
M o d e s t  ( C )  
n = 2 6  
M e r e l y  p h a r m a c o l o g i c a l  o r  
t e c h n o l o g i c a l  i n n o v a t i o n s  
n = 1 0 4  
p r u c a l o p r i d e ,  a p r e p i t a n t ,  t o c o f e r s o l a n ,  l a r o n i d a s e ,  i d u r s u l f a s e ,  s a p r o p t e r i n ,  a n t i t h r o m b i n  a l f a ,  t i c a g r e l o r ,  C l  
i n h i b i t o r  h u m a n ,  e l t r o m b o p a g ,  c o n e s t a t  a l f a ,  d o f e t i l i d e ,  i v a b r a d i n e ,  i c a t i b a n t ,  t o l v a p t a n ,  r e t a p u m u l i n ,  a t o s i b a n ,  
m e c a s e r m i n ,  a z t r e o n a m ,  t e l a v a n c i n ,  p a l i v i z u m a b ,  n e l a r a b i n e ,  a z a c i t i d i n e ,  c a t u m a x o m a b ,  o f a t u m u m a b ,  5 -
a m i n o l e v u l i n i c  a c i d ,  t e m o p o r f i n ,  s o r a f e n i b ,  n i l o t i n i b ,  e v e r o l i m u s ,  p a z o p a n i b ,  m i t o t a n e ,  e c u l i z u m a b ,  f i n g o l i m o d ,  
u s t e k i n u m a b ,  e p t o t e r m i n  a l f a ,  z i c o t o n i d e ,  l e v e t i r a c e t a m ,  d u l o x e t i n e ,  v a r e n i c l i n e ,  a m i f a m p r i d i n e ,  f a m p r i d i n e ,  
r o f l u m i l a s t ,  n i t r i c  o x i d e ,  f o m i v i r s e n ,  b r i n z o l a m i d e ,  b i m a t o p r o s t ,  p e g a p t a n i b ,  d e f e r i p r o n e ,  i b r i t u m o m a b  
b e t a i n e ,  g a l s u l f a s e ,  z i n c  a c e t a t e ,  b i v a l i r u d i n ,  r i v a r o x a b a n ,  r a n o l a z i n e ,  c i n a c a l c e t ,  d o r i p e n e m ,  t e m o z o l o m i d e ,  
t r a b e c t e d i n ,  c e t u x i m a b ,  p o r f i m e r ,  g e f i t i n i b ,  l a p a t i n i b ,  a l i t r e t i n o i n ,  a n a g r e l i d e ,  m i f a m u r t i d e ,  p l e r i x a f o r ,  a b a t a c e p t ,  
b e l i m u m a b ,  f e b u x o s t a t ,  d e n o s u m a b ,  s t i r i p e n t o l ,  m e m a n t i n e ,  s o d i u m  o x y b a t e ,  t a f a m i d i s  
p a l o n o s e t r o n ,  f o s a p r e p i t a n t  d i m e g l u m i n e ,  i n s u l i n  h u m a n  ( f a s t  a c t i n g ) ,  i n s u l i n  l i s p r o ,  i n s u l i n  a s p a r t ,  i n s u l i n  g l u l i s i n e ,  
i n s u l i n  h u m a n  ( i n t e r m e d i a  a c t i n g ) ,  i n s u l i n  a s p a r t  n o v o m i x ,  i n s u l i n  g l a r g i n e ,  i n s u l i n  d e t e m i r ,  s i t a g l i p t i n ,  v i l d a g l i p t i n ,  
s a x a g l i p t i n ,  l i n a g l i p t i n ,  n a t e g l i n i d e ,  e x e n a t i d e ,  l i r a g l u t i d e ,  v e l a g l u c e r a s e  a l f a ,  i l o p r o s t ,  p r a s u g r e l ,  t e n e c t e p l a s e ,  
a p i x a b a n ,  f o n d a p a r i n u x ,  h u m a n  f i b r i n o g e n  /  h u m a n  t h r o m b i n ,  m o r o c t o c o g  a l f a ,  o c t o c o g  a l f a ,  h u m a n  c o a g u l a t i o n  
f a c t o r  I X ,  e p o e t i n  t h e t a ,  m e t h o x y  p o l y e t h y l e n e  g l y c o l - e p o e t i n  b e t a ,  v e r n a k a l a n t ,  b o s e n t a n ,  a m b r i s e n t a n ,  a z i l s a r t a n ,  
a l i s k i r e n ,  n i c o t i n i c  a c i d /  l a r o p i p r a n t ,  e f l o r n i t h i n e ,  e t h i n y l e s t r a d i o l  a n d  n o r e l g e s t r o m i n ,  u l i p r i s t a l ,  l u t r o p i n  a l f a ,  
c h o r i o g o n a d o t r o p h i n e  a l f a ,  c o r i f o l l i t r o p i n  a l f a ,  b a z e d o x i f e n e ,  l a s o f o x i f e n e ,  o x y b u t y n i n ,  d a r i f e n a c i n ,  f e s o t e r o d i n e ,  
a p o m o r p h i n e ,  t a d a l a f i l ,  v a r d e n a f i l ,  s i l o d o s i n ,  s o m a t r o p i n ,  g a n i r e l i x ,  c e t r o r e l i x ,  t e r i p a r a t i d e ,  p a r a t h y r o i d  h o r m o n e ,  
e r t a p e n e m ,  t e l i t h r o m y c i n ,  f i d a x o m i c i n ,  p o s a c o n a z o l e ,  m i c a f u n g i n ,  a n i d u l a f u n g i n ,  o s e l t a m i v i r ,  h u m a n  n o r m a l  
i m m u n o g l o b u l i n ,  b u s u l f a n ,  c l a d r i b i n e ,  c y t a r a b i n e ,  c a p e c i t a b i n e ,  t e g a f u r / g i m e r a c i l / o t e r a c i l ,  d o x o r u b i c i n ,  d e g a r e l i x ,  
p e g f i l g r a s t i m ,  i n t e r f e r o n  a l f a - 2 b ,  i n t e r f e r o n  a l f a c o n - 1 ,  p e g i n t e r f e r o n  a l f a - 2 a ,  p e g i n t e r f e r o n  a l f a - 2 b ,  c e r t o l i z u m a b  
p e g o l ,  g o l i m u m a b ,  c h a r a c t e r i s e d  v i a b l e  a u t o l o g o u s  c a r t i l a g e  c e l l s  e x p a n d e d  e x  v i v o  e x p r e s s i n g  s p e c i f i c  m a r k e r  
p r o t e i n s  ( C h o n d r o C e l e c t ) ,  c a p s a i c i n ,  z o n i s a m i d e ,  p r e g a b a l i n ,  l a c o s a m i d e ,  r e t i g a b i n e ,  r o t i g o t i n e ,  r a s a g i l i n e ,  
a s e n a p i n e ,  p a l i p e r i d o n e ,  z a l e p l o n ,  d e x m e d e t o m i d i n e ,  a g o m e l a t i n e ,  m e m a n t i n e ,  d i h y d r o a r t e m i s i n i n  /  p i p e r a q u i n e ,  
f l u t i c a s o n e  f u r o a t e ,  i n d a c a t e r o l ,  d e s l o r a t a d i n e ,  n e p a f e n a c ,  b r o m f e n a c ,  t r a v o p r o s t ,  e m e d a s t i n e ,  o l o p a t a d i n e ,  
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Part I I  
Regulators base their decision to approve new drugs on an assessment of benefit risk 
balance at the population level as determined in clinical trials. Doctors and patients make 
their decisions at the individual level. Doctors base their decisions to a large part on 
evidence based guidelines, applying these to individual patients, while patients have to 
integrate drugs in their daily life. Some regulatory decisions have been criticised as the 
conclusion on a drug's benefit/risk balance are not always shared by doctors, patients or 
society at large. Demonstration of different views raises doubts whether regulators are 
sufficiently in touch with the clinical reality of doctors and patients. Are their different views 
the result of making decisions at the population level instead of the individual patient level 
or do regulators genuinely value benefits and risks of drugs differently from other 
stakeholders? We therefore wanted to study the (dis)agreement in values that regulators 
attach to different drug effects in comparison to doctors and patients, at the level of an 
individual patient. To do so we performed a discrete choice survey where regulators, doctors 
and patients were asked which of two hypothetical OADs with varying drug effects they 
preferred for a typical patient with type 2 diabetes. 
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Chapter 5: 
Selecting drug effects 




Discrete choice models is a widely used method to elicit preferences. (1) Discrete choice 
models consist of providing respondents a choice between two or more options. In this 
study these options were drugs that were described in scenarios with relevant attributes, i.e. 
drug effects. Every attribute (drug effect) is varied at different levels and shown to 
respondents in a set of different scenarios. Respondents are given these scenarios in pairs 
from which to choose the scenario they prefer most. The strength of the method is that it 
provides information on the relative importance of the attributes. It is therefore a valuable 
approach to understand how trade-offs are made when weighing benefits and risks of drugs 
by the different stakeholder involved; regulators, doctors and patients. The relevance of the 
results of such discrete choice models is determined by the relevance of the selection of 
relevant attributes and the corresponding levels of these attributes. These should reflect 
actual important decision criteria of the respondents. (1,2) 
In this chapter we describe how we selected the attributes and levels used in our discrete 
choice surveys. As in this case the benefit risk balance is the central issue, the attributes 
refer to drug effects, effectiveness and safety. 
Regulators base their decision to approve new drugs on an assessment of benefit risk 
balance at the population level as determined in clinical trials. Doctors and patients make 
their decisions at the individual level. Doctors base their decisions to a large part on 
evidence based guidelines, applying these to individual patients, while patients have to 
integrate drugs in their daily life. In order to provide a common ground for decision, we 
described a hypothetical patient that we ask the respondents to keep in mind while making 
their decisions. In this chapter we also describe how we formulated this hypothetical patient. 
The aim of this part of the study is to identify relevant decision criteria, and the 
corresponding levels to include in the model. In addition we describe the development of 
the patient hypothetical which is constant for all choices. 
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METHODS 
We used a qualitative approach, combining literature review with in-depth interviews of 
relevant stakeholders. 
Literature search 
A search was done in Medline for studies using the discrete choice methodology to assess 
preferences for oral anti-diabetes drugs, spanning the years 2000 to 2011. From the studies 
found we determined which drug effects and characteristics had previously been used as 
attributes in discrete choice surveys regarding drug treatment in diabetes. 
Review of regulatory documents 
The regulatory guideline on clinical investigation of medicinal products in the treatment or 
prevention of diabetes mellitus was reviewed for the requirements of demonstrating 
minimal efficacy and possible side effects. Results from the interviews also prompted a 
review of the relevant guidelines for weight reducing agents. The Summary of Product 
Characteristics for anti-hyperglycaemic drugs on the Dutch and European market were 
reviewed and main benefits and harms extracted. 
Qualitative study, using in-depth interviews 
Open interviews, using a topic guide, were performed with a purposeful sample of 
individuals that are representatives of stakeholder groups in diabetes care; patients with 
type 2 diabetes, nurses involved with diabetes care, general practitioners (GPs), internists 
involved in diabetes care and specialists involved with assessment of diabetes drugs from 
the Dutch Medicines Evaluation Board. The interviews took place at the participant's home, 
at their place of work or in a meeting facility at the researchers' workplace. Participants 
were interviewed independently by MMS (7) or SP (13) both observed by AHA. One 
participant was interviewed by AHA alone. The study is based on grounded theory (3) and 
the topic guide thus re-evaluated and amended after each interview to reflect new topics 
arising in each interview. Respondents were included until no new information was provided 
by the interview. 
Respondents were asked open questions on how they value each drug effect for the 
treatment of type two diabetes mellitus. The interviewer used a list of topics that were 
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identified from literature(4-9) and in theory would be considered important and probed for 
the respondents' views on those topics. 
The topic guide consisted of the following themes: efficacy, safety, ease of use, costs and the 
role of the regulator. (see appendix A,B and C). 
The interviews were recorded using a digital voice recorder, transcribed per verbatim and 
analysed using the "three-step" method: First the transcripts were read to familiarize with 
the content, secondly statements were coded and thirdly themes were identified from the 
coding. 
Compiling the attribute list 
A list of possible attributes, i.e. drug effects was compiled from the results of the literature 
search, review of regulatory documents and the interviews. The list was then narrowed 
down to 6 attributes during a discussion within the project team as generally, 6-7 attributes 
are advised, with no more than 3-5 levels each. (1) 
Creating the hypothetical patient 
The hypothetical patient is constructed based on the 'average' DM2 patient. This was based 
on data from the Groningen Initiative to Analyse Type 2 diabetes Treatment (GIANTT). 
GIANTT includes over 20.000 patients with type 2 diabetes in GP practices in the northern 
part of the Netherlands and collects from electronic health records . 
RESULTS AND DISCUSSION 
literature search 
We found four studies using a discrete choice design for eliciting preferences in diabetes 
treatment (table 1). All four studies included glycated haemoglobin (HbAlc) value, nausea or 
stomach upset and incidence of hypoglycaemias in their list of drug effects. Overall 14 drug 
attributes were used in these four studies. All studies included changes in HbAlc, frequency 
of hypoglycaemias and gastro-intestinal (GI) problems. (10-13) Three studies included 
changes in weight (10,11,13) and two studies included mode of administration, frequency of 
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Table 1:Attributes used in previous discrete choice surveys regarding diabetes 
Authors 
Hauber et.a l  (10) 
Jendle et.a l  (11)  
Polster et.a l  (12) 









Number of 'hypos' per month 
Water retention 
Weight gain in first 6 months 
Mild stomach upset 
Chance of a heart attack with in 1 year 
Mode of administration 
Blood glucose monitoring 
Payment per month 








Control of glucose levels 
Incidence of nausea 
I ncidence of hypoglycaemia 
Mode of admin istration 
Blood glucose mon itoring 
Payment per month 







Driver's l icence 
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Table 2: Drug groups for the treatment of diabetes 
Drug (group) Function Main advantages Main ADES 
Biguanides .U. hepatic glucose production Effect on CV risk shown GI complications 
(Metformin) Little risk of hypos Lactic acidosis 
No weight increase 
Positive effect on lipids 
Sulfonylureas fi pancreatic insulin OK in decreased kidney Hypoglycaemia 
(glibenclamide, gliclazide, production function (repaglinide) Weight gain 
glimepiride, tolbutamide & 
repaglinide) 
Thiazolidinediones (THZ) Improve insulin resistance OK when metformine Weight gain 
(rosiglitazone, (nuclear hormone receptors or SU derivates are not Congestive Heart 
pioglitazone) and changes in gene Little risk of hypos Failure 




lncretin mimetics .U. glucagon secretion and Weight loss GI complications 
(exenatide, liraglutide) fi insulin secretion. Little risk of hypos 
DPP-4 inhibitors .U. degradation of incretins No weight increase Hypersensitivity 
(sitagliptin, vildagliptin, No GI problems Pa ncreatitis 
saxagliptin) 
a-glucosidase inhibitors .U. digestion of carbohydrate ➔ Little risk of hypos GI complications 
(Acarbose) .U. absorption of glucose No weight increase (severe) 
Insulin fi blood insulin Maximum control Weight gain 
Positive effect on lipids Hypoglycaemia 
blood glucose monitoring, patient payment per month, antihypertensive treatment, blood 
pressure and heart function in the terms of improvement in how far the patient can walk 
without exertion. (11,13) Water retention (10), increased risk of a heart attack (10), 
frequency of dosing (12) and the ability to keep their drivers licence (13) were included by 
one study each. 
86 
Selecting drug effects for a discrete choice study 
Review of regulatory documents 
The regulatory guideline directly relating to clinical development of anti-hyperglycaemic (14) 
is the guideline on clinical investigation of medicinal products in the treatment of diabetes 
mellitus. According to the guideline, the main efficacy parameter to be determined for 
registration of oral anti-diabetes drugs (OAD) is the effect on blood glucose control in terms 
of decrease in HbAlc. Hypoglycaemia is considered an important safety parameter and is 
also discussed specifically in the guideline, as well as cardiovascular (CV) risk. (14) 
The regulatory guideline directly relating to clinical development of weight reducing agents 
is the guideline on clinical evaluation of medicinal products used in weight control. 
According to the guideline, weight loss is the primary endpoint and drugs that are to be 
registered as weight reducing agents need to demonstrate at least a weight loss of 10% of 
the baseline weight (and at least 5% greater than a placebo) in a 12 month period. (15) 
The review of summary of product characteristics of OADs and insulin resulted in a summary 
of the mechanism of action, the main advantages and main disadvantages of each drug 
group [table 2]. The main adverse drug reactions of the groups are symptomatic, such as GI 
complications, hypoglycaemia and weight gain, although some drug groups did have 
uncommon serious adverse drug effects listed, such as lactic acidosis, bladder cancer and 
hypersensitivity. Only one drug, metformin, has shown to reduce the risk of experiencing 
cardiovascular events. (16) 
Qualitative study, using in-depth interviews 
A total of 22 interviews were performed, involving three specialists from the Dutch 
Medicines Evaluation Board (MEB), four practicing internists (all male, 5 to 24 years of 
experience), five practicing General Practitioners (GPs) (20% female, 1 to 34 years of 
experience), two diabetes nurses and one specialized GP assistant (67% female, 9 to 16 years 
of experience), one pharmacist (male, 11 years of experience) and six patients with type II 
diabetes (50% female, age range 56 - 85 years). 
Table 3 provides a summary of the most relevant criteria mentioned by the respondents, 
illustrated by quotes from the different groups. 
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With regards to efficacy the respondents mostly mentioned expectation of glucose control 
and weight loss (Table 3). Expectations of stopping disease progression and long term effect 
were also expressed, as well as expectations of effect on complications. 
With regards to safety the respondents mostly mentioned that safety and efficacy should be 
balanced. Healthcare professionals and regulators acknowledged that there is an aspect of 
uncertainty regarding safety of drugs and some expressed reluctance to use a drug due to 
lack of knowledge of (long term) safety and efficacy. Symptomatic ADEs were considered to 
be manageable by respondents from all groups, for example by dose-adjustments or 
switching to another medicine. 
Some respondents expressed the wish to avoid hypoglycaemias. Risk awareness of drugs 
new to the market clearly differed with some respondents expressing high risk awareness, 
while others, notably some of the patients, did not. 
With regard to ease of use the respondents mostly mentioned that fewer administrations 
per day were preferred. When probed further most respondents had positive opinions on 
fixed combination products, although negative opinions were also expressed. Respondents 
found that dosing frequency was very important and that taking drugs should not interfere 
with a patients' daily life. Regulators indicated that other drug effects have a higher priority 
than issues of ease of use, although one regulator shared with other stakeholders the view 
that a drug should not interfere with daily life. 
Aspects regarding costs were not discussed if not prompted. When asked some respondents 
found that patient participation in costs would be a hindrance to using the drug, while 
others did not see that as a problem. 
An additional topic arose in the interviews and was added to the topic guide, stakeholder's 
attitude towards patient registries as a method for post-marketing surveillance. When asked, 
most stakeholders had a positive view of introducing patient registries as a requirement for 
prescriptions of new OADs, provided that it would not take too much time and provided that 
the information could not be traced to individual patients. 
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Table 3:Examples of respondent remarks. 
Drug related properties (efficacy) 
Expectations of glucose control 
Expectations of effect on 
complications 
Expectations of long term effect 
Expectations of stopping 
progression 
Expectations (desire) of weight loss 
due to drug 
Drug related properties (safety) 
Safety and efficacy need to be 
balanced 
Symptomatic ADEs manageable 
Adjusting dose or changing 
medication to avoid ADEs 
Avoidance of hypo's 
Reluctance due to lack of (long 
term) knowledge (safety and 
efficacy) 
Acknowledgement of uncertainty 
New drugs are not risky 
New drugs are/can be risky 
Well, mainly that it needs to bring the HbAlc down, as an example 
[internist] 
... the applicant should show that HbAlc is going down, to well, at 
least 0.5%, for a large population [Assessor] 
... you would like to know that something is known on [the impact on] 
secondary endpoints in the sense of micro- and macro-vascular 
complications [GP] 
You don't only want to know what it does now, but also what the 
effect is after 10 years [GP] 
... that the drug will be able to stop the deterioration of the beta cell 
function, what causes the progression of the disease and causes 
patients needing to take always more tablets [internist] 
... because of the fact that I lose weight using it, and that has always 
been a problem for me [Patient] 
... if quite a lot of patients experience, diarrhoea or something ... and 
then if the efficacy is only minor, well that might influence then the 
decision for approval or not [Assessor] 
Maybe I would be satisfied with a drug that is less effective, as long as 
it has fewer adverse effects [GP] 
... when you see that with GLPl [drugs] at first all adverse effects such 
as diarrhoea and those kind of things occur, but knows that these 
disappear after some time, then - you can still sell that your patients 
[Internist] 
... yes, and therefore I have also had a brother or a sister of Victoza 
[Patient] 
Of course you also want to avoid complaints of hypoglycaemia [GP] 
You know what you have, but not what you are getting [Nurse] 
... you don't want to stop development of new drugs ... But on the 
other hand you don't want to expose your patients to risks that might 
have been discovered if they had analyzed better [GP] 
Earlier we also started using metformine even if we did not know if it 
was useful in the long term. We started using SU derivatives, not 
knowing if they were useful. .. [SU derivatives] even seemed harmful 
and yet we prescribed them [Internist] 
No, I did not think it was risky (starting to use a drug that was new to 
the market) [Patient] 
[Asked if prescribing new drugs is risky] Yes! [GP] 
[Asked if a new drug to the market carries risks] Of course! [Assessor] 
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Table 3:Examples of respondent remarks. (cont'd) 
Drug related properties {ease of use) 
Positive view of combinations 
Negative view of combinations 
Fewer dosings per day preferred 
Dosing routine is important 
Drugs should not interfere with daily 
life 
Drug related properties {costs) 
Patient payments a hindrance 
Patient payments not a hindrance 
Compiling the attribute list 
That both drugs can be in one tablet, that would be nice [Patient] 
I think that generally in well controlled patients, with a chronic 
disease, there certainly is room for [FDCs] [GP] 
I never prescribe Fixed Dose Combinations (FDCs)! [GP] 
.. . then you might have to swallow a lesser amount with the same 
effect [Patient] 
It is easier for your routine to take one pill a day, than to take one 
pill a week. I can imagine that you would forget your once weekly 
pill [GP] 
... if patients are using insulin, then, they have to control themselves 
so many times a day . . .  the patients should live ... without controlling 
himself every moment [Assessor] 
... Sometimes you have to take your  medicine in the presence of 
someone else [due to circumstances], I always try to do that a bit 
sneaky and now I don't have to because I take it only once a day 
[Patient] 
Only financially it is just not feasible for me [to pay the drug myself] 
[Patient] 
But it could also be that people say "yes but I do not want to wait 
any longer, I want to start already." Okay, you can, but you must pay 
for it yourself first [Nurse] 
After consideration of the interviews and results from the literature search, we compiled a 
list of possible attributes to include to depict a glucose lowering drug. This list comprised of 
13 attributes; Change in HbAlc, effect on complications, effect on CV risk, mechanism of 
action, positive adverse effects, transient adverse events, persistent adverse events, 
uncertainty about safety of newly marketed drugs, extent of clinical trials performed, plans 
for post-marketing follow-up, dosing frequency, method of administration, ease of use and 
costs. 
Thirteen attributes is too much to include in any discrete choice model. With 13 attributes, 
respondents would not be able to make decisions based on all of them and would revert to 
excluding some of them or decide not to participate. Generally, 6-7 attributes are advised, 
with no more than 3-5 levels each. (1) We therefore needed to narrow our selection down to 
6 attributes. The attributes selected should be relevant in the registration setting, as well as 
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for doctors and patients. The levels chosen for each attribute should be based on what has 
been seen for diabetes drugs or the requirements needed for registration. 
Inclusion criteria were that different stakeholders would at least have adequate background 
knowledge to weigh the different drug effects. We excluded attributes that a priori would be 
expected to be very different between different stakeholders. 
We decided to exclude attributes that are not considered in the regulatory setting, and 
therefore excluded attributes related to costs, dosing frequency, and ease of use {including 
method of administration). 
Although plans for post-marketing follow-up studies, the mechanism of action and the size 
of clinical trials are of considerable importance in the regulatory process, for patients and 
doctors these issues are difficult to understand, specifically in the context of a discrete 
choice experiment, and were excluded. 
We excluded effects on complications, because healthcare professionals in our interviews 
indicated that treatment of many complications, such as foot-ulcers and neuropathy, has 
improved considerably in recent years. Additionally, patients did not mention effects on 
complications in the interviews. 
Although many respondents mentioned that they would like more certainty in the 
knowledge of the safety of drugs, we found that it would be difficult to include uncertainty 
as a measure that would be understood by patients. When looking at the other possible 
attributes, we found that including the (un)certainty of a specific adverse event might 
introduce the possibility that patients might understand that attribute differently from 
regulators or doctors. We therefore decided to exclude it from the list. 
The final lists comprises of efficacy and safety parameters. Firstly there is the efficacy 
parameter of reducing HbAlc. The CV risk characteristic is on both efficacy and safety 
parameter levels, as a reduction in CV risk is considered efficacious, while an increase in CV 
risk is an ADR. Effect on weight is likewise on both efficacy and safety parameter levels, as a 
reduction in weight is considered a positive side effect and an increase in weight a negative 
side effect. Hypoglycaemia, gastrointestinal complications and risk of bladder cancer were all 
included as safety parameters, with both transient/infrequent levels and persistent/frequent 
levels. The final attribute and level list is provided in table 4. 
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At the time of development of this discrete choice model, the safety of pioglitazone was 
heavily debated, as it had been associated with the risk of bladder cancer. (17-21). Because 
of the actuality of this issue, We decided to include risk of bladder cancer in our final 
attribute list. The levels chosen are based on the baseline risk of bladder cancer in the 
diabetes population and the 50% relative risk increase associated with pioglitazone. 
Control of diabetes in terms of improved HbA1c levels was included as an attribute, as it is 
the efficacy parameter used in trials for market authorisation applications. Additionally it 
was mentioned by several responders in our interviews and has been seen as an important 
characteristic in earlier studies. (10-13,22). The levels chosen reflect changes that are small 
(HbAlc remains too high), intermediate (HbAlc might be acceptable, but is still not optimal) 
and large (HbAlc goal of less than 7.0% is reached) (23,24) The levels of blood glucose 
lowering presented is based on actual effects. Guidelines recommend that patients with an 
HbAlc of 8.5% should receive anti-hyperglycaemic therapy in addition to life style advice. 
(24) In clinical registration trials usually patients have a baseline HbAlc in the range of 7.5 to 
10 % and reductions are achieved in the range from 0.5 to 1.5% after 24 weeks of treatment. 
(25) The largest reduction described here is not usually seen after the administration of a 
single OAD, but was added as it provides a change that results in reaching the 7% treatment 
target. (24) 
OADs are approved to the market based on demonstration of lowering of blood glucose. It is 
assumed that lowering of blood glucose results in lowering the long term risk of CV events, 
although only metformin has been shown to lower CV risk. (16) However, as rosiglitazone 
has been shown to increase the risk of CV events, we found a potential detrimental effect on 
CV events an important drug effect. Therefore, both lowering and increasing the risk of CV 
events were included, as well as no change in CV risk. {26) The levels of changes in CV risk 
presented are based on actual observed effects. In the high risk ACCORD population CV risk 
was approximately 2 % per year. (29) We used a lower baseline risk - 3% per two years - that 
is more appropriate for a more general T2DM population that comprises patient with and 
without previous cardiovascular events. In view of the increased 1.4 risk of myocardial 
infarction as described by Nissen and Wolski we set the increased risk at 4%. (26) 
In our interviews, both a capacity to lose weight (considered an added value) as well as 
weight gain (considered as an ADR) were mentioned as being important drug characteristics. 
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Table 4: Drug characteristics and levels used as attributes 
Drug attribute 
HbAlc 
Cardiovascu lar d isease 
Effect on weight 
Mi ld nausea, vomiting 
or d ia rrhoea 
Hypoglycaemia 
Risk of cancer 
Levels 
Decreases from 8.5% to 8.0% (too high) 
Decreases from 8.5% to 7.5% (suboptimal) 
Decreases from 8.5% to 6.9% (optimal )  
An increased (4%) risk; 4 instead of 3 out of 100 patients. 
Unchanged (3%) risk; 3 out of 100 patients. 
A decreased (2%) risk; 2 instead of 3 out of 100 patients. 
5% (4,5 kg) weight gain .  
No influence on weight 
10% (9 kg) weight loss. 
Throughout the use of the d rug (persistent) 
During the first two weeks of use of the d rug (transient) 
No stomach compla ints 
More than 2 per month (more frequent) 
1-2 per month ( less frequent) 
None 
I ncreased (0,06%) risk; 6 instead of 4 out of 10.000 patients. 
Unchanged (0,04%) risk; 4 out of 10.000 patients. 
HbAlc: glycated haemoglobin 
Additionally, earlier studies reported impact on weight to be important to patients. 
(10,11,13,22) The levels chosen are according to the weight increase seen for insulin therapy 
(27) and the regulatory guideline for weight reducing agents. (15) 
Gastrointestinal (GI) complaints and risk of hypoglycaemia are both common AD Rs of various 
OADs. In our interviews these attributes were considered important, as well as in earlier 
studies. (10,12,13) The levels were chosen to represent a transient or not frequent event on 
one hand and persistent or more frequent on the other, in addition to no risk of the event. 
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Creating the hypothetical patient 
The average age of the GIANTT population in 2007 was 67 years, with an average duration of 
diabetes of 5.8 years and an average BMI of 30 kg/m2 • Fifty-two percent of the population 
were female. Glucose-regulating medication was used by 83%, blood-pressure regulating 
medication by 76% and lipid-regulating medication by 72% of the population. (28) 
We therefore described the hypothetical patient as a 67 year old man, who weighs 90kg, has 
diagnosis of type 2 diabetes and high blood-pressure that is well controlled with an ACE­
inhibitor and is using a statin. He has no other chronic conditions and is not using any other 
medication. 
To demonstrate that the patient needs additional treatment we included in the description 
that the patient is currently using the maximum dose of metformin that he tolerates but still 
has had an elevated HbA1c (8.5%) for the past 6 months, which is considered to be too high 
in the Dutch clinical guideline for the treatment of type 2 diabetes. (24) 
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APPENDIX A: TOPIC GUIDE FROM QUALITATIVE INTERVIEWS - PATIENTS 
Introduction 
We are performing research on the expectation of patients towards new drugs coming to 
the market - specifically drugs to treat type II diabetes. 
We interview a number of patients to select the appropriate questions to ask in a more 
quantitative survey. 
First I will be asking a few general questions about your experience with your diabetes and 
your medication to get the general picture of the process and thereafter more specifically 
into requirements and expectations for new diabetes drugs. 
Demographic aspects 
• How old are you? 
• Do you live alone or do you have a partner? 
• What kind of work do you do/have you done? 
• For how long have you been diagnosed with diabetes? 
• Who is the physician that handles your diabetes? Your GP or a doctor in the hospital? 
o Are you happy with your treatment? 
• Are there any other healthcare professionals involved in your treatment? 
(nurses/home care/pharmacists) 
• Do you have other illnesses apart from the diabetes 
• What are the drugs that you are using at the moment? 
• Do you know what these drugs are for? 
Experience with diabetes and glucose lowering drugs 
Disease related experience 
• Have you had complications of you diabetes? 
• Have you had problems with too low blood sugar (hypoglycaemia)? 
• Do you monitor your blood glucose yourself? Do you go the lab for blood glucose 
measurements? 
o Does the term HbAlc mean anything to you? 
o Are you informed of your values from your 3-monthly tests? Do you know what 
they mean? 
Medication related experience 
• What is your experience with your diabetes medication? 
o Is your blood glucose well controlled using these drugs? 
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o Have you had any problems with your diabetes medication? 
• Do you feel that your drugs affect your quality of life? 
• Do you think your medication is user friendly? 
o How many times per day do you need to take your medication? 
• Have you had side effects of your diabetes medication? 
o If yes; which ones? 
o If yes; did you report it and to whom? 
o If yes; how did your doctor handle that? 
• Has your diabetes medication ever been changed? 
o How? 
o Why? 
• Are there any medicines that you would rather not take? 
o If yes; which ones? 
o If yes; why? 
• Do you have an idea of how your drugs can help you? 
o If yes; how? 
o Do you have an idea of how your medicines work? Do you also know what you 
might expect in the long term? 
• Do you worry about taking diabetes medication? 
o If yes; how? 
• Does your doctor involve you in the decision of which drugs to choose for your therapy? 
o If yes; do you like that? 
Information regarding medication 
Information for patients 
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• Who explains your medicine to you? 
o How? 
• Do you read the information sheet that comes with the drug (patient information 
leaflet) 
o Do you think it is easy to understand? 
• If you want to know more about drugs, how do you seek that information? 
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New drugs on the market 
Efficacy 
• What kind of expectations do you have to new diabetes medication with regards to 
efficacy? 
• In what way do you feel that a new drug should differ from the existing drugs with 
regards to efficacy? What do you think is the most important? 
• What do you want to know about the efficacy of a new drug before you agree to use it? 
Safety 
• What kind of expectations do you have to new diabetes medication with regards to 
safety? 
• In what way do you feel that a new drug should differ from the existing drugs with 
regards to safety? What do you think is the most important? 
• What do you want to know about the safety of a new drug before you agree to use it? 
• Do you think it is risky to take a drug that is new to the market? 
o What are those risks? 
• How much risk are you willing to accept? 
o What if the risks are not known? (short/long term) 
Ease of use 
• Would you accept a new drug if you only need to take it once a day? Do you think that 
would be better for you than your current dosing schedule? 
• If a new product contains two known drugs combined in one tablet, would that appeal 
to you? Do you think that would be better for you than your current medication? 
• Would you be willing to use a new drug if it could be administered with a once three­
monthly injection instead of a daily oral medication? Do you think that would be better 
for you than your current medication? 
• Would you be willing to use a new drug that require you to have your checkups more 
often, but would make your daily routine easier? Do you think that would be better for 
you than your current medication? 
Costs 
• Would it be a problem for you if your insurance company does not pay for your 
medication (at all or partly)? 
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The role of the authorities 
• What do you know about development and registration of new drugs? 
o E.g. number of patients in trials, how efficacy is evaluated etc. (make this more 
open ... ) 
o What is your opinion of the current system of allowing marketing of new 
medications? 
• If a new drug comes to the market, the manufacturer is obliged to monitor if the drug 
works as well in daily practice as it did in clinical trials and if it is as safe. There are 
several different ways to conduct this monitoring. One of those is a user registry 
system, where all new users of the drug must be registered in the system and all 
relevant information regarding the drug use and disease progression are monitored by 
the system. 
o Would you object to being enlisted in such a system? 
o What kind of questions would you be willing to answer if you were? 
o How much time could it cost you? 
Do you have any questions or remarks regarding the subject of the interview? 
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APPENDIX B: TOPIC GUIDE FROM QUALITATIVE INTERVIEWS - HEALTHCARE PROFESSIONALS 
Introduction 
We are performing research on the expectation of doctors/nurses towards new drugs 
coming to the market - specifically drugs to treat type II diabetes. 
We interview a number of doctors/nurses to select the appropriate questions to ask in a 
more quantitative survey. 
First I will be asking a few general questions about your work as a doctor to get the general 
picture of how diabetes care is organized in your practice and thereafter more specifically 
into requirements and expectations for new diabetes drugs. 
Demographic aspects 
• How long have you worked as a doctor/specialist/nurse? 
• How long have you worked in this practice? 
• How many patients does your practice service? 
• How does the patient population look like (e.g .. old/young)? 
• Can you estimate how many of your patients have diabetes type 2? 
o Can you estimate their average age? 
Diabetes care in the practice 
• How is diabetes care organized in your practice (monitoring)? 
• Do you have a specialized diabetes nurse or assistant involved in the diabetes care? 
o If yes; how is the care divided? 
• When you diagnose diabetes type II, what are the drugs you prescribe as first therapy? 
o How do you make your choice? 
• Do you generally follow clinical guidelines in your diabetes care? 
• Do you encounter instances where the guidelines are not sufficient? 
o What do you do then? 
• Is the diabetes of your patients in general well controlled? 
• Do you think your patients know what HbAlc is? 
• Do you think you patients know what their HbAlc levels mean (regardless of whether 
they know the term)? 
Experience with diabetes and glucose lowering drugs 
Disease related experience 
• Have you had patients that suffer from diabetes related complications? 
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Medication related experience 
• Have you had patients that suffer from (diabetes) medication related complications? 
• Do you take the quality of life of patients into account when you choose their 
medication? 
o If yes; in what way? 
• Do you think the quality of life of patients is important? 
• Have you treated patients that reported side effects of their diabetes medication? 
o If yes; has that change the way you prescribe those medications? 
o If no; do you think that would change the way you prescribe those medications? 
o If yes; serious/non serious? 
o If yes; frequent/infrequent? 
• Are there any medicines that you prescribe more than others? 
o Why? 
o Why not? 
• Are there any medicines that you would rather not prescribe? 
o If yes; which ones? 
o If yes; why?? 
• Do you involve your patients in the choice of which drug to prescribe? 
o If yes; why? 
o If yes; do you think that leads to better control of the blood glucose? 
o If no; why not? 
• Does the effect a medicine has on weight influence the medication choices? 
o If yes; how? 
• Do you consider a delay in insulin use to be a measure of effectiveness of a drug? 
Information regarding medication 
Information for patients 
• Do you provide information regarding the prescribed drugs to your patients? 
(agreement with pharmacies?)? 
o If yes, how? When? 
o If no; why not? 
• Do you expect you patient to read the patient information leaflet? 
Information for healthcare professionals 
• How do you access information regarding drugs that are new to the market? 
o Do you trust your information? 
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New drugs on the market 
Efficacy 
• What kind of expectations do you have to new diabetes medication with regards to 
efficacy? 
• In what way do you feel that a new drug should differ from the existing drugs with 
regards to efficacy (soft / hard endpoints)? What do you think is the most important? 
(choose one aspect that is important to you) 
• What do you want to know about the efficacy of a new drug before you prescribe it? 
Safety 
• What kind of expectations do you have to new diabetes medication with regards to 
safety? 
• In what way do you feel that a new drug should differ from the existing drugs with 
regards to safety (soft / hard endpoints)? What do you think is the most important? 
(choose one aspect that is important to you) 
• What do you want to know about the safety of a new drug before you prescribe it? 
• Do you think it is risky to prescribe a drug that is new to the market? 
o What are those risks? 
• How much risk are you willing to accept? 
o What if the risks are not known? (short/long term) 
Ease of use 
• Would you prescribe a new drug if the patient only needs to take it once a day instead 
of an alternative that needs to be taken multiple times a day? 
• If a new product contains two known drugs combined in one tablet, would you 
transfer patients from the two pills to the combination tablet? 
• Would you be willing to prescribe a new drug if it could be administered with a once 
three-monthly injection instead of a daily oral medication? 
• Would you be willing to prescribe a new drug that requires you to monitor the patient 
more often, but would make the patients daily routine easier? 
Costs 
• Would it affect your prescription of a new drug if the patients would need to pay partly 
or fully the costs of the drug? 
The role of the authorities 
• What is your opinion of the current system of allowing marketing of new medications? 
• What do you think of using user registries to monitor new drugs? 
Do you have any questions or remarks regarding the subject of the interview? 
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APPENDIX C: TOPIC GUIDE FROM QUALITATIVE INTERVIEWS - REGULATORS 
Introduction 
We are performing research on the expectation of different stakeholders towards new drugs 
coming to the market - specifically drugs to treat type II diabetes. 
We interview doctors, patients and assessors to select the appropriate questions to ask in a 
more quantitative survey. 
First I will be asking a few general questions about your work as an assessor to get the 
general picture of the process and thereafter more specifically into requirements and 
expectations for new diabetes drugs. 
Demographic aspects 
• How long have you worked as an assessor? 
• How long have you worked in the assessment of diabetes drugs? 
Assessment of diabetes drugs 
• How does the assessment procedure for diabetes drugs work? 
• What do you keep in mind when you assess diabetes drugs? 
Experience with diabetes and glucose lowering drugs 
Medication related experience 
• Have you ever assessed a drug that, after some time on the market, appeared to have 
a safety issue? 
o If yes; does that change how you regard applications for new drugs? 
o If no; do you think that would change how you regard applications for new drugs? 
• Do you think of quality of life of patients when you review a new diabetes drug? 
o If yes; How? 
o A drug can have different influence on a patient's quality of life for various 
reasons. How does that affect the evaluation of the drug? 
• Are there certain diabetes drugs you find should be prescribed most often? 
o If yes; which ones? 
o If yes; why? 
o If not: Why not? 
• Are there certain diabetes drugs you find should be used less that other drugs? 
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o If yes; Which ones? 
o If yes; Why? 
Selecting drug effects for a discrete choice study 
• Do you think patients should be involved in deciding if a drug should be prescribed to 
them? 
o If yes; Why? 
o If no; Why not? 
• Do you think patients should be involved in deciding if a drug should be allowed to the 
market? 
o If yes; Why? 
o If no; Why not? 
Information regarding medication 
Information for patients 
• Do you expect patients to read the patient information leaflet of their drugs? 
• How do you expect patients receive their information on their diabetes drugs? 
o Do you think the information they receive is trustworthy? 
Information for doctors 
• How do you think doctors get their information on new diabetes medication? 
o Do you think the information they receive is trustworthy? 
Information for assessors 
• How do you keep up to date with what is in the pipeline for diabetes drugs? 
o Do you trust the information? 
o Do you think information you receive before the process starts could influence 
how you assess the application? 
New drugs on the market 
Efficacy 
• What do you require the applicant to demonstrate for their drug in the context of 
efficacy before you recommend granting marketing authorization? 
• In what single aspect do you feel a new drug should be different from the drugs 
currently on the market when it comes to efficacy? 
Safety 
• What do you require the applicant to demonstrate for their drug in the context of 
safety before you recommend granting marketing authorization? 
• In what single aspect do you feel a new drug should be different from the drugs 
currently on the market when it comes to safety? 
• Would you think a drug that is new to the market poses some risk? 
o How much risk would you accept? 
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Ease of use 
• If a drug could be administered once daily in stead of multiple times a day, would that 
be a reason to recommend marketing authorization? 
• Would you recommend marketing authorization to a combination preparation of two 
known glucose lowering drugs? 
• If a drug could be administered with a once three-monthly injection in stead of a daily 
oral medication, would that be a reason to recommend marketing authorization? 
• If a drug would be easier for patients with regards to ease of use but would require 
extra monitoring, would that be a reason to recommend marketing authorization? 
Costs 
• Does the cost of medication play any role in the decision to recommend marketing 
authorisation? 
The role of the authorities 
• What is your opinion of the current regulatory system? 
• What do you think of using user registries to monitor new drugs? 
Do you have any questions or remarks regarding the subject of the interview? 
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Objective: To evaluate the importance that patients with diabetes attach to glucose 
regulating and cardiovascular benefits of oral anti-diabetes drugs (OAD) relative to 
symptomatic adverse drug reactions (ADRs) and serious ADRs when choosing an OAD. 
Research Design and Methods: A discrete choice survey was administered to 315 patients 
with type 2 diabetes, aged 60 to 75. Eighteen choice sets of two hypothetical drugs were 
created varying in their drug effects: level of HbAlc control, risk of cardiovascular disease, 
weight, gastro-intestinal symptoms, and hypoglycaemic episodes. Additionally, all 
hypothetical drugs had either a baseline or increased level risk of bladder cancer. Patients 
were presented with six choice sets each and asked to indicate which of the two they 
preferred. Analysis was done using conditional multinomial legit modelling. 
Results: Response was 72%, of the patients with mean age 67 (SD: 4.5) years and 48% 
women. Patients preferred drugs that reduced CV risk (OR: 1.74, p = 0.028) and avoided 
drugs that had the following drug effects: persistent GI problems (OR: 0.16, p < 0.001); 
frequent hypoglycaemia (OR: 0.24, p < 0.001); weight increase (OR: 0.39, p < 0.001); CV risk 
increase (OR: 0.47, p = 0.004), and less frequent hypoglycaemia (OR: 0.50, p = 0.020). HbAlc 
control, risk of bladder cancer, and other levels of drug effects did not statistically affect a 
patient's choice for a hypothetical drug given its other drug effects. 
Conclusion: Patients weigh heavily ADRs that influence their daily life. Control of glucose and 
a small increased risk of cancer are not as important for the drug choice. 
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INTRODUCTION 
Currently a patient-centred approach in health care is being adopted, in particular in chronic 
diseases, where the focus is on how patients can be (more) actively involved in treatment 
decisions and self-management (1). For treatment of diabetes, many pharmaceutical options 
are available, varying in mechanism of action, impact on clinical outcome and profile of 
adverse drug reactions (ADR) (2,3). All of these anti-diabetes drugs have shown to lower 
blood glucose levels, but evidence of long term benefit may be uncertain (3). Safety 
concerns range from common, often symptomatic ADRs, such as gastrointestinal (GI) upset 
and hypoglycaemia, to more unusual, long term ADRs like a possible increased risk of 
cardiovascular events or cancer (2-4). Therefore, the benefits and risks between may vary 
with patients and physicians differing in their treatment goals and preferences (5,6). 
Although clinical guidelines are available on how best to treat patients with diabetes, these 
are more physician oriented and do not take into account patient preferences that need to 
be considered when determining an optimal treatment plan. 
Several studies have assessed treatment preferences of patients with diabetes (7-12). 
In general, patients value clinical outcomes, such as glycaemic control and ADRs, more than 
convenience of the medication, including dosing schedules and administration forms. When 
considering these clinical outcomes, avoiding side effects, especially GI effects, and weight 
gain as well as improving HbA1c levels, appears to be more important for patients than 
avoiding hypoglycaemic events (6, 7,11). The relative ranking, however, depends on the 
extent or frequency of these positive or negative outcomes. Patients may differ in their 
preferences (7-11). One study included long term benefits, showing that these were 
considered more important than convenience of the treatment regime (8). Another study 
included possible serious safety outcomes, indicating that these can be at least as important 
to patients with diabetes as the short term benefits and risks (10). None of these studies, 
however, combined the full range of clinical outcomes, including short term and long term 
benefits as well as common and serious ADRs. 
The aim of this study is to evaluate the importance to diabetes patients of short term 
glucose regulating and long term cardiovascular benefits of OADs relative to symptomatic 
ADRs (gastrointestinal problems, change in weight, hypoglycaemia) and serious ADRs 
(cardiovascular, cancer). A secondary aim is to explore whether the importance patients 
attach to these drug effects is affected by their current status of glucose control or weight or 





We conducted a cross-sectional survey of patients with type 2 diabetes in the Netherlands. 
We used a discrete-choice experimental design to estimate the relative importance of 
different drug effects. Patients were asked to choose between pairs of hypothetical oral 
anti-diabetes drugs which vary in their drug effects An example is depicted in Figure 1. The 
method incorporates a trade-off to elicit patients' willingness to accept certain risks in 
exchange for a certain amount of benefit (13). Subsequently, the collected responses were 
used in a statistical model to estimate the relative importance of different drug effects. A 
waiver was obtained from the medical ethical committee of the University Medical Centre 
Groningen for this survey. 
Selection of drug characteristics and levels 
The drug effects selected to create the hypothetical OADs were based on 22 in-depth 
interviews; 6 patients, 3 nurses, 9 doctors, 3 regulators and a pharmacist, and an informal 
review of the literature, regulatory requirements and product labelling of OADs. The drug 
effects chosen were [Table 1]: 
• Control of diabetes in terms of improved glycated haemoglobin (HbA1c) levels. This is an 
important in earlier studies and in our interviews and a major efficacy parameter in 
trials for market authorisation applications (6,7,10-12). 
• Impact on cardiovascular outcomes. One of the major reasons for controlling blood 
glucose levels is ultimately to reduce cardiovascular (CV) risk but some OADs may even 
increase CV events as shown with rosiglitazone (14). 
• Impact on weight. This has been reported to be important to patients with diabets 
(6,7,10,11), both as a capacity to lose weight (considered an added value) as well as to 
gain weight (considered as an ADR). 
• Gastrointestinal (GI) complaints and risk of hypoglycaemia. These are both common 
ADRs of various OADs, which have been shown to be important to patients in earlier 
studies and our interviews (7,10,12). 
• Risk of bladder cancer, a serious but rare ADR that has led to debate about the safety of 
another OAD, pioglitazone (15-19). 
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The hypothetical drugs varied on these drug effects [Table 1]. We selected levels of variation 
that were considered to be plausible and representative of current OAD therapy. 
Table 1 Drug characteristics and levels included in the hypothetical drugs 
Drug attribute 
HbAlc 
Cardiovascular d isease 
Effect on  weight 
M i ld nausea, vomiting 
or dia rrhea 
Hypoglycemia 
Risk of cancer 
HbAlc: glycated haemoglobin 
Choice tasks 
Levels 
Decreases from 8.5% to 8.0% (small) 
Decreases from 8.5% to 7.5% (medium) 
Decreases from 8.5% to 6.9% ( large) 
An increased (4%) risk; 4 i nstead of 3 out of 100 patients 
Unchanged (3%) risk; 3 out of 100 patients 
A decreased (2%) risk; 2 instead of 3 out of 100 patients 
5% (4,5 kg) weight gain 
No influence on weight 
10% (9 kg) weight loss 
Throughout the use of the drug 
During the first two weeks of use of the drug 
No stomach compla ints 
More than 2 per month 
1-2 per month 
None 
I ncreased (0,06%) risk; 6 instead of 4 out of 10.000 patients 
Unchanged (0,04%) risk; 4 out of 10.000 patients 
Patients were asked to choose between several sets of hypothetical OADs. An orthogonal 
algorithm (Orthoplan, SPSS) was used to select the minimum number of choice sets needed 
to facilitate the estimation of all main effects. The final selection comprised 18 choice sets 
with two OADs each. At least two drug effects differed in level between the two OADs within 
each choice set. To reduce the burden in time on respondents, three versions of the survey 
were created containing a random set of six choice sets each. 
At the start, a description of a hypothetical diabetes patient was presented. This patient was 
a 67 years old man, weighing 90 kilos, and using metformin, as well as medication to control 
his high blood pressure and a statin. His blood glucose was poorly controlled and he needed 
another drug in addition to his metformin. Responders were asked to indicate which of the 
OADs they preferred, imagining being this patient. The patient description was repeated 














Decreases from 8.5% to 7.5% 
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5% (4,5 kg) weight gain 
During the first two weeks of use 
1-2 per month 
Unchanged (0,04%) risk; 
4 out of 10.000 patients 
My preference goes to: 
Medicine A D  
Figure 1Example of a discrete-choice task 
Patient population 
Medicine B 
Decreases from 8.5% to 7.5% 
80 8 5  7,0 7 5  8 0  8.5 9,0 9,Sll. 
An increased (4%) risk; 
4 instead of 3 out of 100 patients 
. . . . :.: �{:: � 
No influence on weight 
No stomach complaints 
None 
Increased (0,06%) risk; 6 instead 
of 4 out of 10.000 patients 
Medicine B D 
Patients between the age of 60 and 75 years, receiving at least one prescription of an anti­
diabetes drug {non-insulin) in the preceding four months were identified from pharmacies in 
the northern part of the Netherlands. The age limit was selected to include patients that 
could relate to our hypothetical patient. Pharmacy interns at the pharmacies contacted the 
identified patients by telephone and asked permission to send the patients the 
questionnaire. In case no response was obtained two weeks after the questionnaire was 
sent, the patient was contacted again as a reminder. 
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Patient characteristics 
At the end of the survey, patients were asked to fill in their gender, age, and highest 
completed education. In addition, they were asked for the year they were diagnosed with 
diabetes, and to report their current height and weight, as well as the HbAlc value from 
their last 3-monthly check-up. These data were used to estimate the patients' diabetes 
duration, body mass index (BMI), and to whether their blood glucose was under control or 
not (HbAlc < 7% or � 7%). Finally, the patients were asked if they had experienced any side 
effects of their diabetes medication in the last year. 
Analyses 
For the modelling of the data collected in the discrete choice experiments multinomial 
statistical models were used, in which one of the levels for each drug effect is set as 
reference level. The following levels were chosen as reference: a small decrease in HbAlc 
level, no change in CV risk, no effect on weight, no stomach complaints, no hypoglycemias, 
and no change in risk of bladder cancer. We applied a multinomial conditional logit model 
(asclogit, Stata). The main effect model included 11 dummy variables, since five of the drug 
effects varied on three levels and one drug effect on two levels. 
Subgroup analyses 
Subgroup analyses were performed to examine whether benefit and risk preferences were 
different for patients with different levels of (< 30 and � 30 kg/m2), HbAlc control (<7% and 
�7%), or previous experience with ADRs (yes or no). Patients with BMI over 30 kg/m2 were 
compared with patients with BMI under 30 kg/m2 regarding their preferences for changes in 
weight, patients reporting an HbAlc of 7% or more were compared to those reporting 
HbAlc under 7% regarding their preferences for HbAlc control, and patients reporting 
experience with ADRs were compared to those reporting no such experiences regarding 
their preferences for avoiding hypoglycaemias and GI problems. 
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Table 2: Demographic and clinical characteristics of respondents 
Demographics and clinical characteristics Number (%) or mean (sd) 
Gender [female; n (%)] 108 (47.8%) 
Age [years; mean (sd)] 67 (4.5) 
Highest education 
High school diploma or less [n (%)] 
More than high school diploma [n (%)] 
Weight [kg] 
BMI [mean (sd)] 
Non-obese [BMI < 30; n (%)] 
Obese [BMI � 30; n (%)] 
Duration of diabetes [years; mean (sd)] 
Last HbAlc value [mean (sd)] 
< 7% [n (%)] 
� 7% [n (%)] 












sd :  standard deviation, BM I :  Body Mass Index; HbAlc: G lycosylated haemoglobin 
Table 3: Perceived importance of drug characteristics for specific subgroups 
Patients with HbAlc under 7% Patients with HbAlc over 7% 
OR 95% CI p-value OR 95% CI p-value 
HbAlc smal l change 1 .49 0.57 - 3.88 0.414 2 .31 0.84 - 6.39 0.105 
HbAlc large change 1.89 0.49 - 7.38 0.358 4.50 1.02 - 19.83 0.047 
Patients with BMI  under 30 Patients with BMI over 30 
OR 95% CI p-va lue OR 95% CI p-value 
Weight i ncrease 0.39 0.23 - 0.68 0.001 0.43 0.22 - 0.82 0.010 
Weight decrease 0.85 0.55 - 1.31 0.453 0.77 0.48 - 1.25 0.291 
Patients without ADR experience Patients with ADR experience 
OR 95% CI p-va lue OR 95% CI p-value 
Long term G I  0 .19 0 .11 - 0.32 < 0.001 0.06 0.02 - 0.18 < 0.001 
Short term G I  0.84 0.50 - 1.41 0.514 1 .22 0.47 - 3.19 0.678 
Frequent hypos 0.30 0.13 - 0.70 0.005 0.21 0.04 - 1.26 0.088 
I nfrequent hypos 0.62 0.32 - 1 .21 0.163 0.36 0.10 - 1.39 0.139 
HbAlc: G lycosylated haemoglobin; OR: odds ratio; Cl; confidence interval; BM I :  Body Mass Index; 
ADR: Adverse Drug Reaction; G I :  Gastro-intestinal 
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RESULTS 
Response 
Of the 315 patients that received the survey, 226 responded (72%), with mean age 67 (sd: 
4.5) years and 48% were women. The mean self-reported HbAlc was 6.8% (sd: 1.1), the 
reported mean duration of diabetes was 9 years (sd:8.8), and the mean BMI was 29 kg/m2 
(sd: 5.2). Fifty-one (23%) of patients reported to have experienced adverse drug reactions 
(ADRs) from their current OADs in the previous year. [Table 2] 
Preferences 
Patients preferred drugs that had as one of their drug effects that they reduced CV risk (OR: 
1.74, p = 0.028) [Figure 2]. Patients were less inclined to choose drugs that had the following 
drug effects: persistent GI problems (OR: 0.16, p < 0.001); more than 2 episodes of 
hypoglycaemia per month (OR: 0.24, p < 0.001); weight increase (OR: 0.39, p < 0.001); CV 
risk increase (OR: 0.47, p = 0.004), or 1-2 episodes of hypoglycaemia per month (OR: 0.50, p 
= 0.020). HbAlc, the risk of bladder cancer and other levels of drug effects did not 
statistically affect a patient's choice for a hypothetical drug given its other drug effects. 
Subgroup analyses 
A large decrease in HbAlc level was valued higher by patients with inadequate control of 
HbAlc than by patients with good glucose control, while both groups had similar values for 
smaller changes in HbAlc. Patients that had experienced ADRs were less inclined to choose 
OADs with persistent GI problems than those who had not, but they did not differ in their 
preference regarding transient GI problems or hypoglycaemias. [Table 3] 
Obese patients valued increase in weight and weight loss similarly to patients that were not 
obese. 
DISCUSSION 
Our results show that long term cardiovascular benefit and risk and persistent symptomatic 
ADRs influence patients' preferences for a specific OAD more than glucose regulating 
benefits or an increase in small cancer risk. These preferences were in part affected by 
previous or current experiences of the patient, especially regarding HbAlc control and AD Rs. 
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HbA1 c control 
-smal l (8.5 ---+- 8.0) [reference] 
-intermediate (8 .5 � 7.5) 
-large (8.5 ---+- 6.9) 
CV risk 
-decreased (3 � 2%) 
-unchanged (3%) [reference] 
-increased (3 � 4%) 
Weight 
-decrease 
-no change [reference] 
-increase 
GI problems 





-1 -2 per month 
-more than 2 per month 
Bladder cancer risk 
-unchanged (0.04%) [reference] 
-increased (0.04 ---+- 0.06%) 
0, 1 
� • 
1 10  
Figure 2Perceived importance of drug characteristics by patients (Log of Odds Ratios and 
95% Confidence Intervals) 
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An OR>l indicates that patients are more inclined to choose a drug with a specific 
characteristic and level. Vice versa, patients are less inclined to choose drug 
characteristics and levels with an OR<l. 
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As could be expected patients preferred OADs that decrease their CV risk and avoided drugs 
increasing their CV risk, which is in line with a similar study {10). In our study this long term 
benefit had a greater weight than short term changes in HbAlc but smaller than of ADRs 
experienced; i.e. persistent GI problems and frequent hypoglycaemias. Patients are less 
likely to adhere to drug treatments that have intangible benefits, especially when ADRs are 
experienced (10,20). Our results underline the need to take into account patients' concerns 
about ADRs and to discuss with them not only the long term benefits of OADs but also the 
possible negative effects and how to manage them (21). 
We saw very little effect of changes in HbAlc on patient preferences, except in those 
patients whose HbAlc was uncontrolled (higher than 7%). Previously, a large decrease in 
HbAlc was reported to be the largest influence on patient preferences (10). This difference 
may be explained by the levels of the HbAlc selected by other researchers where their 
largest decrease was from 10.5% to 6.5%. This change is very large and is unlikely to be 
achieved by one drug (2). However, others have reported changes in HbAlc being important 
to patient preferences, although not always as the most important drug effect (6, 7,11,12). 
These studies did include a younger study population than is presented here. In a study in 
the elderly glucose control did have a lower importance to patients than diet and exercise 
and the more vulnerable patients did have an even lower preference for intense glucose 
control than non-vulnerable patients (22). 
Patients preferred to avoid persistent GI problems while they did not seem particularly 
worried about transient GI problems. This is in line with earlier results that showed that 
persistent stomach problems are considered important, in contrast to transient stomach 
problems (7,10). On a similar note, patient find it more important to avoid drugs with more 
than two hypoglycaemias per month than drugs with one or two hypoglycaemia attacks per 
month, suggesting that they find the magnitude of the problem relevant. Patient 
preferences regarding transient ADRs and frequency of recurrent ADRs underline the 
importance of improving understanding of the time course and frequencies of ADRs 
(7,10,11,23,24). Routine collection of data about the time course of ADRs (e.g., when an ADR 
can be expected, how frequently it occurs and how long it will last with or without stopping 
therapy) is usually not performed in clinical drug trials (25,26) and not addressed in the 
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drugs' patient information leaflet or the summary of product characteristics (27). Given our 
results of patients discriminating between ADRs with short or long duration, this information 
should be investigated more thoroughly and be available to patients. 
Additionally, patients having experienced ADRs were even less inclined to choose 
hypothetical drugs that caused persistent GI problems than patients that did not report 
having experienced ADRs. These results, coupled with the results of patients that have 
uncontrolled HbA1c, suggest that patients that have had difficulties with their treatment, 
have different preferences for drug effects. However, patients that have experienced ADRs 
did not differ with regard to avoiding hypoglycaemia as found in earlier studies. (10,11) 
Therefore, we cannot extrapolate these findings to all ADRs. 
Patients tried to avoid increase in weight as an ADR, while a possible benefit of weight loss 
did not seem to affect their preferences. The former is in line with what has been seen 
previously (6,7,10,11,28), while the non-effect of weight loss seems contradictory to results 
from similar studies, where preferences for weight loss were high (6,7,11). Additionally, 
presence of obesity has been shown to influence patient preferences for OADs that may give 
weight loss while our results show no differences between obese patients and those who 
are not obese (6,7,11). The overall difference in weight loss preferences is unlikely to be a 
result of the levels/scale used by the researchers, as the weight loss presented in our study 
was higher than in the previous studies. Also it cannot be attributed to lack of statistical 
power in our sub-population analysis as the odds ratios for weight increase were statistically 
significant for both sub-groups. A more likely explanation is that the study population in the 
previous studies was much younger than the population in this study, while they did not 
differ in gender ratio and might therefore have a stronger preference for weight loss, 
particularly for the young obese (6,7,11). 
The apparent lack of effect of at 50% increased risk of bladder cancer seems surprising in 
view of the concerns raised in response to the association with pioglitazone use. This could 
have two possible explanations. One is that the baseline risk of bladder cancer in the 
diabetes population is very small and small risks are difficult to grasp for the studied patients 
(29). The other is that patients actually have understood the risk but identified more 
common risks as being more relevant to them. 
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limitations/strengths: 
The results of the discrete-choice method is subjective to the drug effects and levels chosen. 
As discussed earlier, when larger differences in levels are given, more effect on patient 
preferences may result. (30) We tried to minimize this effect by selecting levels that are 
plausible and representative of what is known about the OADs already on the market. 
In presenting the drug scenarios to patients, some of the drug effects were depicted only 
with text and numbers, while others were depicted with coloured pictures, hence being 
more noticeable on paper. The design of the scale figure used to describe changes in HbA1c is 
based on a previous discrete choice study (10). The design of the 'smiley-face' matrix used to 
describe changes in risk of CV events was intended to make the proportions presented more 
understandable to patients (31,32). The results show that most value was attached to two of 
the drug effects presented with text and numbers, indicating that this difference in 
presentation did not lead patients to disregard those drug effects. 
The population was selected from pharmacies in the northern part of the Netherlands and 
might not necessarily represent patients with diabetes from outside the Netherlands. The 
patients selected for the study were ranging from 60 to 75 years of age and might differ in 
their preferences or values from those older or younger. However, this age group consisted 
of a large group of users of OADs in the Netherlands (43% of total OAD users in 2009 (33)) 
and with a response rate of more than 70% we may assume that the responders are 
representative of Dutch diabetes type 2 patients. Finally, the subgroup analysis of patient 
characteristics was based on self-reported values. We did not have access to the patients' 
medical files and could not verify that those values were accurate. 
Implications for practice: 
Diabetes patients have clear preferences about treatment options, which are partly driven 
by their own experiences. Patients value CV risk reduction, one of the main goals of diabetes 
treatment, but also prefer drugs more that do not lead to persistent symptomatic ADRs. This 
calls for a dialogue between prescriber and patient to ascertain that the OAD chosen is 
appropriate for each patient. Following prescription, active monitoring for and management 
of ADRs by both patient and prescriber is necessary. Symptomatic ADRs affecting patients' 
quality of life and CV risk are indicated as being more important to patients than other drug 
effects, including a small realistic risk of bladder cancer. 
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Regulatory decisions are criticised for not always reflecting the benefit/risk assessment as 
made by doctors and patients. We investigated whether the value regulators attach to 
benefits and risks of oral anti-diabetes drugs (OAD) is in agreement with these stakeholders. 
We administered a discrete choice survey to 79 regulators, 845 doctors and 315 patients 
with type 2 diabetes. Eighteen choice sets were made comparing two hypothetical OADs 
with varying drug effects on glycated haemoglobin (HbAlc), cardiovascular (CV) risk, weight, 
duration of gastrointestinal (GI) complaints, frequency of hypoglycemia, and bladder cancer 
risk. Responders were asked each time which OAD they preferred. Multinomial conditional 
logit analyses were conducted. CV risk reduction was valued by regulators positively, 
whereas drug choices were negatively affected by persistent GI problems and CV risk 
increase in the same way as doctors and patients. This shows that they can support 
regulators in making decisions at an individual patient level. 
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INTRODUCTION 
Regulators base their decision to approve new drugs on an assessment of the balance 
between their benefit and risks at a population level as determined in clinical trials. Doctors 
and patients make their decisions at the individual level. In their decision making, doctors 
rely to a large part on evidence based guidelines, applying these to individual patients, while 
patients may value benefits and risk from the perspective of having to integrate drugs in 
their daily life based on the information that they receive from their physician and other 
information sources, including the patient leaflet. As in clinical practice, where patient 
participation in decision-making has been accepted as an integral part of the management of 
chronic diseases, (1) also regulators acknowledge a growing role of the patient in the drug 
approval process. The European Medicines Agency (EMA) has formalised collaboration with 
patient organisations in the Patients' and Consumers' Working Party and in the USA, the 
Food and Drug Administration (FDA) did the same in the Patient Representative Program. 
(2,3) Nevertheless, to date the patient role in the scientific discussions and decision making 
regarding the approval of drugs has been very limited. (2) 
Occasionally, regulatory decisions have attracted the attention or even opposition from 
doctors and patients. Clear examples were in the field of HIV/AIDS and vaccines. For instance, 
there has been strong opposition from certain consumer groups to the approval and 
subsequent use of human papilloma virus vaccine and the combined measles, mumps and 
rubella vaccine. (4-8) On the other hand, patients with HIV/AIDS have pressured regulators 
to approve new drugs faster. Recently, natalizumab, a drug to treat multiple sclerosis (MS), 
was taken off the market by the FDA because it could cause progressive multifocal 
leukoencephalopathy (PML). However, when patient benefit risk perception was made 
explicit, and the risk of PML was found to be acceptable to the individual MS patient, 
natalizumab was re-introduced to the market. (9,10) 
Cases like these raise doubt whether regulator decisions sufficiently reflect the clinical needs 
and reality of doctors and patients. Their different views could be the result of making 
decisions at the population level instead of the individual patient level but it could also be 
that regulators genuinely value benefits and risks of drugs different than other stakeholders. 
Several studies have evaluated how patients and doctors value drug benefits and risks, for 
example in the field of diabetes, (11-15) but not in relation to regulators' assessments. 
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The field of diabetes provides a good case to assess whether values that regulators attach to 
different drug effects are in agreement to the values of doctors and patients. In this field, 
several oral anti-diabetes drugs (OADs) from different pharmacological classes are available 
that all provide some level of glucose control but have different immediate and long term 
risks. To compare the values underlying drug decisions at the level of an individual patient, 
we conducted a 'discrete choice' survey where regulators, doctors and patients were asked 
which of two hypothetical OADs with varying drug effects they preferred for a typical patient 
with type 2 diabetes. 
METHODS 
We performed a survey to estimate the relative value that regulators, doctors and patients 
with type 2 diabetes assign to different drug effects. A discrete-choice experimental design 
was used where responders were asked to choose between several pairs of hypothetical 
OADs. The method incorporates a trade-off to elicit responders' willingness to accept certain 
risks in exchange for a certain amount of benefit. (43) A waiver was obtained from the 
medical ethical committee of the University Medical Center Groningen for this survey. 
Study participants and recruitment 
All 65 clinical and pharmacovigilance assessors and 14 members of the Board identified from 
the internal telephone directory of the Dutch Medicines Evaluation Board (MEB) were sent 
an e-mail containing a link to the survey website and unique log-in information. Two and 
three months later an e-mail reminder was sent to non-responders. 
Doctors included were general practitioners and internists practicing in diabetes care. A 
randomly selected list of 593 general practitioners was obtained from the Dutch institute of 
research in healthcare (NIVEL). A list of 252 internists practicing in diabetes care was 
compiled from the websites of all Dutch hospitals. These doctors were sent a paper-based 
questionnaire including an option to respond electronically through a secure website. Two 
months later non-responders were reminded to fill in the questionnaire. 
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Patients between the age of 60 and 75 years, receiving at least one prescription of an OAD in 
the preceding four months, were identified from pharmacies in the northern part of the 
Netherlands. Pharmacy interns contacted these patients by telephone and requested 
permission to send a questionnaire. Two weeks after the questionnaire was sent, the interns 
phoned again to follow up on non-responders. 




Effect on weight 
Mild nausea, vomiting or 
diarrhea 
Hypoglycemia 
Risk of cancer 
HbAlc: glycated haemoglobin 
Levels 
Small decrease from 8.5% to 8.0% (too small) 
Intermediate decrease from 8.5% to 7.5% (suboptimal) 
Large decrease from 8.5% to 6.9% (optimal) 
An increased (4%) risk; 4 instead of 3 out of 100 patients. 
Unchanged (3%) risk; 3 out of 100 patients. 
A decreased (2%) risk; 2 instead of 3 out of 100 patients. 
5% (4,5 kg) weight gain. 
No influence on weight 
10% (9 kg) weight loss. 
Throughout the use of the drug 
During the first two weeks of use of the drug 
No stomach complaints 
More than 2 times per month 
1-2 times per month 
None 
Increased (0,06%) risk; 6 instead of 4 out of 10.000 
patients. 
Unchanged (0,04%) risk; 4 out of 10.000 patients. 
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Selection of drug effects and levels presented 
The drug effects selected to create the hypothetical OADs were based on 22 in-depth 
interviews (with 6 patients, 3 nurses, 9 doctors, 3 regulators and a pharmacist), and an 
informal review of the literature, regulatory requirements and product labelling of OADs. 
The effects selected were [Table 1]: 
• Control of diabetes in terms of improvement in the HbAlc levels. This is the efficacy 
parameter used in trials for market authorisation applications and earlier studies have 
shown it to be an important drug effect. (11-15) 
• Impact on cardiovascular outcomes. Controlling blood glucose levels should ultimately 
lead to a decreased cardiovascular (CV) risk. However, an increase in this risk can also 
occur, as shown by the OAD rosiglitazone. (20) 
• Impact on weight. In our interviews, both weight loss (considered an added value) as 
well as weight gain (considered as an ADR) were seen as being important. Others have 
found it to be important to patients. (11-13,15) 
• Duration of GI complaints and risk of hypoglycaemia. Both are common ADRs of various 
OADs and have been shown to be important to patients in earlier studies as well as our 
interviews. (11,13,14) 
• Risk of bladder cancer. A serious but rare ADR that has led to debate about the safety of 
pioglitazone. (44-48) 
The hypothetical drugs varied on these drug effects [Table 1]. We selected levels of variation 
that were considered to be plausible and representative of existing OADs. 
Choice tasks 
Responders were presented several sets of two hypothetical OADs and asked each time to 
choose between the two OADs. Each set differed on at least two drug effects. An orthogonal 
algorithm (Orthoplan, SPSS v.19) was used to select the minimum number of choice sets 
needed to facilitate the estimation of all main effects. The final selection comprised 18 
choice sets and regulators received all choice sets. To minimize the time burden on patients 
and doctors, three versions of the survey were created containing a random set of six choice 
sets each. [Figure 1] 
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Medicine B D 
At the start of the survey, the participants were presented with a description of a 
hypothetical diabetes patient; the patient vignette. This patient was a 67 years old male, 
weighing 90 kilos, and using metformin, antihypertensive medication, and a statin. His blood 
glucose was poorly controlled and he was in need in need for a second drug in addition to 
the metformin. The regulators were asked to indicate which of the two OADs they felt was 
more appropriate for the patient. Doctors were asked to imagine that they were treating this 
patient and base their choices on their treatment preferences for that patient. The patients 
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were asked to imagine being this patient and to indicate which drug they preferred based on 
their own preference. The patient vignette was repeated above each choice question. 
Additional data collection 
At the end of the survey, a number of general questions were included. Regulators were 
asked their gender and how many years they had worked for the Dutch MEB. Doctors were 
asked their gender, whether they were GPs or specialists, and how many years they had 
been registered as practitioners. Patients were asked their gender, age, highest completed 
education, and the year they were diagnosed having diabetes. 
Analyses 
Separate analyses were performed for each stakeholder group. For the modelling of the data 
collected in the discrete choice experiments multinomial statistical models were used, in 
which one of the levels for each drug effect is set as reference level. (43,49) The following 
levels were chosen as reference: a small decrease in HbAlc level, no change in CV risk, no 
effect on weight, no stomach complaints, no hypoglycaemias, and no change in risk of 
bladder cancer. The main effect model included 11 dummy variables, since five of the drug 
effects varied on three levels and one drug effect on two levels. 
To detect whether regulator responses differed significantly from the responses of doctors 
or patients, we performed separate analyses. In these analyses, not the three groups of 
interest, but only two groups of interest (regulators vs. doctors; regulators vs. patients) were 
analysed. A dummy variable was created to indicate the membership of the 2 groups to 
assess whether being a regulator lead to significantly different drug choices. 
RESULTS 
Respondents 
The survey using hypothetical drug scenarios to elicit what values regulators', doctors' and 
patients' attach to OAD benefits and risks was returned by 52 (66%) regulators, 175 (21%) 
medical doctors and 226 (72%) patients. The regulators had a median work experience of 5 
years (interquartile range (IQR) 3 - 11 years) and comprised a mixture of clinical and 
pharmacovigilance assessors as well as seven independent members of the Dutch Medicines 
Evaluation Board (MEB). The doctors comprised a group of 130 GPs and 45 internists of 
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whom 49% had more than 20 years' experience in clinical practice. The median age of the 
patients was 67 years { IQR 64 - 71); 48% were women and they had a median disease 
duration of 7.5 years { IQR: 3 - 13). [Table 2] 
Table 2: Demographic characteristics of responders 
Demographics 
Regulators (n=52} 
Gender [female; n {%)] 
Experience at the MEB [years; median (IQR)] 
Doctors (n=175} 
Gender [female, n {%)] 
GPs [n (%)] 
Years of experience [n (%)] 




> 20 years 
Patients (n=226} 
Gender [female; n (%)] 
Age [years; median (IQR)] 













67 {64 - 71) 
7.5 (3 - 13) 
MEB = Dutch Medicines Eva luation Board, GP = Genera l  Practitioner, 
BMI :  Body Mass Index; HbAlc: G lycosylated haemoglobin, IQR: interquartile range 
Values attached to drug effects by regulators 
Regulators received 18 choice sets of two hypothetical drugs as depicted in figure 1, which 
differed on six drug effects, i.e impact on; glycated haemoglobin (HbAlc) levels, associated 
cardiovascular (CV) risk, weight change, presence and duration of gastro-intestinal {G I) 
complaints, frequency of hypoglycemia, and potential risk of bladder cancer [Table 2]). A 
reduction in CV risk was the drug effect that positively affected the regulator's choice (Odds 
Ratio (OR) 1.98, 95% Confidence Interval (Cl) 1.11 - 3.53). Persistent G I  problems (OR 0.24, 
95% Cl 0.14 - 0.41) and CV risk increase (OR 0.49, 95% Cl 0.27 - 0.87) were considered as 
significant negative drug effects. A 5% weight gain was considered a negative drug effect, 
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but was marginally significant (OR 0.64, 95% Cl 0.41 - 1.00). Risk of bladder cancer and 
decrease in HbAlc did not significantly affect the choices made by the regulators. [Figure 2] ). 
These data indicate that in the context of the studied drug effects, the regulators preferred 
OADs that reduced CV risk (OR>l) and avoided OADs that had persistent GI problems, 
increased CV risk or resulted in weight gain (OR<l). 
Agreement with doctors and patients 
When comparing the results of the analyses for each group of respondents, there was a clear 
difference in the value attached to frequency of hypoglycaemias [Figure 2] . Regulators' 
choices were not significantly affected by any level of frequency of hypoglycaemias, frequent 
(> 2 episodes per month) versus less frequent (1-2 episodes per month) or no 
hypoglycaemias, [OR 0.46, 95% Cl 0.19 - 1.11, OR 1.30, 95% Cl 0.64-2.62, for frequent and 
less frequent respectively], whereas doctors' choices were affected by frequent 
hypoglycaemias [OR 0.16, 95% Cl 0.07 - 0.37] and patients' choices were affected by both 
levels [OR 0.24, 95% Cl 0.11 - 0.51, OR 0.50, 95% Cl 0.28 - 0.90, for frequent and less 
frequent respectively]. 
While weight gain as a negative drug effect was only marginally significant for the regulators' 
choices (OR 0.64, 95% Cl 0.41 - 1.00), it had a similar but significant value for doctors (OR 
0.62, 95% Cl 0.41 - 0.94) and a more pronounced significant value for patients (OR 0.39, 95% 
Cl 0.26 - 0.59). 
Regulators were in agreement with doctors and patients regarding the value of changes in 
CV risk and persistent GI problems for the drug choice, and the lack of importance of 
changes in risk of bladder cancer. [Figure 2] 
Regarding HbAlc, minor differences were seen. While there was no significant impact of 
either intermediate or large decreases in HbAlc for the regulators' or patients' choices, 
doctors did prefer OADs with a large decrease in HbAlc levels (OR 3.24, 95% Cl 1.25 - 8.43). 
In additional analyses in which regulators were compared with doctors, respectively patients, 
no statistically significant differences were observed regarding the specific drug choices they 
made (p=0.13 and p=0.19, respectively). 
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-small (8.5 ---. 8.0) (reference) 
-intermediate (8.5 - 7.5) 
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CV risk 
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Weight 
-weight loss 
-no change [reference] 
-weight gain 
GI problems 





-1 -2 per month 
-more than 2 per month 
Bladder cancer risk 
-unchanged (0.04%) [reference) 





















Figure 2: Perceived value of drug effects by regulators, doctors and patients (Log of Odds Ratios and 95% Confidence 
Intervals) An OR>l indicates that responders are more inclined to choose a drug with a specific drug effect and level. 
Vice versa, responders are less inclined to choose drug effects and levels with an OR<l. 
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Our results indicate that regulators value drug effects of OADs similar to doctors and 
patients when a benefit risk assessment is made at an individual patient level. Regulators 
valued the presented long term cardiovascular benefits and symptomatic adverse drug 
reactions (ADR) as more important for the drug choice than the other drug effects including 
an increase in bladder cancer risk, which was in agreement with both doctors and patients. 
Values attached to drug effects by regulators 
Regulators did not value reduction in HbAlc level significantly when taking into account the 
other drug effects of the hypothetical drugs included in our study despite the fact that the 
European Medicines Agency guidelines acknowledge HbAlc as the surrogate outcome 
measure on which new OADs can be approved. Although our data suggest that regulators 
may be inclined to prefer hypothetical drugs causing increasing levels of glucose control, this 
observation did not reach statistical significance. This could be due to recent evidence that 
more aggressive strategies to control glucose levels have not always translated in better long 
term patient outcomes; i.e micro and/or macrovascular benefit. (16,17) Also, we 
simultaneously presented the effect of our hypothetical drugs on CV risk, while the scenario 
read that all drugs had a similar impact on microvascular outcomes. Therefore, the impact 
on the long term patient outcome appears to have dominated the regulator's choice, an 
effect that is usually not known when the drug receives market approval. (18) 
It is in line with the increasing regulatory perception of the relevance of improved clinical 
outcome measures, especially since rosiglitazone was shown to increase the risk of 
cardiovascular disease and heart failure despite a significant glucose lowering effect. 
Ultimately its marketing authorisation in the EU was suspended in the EU and the guideline 
on clinical investigations for anti-diabetes drugs amended to include a more systematic 
collection of data on CV safety in the clinical studies before authorisation. (18-21) In the USA, 
similar measure were taken by the Food and Drug Administration (FDA) with a restriction to 
the use of rosiglitazone in a small subset of patients. (22,23) 
Concerning other effects, regulators avoided choosing drugs causing persistent GI problems 
whereas transient GI problems had little influence on their choices. These types of problems 
are usually considered in the context of overall occurrence of symptomatic ADRs or 
discontinuations due to ADRs and not unusual. (18) More surprising was the fact that 
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regulators did not attach much value to drugs causing hypoglycemic events. The EMA 
diabetes guideline (18) specifies detailed analyses of occurrence and severity of 
hypoglycaemias, but it might be that regulators regard hypoglycaemia as an inevitable ADR 
that is linked to the working mechanism of the drug. Our finding that persistent ADRs are 
seen as more important than transient ADRs, is in line with other studies. (11,13) 
Regulators valued weight gain as an effect of OADs negatively, albeit only marginally 
significant whereas weight loss did not affect the choices made by regulators. Although it is 
possible to use a clinically meaningful reduction in weight as a measure for metabolic control 
in clinical trials, regulators might be wary of any claims on effects on weight loss as the 
extent to which weight loss contributes to the CV benefit is not unequivocally established 
and an effect on weight is easily misused in a marketing context. (18,24) Inversely, some 
increase in weight might be considered a less serious ADR, partly cosmetic and therefore 
might have less weight in the assessment of the benefit-risk balance than e.g. persistent GI 
upset. 
The lack of a significant effect of an increased risk of bladder cancer in our study is in line 
with the position taken by the Dutch MEB and the EMA that considered the absolute 
increase in risk of bladder cancer too small to remove pioglitazone from the market. (25,26) 
While the FDA and EMA decided that the benefit-risk balance for pioglitazone was still 
positive in a limited population, the French and German authorities suspended its use. 
(25,27-29) The increase was displayed in absolute terms, and not as a relative risk, giving a 
more accurate picture of the clinical relevance attached to this drug effect and this may have 
contributed to its interpretation. (30) 
Agreement with doctors and patients 
Regulators did agree with doctors and patients on the value of changes in CV risk. This 
agreement suggests that all groups value what is considered to be one of the most 
important aims of OAD treatment, even though only metformin has actually shown to 
reduce CV events in patients with type 2 diabetes. (31) Additionally, regulators placed similar 
values on persistent GI complications as doctors and patients, acknowledging the disruptive 
effect persistent symptomatic ADRs can have on the patients quality of life and, most likely, 
treatment compliance. Regulators, doctors and patients also agreed in the value they 
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attached to changes in weight, although patients were even less inclined to choose drugs 
that resulted in weight gain. This may be explained by the fact that regulators look at weight 
as an indicator of metabolic control while patients may have already struggled with losing 
weight as means to control their diabetes or because of social pressure to be thin. (32) 
Finally, an interesting observation was that also the doctors and patients agreed in the lack 
of value they attached to an increased risk of bladder cancer. It seems that they also 
interpreted that risk as less relevant in view of its low absolute risk. 
On two drug effects regulators differed from patients and doctors. Frequent hypoglycaemic 
events significantly affected drug choice by patients and doctors, but not by regulators. The 
regulators may be more willing to accept hypoglycemia as a pharmacologically inevitable 
ADR of some OADs. Patients and doctors may have actual experience with hypoglycemia and 
its effects on quality of life and hence put more value on this ADR. (11,12,33) Finally, 
regulators and patients both did not place a significant weight on changes in HbAlc in 
relation to the other included drug effects, while doctors did. Doctors are nowadays faced 
with benchmarking and quality indicators that may explain the higher value they attach to 
achieving control on a surrogate measure. (34) A previous study showed that patients also 
considered HbAlc an important drug effect but in that study an effect on HbA1c was not 
shown in the context of a beneficial effect on CV risk. (11) Patients may therefore in our 
study have valued an improvement on CV risk more relevant, s imilar to the regulators. 
Limitations: 
The results of a discrete-choice method are inherently subjective to the drug effects and 
levels chosen. When larger differences in levels are presented, different effects on 
preferences may result. (35) To minimize this effect we selected levels that are plausible and 
representative of what is known about real OADs. By focusing on OADs, we could include a 
range of different drug effects. However, for other drug classes with other drug effect 
profiles the results might have been different. 
Drug scenarios were presented in various ways. Some of the effects were depicted only with 
text and numbers, while others with coloured pictures, hence being more noticeable. The 
design of the scale figure used to describe changes in HbAlc is based on a previous discrete 
choice study. (11) The design of the 'smiley-face' matrix used to describe changes in risk of 
CV events was intended to make the proportions presented understandable to all groups of 
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respondents. (36,37) The results show that most value was attached to a drug effect 
(persistent GI problems) that were presented with text only, indicating that this difference in 
presentation did not lead respondents to disregard those drug effects. 
We used a typical 67 year old diabetes patient for which a drug choice had to be made. A 
different patient vignette, e.g. an elderly patient, might have changed the responses. 
Gastroenterologists valued ADRs less important when presented a vignette of an elderly 
patient than of a younger patient. (38) However, the aim of this study was to assess 
differences between groups when presented with the same patient. 
The patient population was selected from pharmacies in the northern part of the 
Netherlands and might not necessarily represent patients from outside the Netherlands. The 
patients selected for the study were 60 to 75 years of age and might differ in their 
preferences or values from those older or younger. However, this age group represents the 
largest user group of OADs in the Netherlands (43% of total OAD users in 2009 (39)) and, 
with a response rate of more than 70%, we assume that the responders are fairly 
representative of Dutch diabetes type 2 patients. Likewise the doctors and regulators 
selected for this study were working in the Netherlands and could have different values than 
those working in other countries. The low response rate of doctors is a limitation, but 
respondents were representative in terms of gender (40) and location in the Netherlands. 
(41) A low response by doctors has been more often reported and we cannot exclude that it 
may have biased our results in a sense that doctors that are especially interested in diabetes 
treatment may be overrepresented. There is no indication, however, that more interested 
doctors would value drug effects differently. 
Implications for policy and practice: 
I n  conclusion, our resu lts indicate that regulators may value major benefits and risks of drugs in the 
same way as doctors and patients . As such, the input of these other stakeholders in  the regulatory 
process cou ld support regulators in making decisions that are not that straightforward and may 
provoke debate, such as regarding the impact of smal l  risks for serious adverse effects or of certa in 
benefits. Specifica l ly, doctors and patients could influence the benefit/risk d iscussion by expressing 
their views at an individua l  patient level instead of a population level that is often the basis for 
regu latory decision making. So far, selected patients and doctors are being involved in selected 
regulatory activities in Europe, such as by participation in scientific advisory groups, but their ro le 
needs further strengthening as suggested elsewhere. (42) 
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The costs of developing new drugs is increasing and the drug regulatory requirements are 
becoming stricter. At the same time the number of new drug registrations is decreasing. (1) 
At the same time for already marketed drugs new safety concerns are identified that lead 
to warnings being issued or even withdrawals. (2,3) Finding safety issues post marketing is 
not surprising as clinical trials have limited power to detect safety issues that are not 
directly linked to a drug's pharmacology. (4) However, others have criticised the regulators 
for not evaluating thoroughly enough potential known safety issues, e.g. through knowledge 
of the safety profile of similar drugs. (5) Therefore, striking a balance of regulatory 
requirements, safety ascertainment and stimulating drug innovation is complex, but 
essential. Over-regulation could prevent important therapeutic options from reaching 
patients, while insufficient post-marketing surveillance might leave harmful effects of drugs 
undetected. (4) For diseases with unmet medical need, regulators have responded with 
specific registration procedures that allow for less data to be collected pre-marketing. (6-8) 
In the first part of this thesis I focused on the ability of the regulatory process to safeguard 
that new drugs entering the market are sufficiently safe and whether regulators learn from 
earlier experience with related drugs. I explored the relationship between knowledge at 
market approval and the risk of safety issues arising post-marketing. 
In Chapter 2 we focused on regulatory learning by evaluating the extent to which regulators 
and industry have addressed the risk of safety issues focusing on the example of HIV drugs 
based on experience with other drugs in the same class. We focused on HIV drugs as for 
these more often than for any other drug class new safety issues were identified post 
approval. We evaluated whether the regulators and industry considered earlier identified 
safety concerns in the development and assessment of new drug class from the same class. 
Safety issues were identified from Direct Healthcare Professional Communication (DHPC) 
letters issued for HIV drugs. We reviewed the European Public Assessment Reports (EPARs) 
of drugs to assess whether the safety issues had been considered during the drug 
development and approval. In addition, we reviewed whether this knowledge led to 
appropriate changes in the Summary of Product Characteristics (SmPC). We found that 
regulatory learning was appropriate as in most cases class-related safety issues were taken 
into account in the approval process of new drugs. How this was done varied and was 
mostly determined by the nature of the safety issue. For drugs already on the market, the 
majority of the safety issues were addressed in the drug label. 
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In chapter 2 we also explored whether increasing regulatory requirements have an impact 
on the development times of new HIV drugs by assessing clinical development time, using 
time from first patent application to market authorization as proxy. We compared the 
clinical development times between drugs with a safety issue and drugs receiving market 
authorisation after issuance of the DHPCs. We found that although regulators and industry 
addressed class-related safety issues in the new drug development and approval process, 
this did not seem to have had an impact the duration of the pre-approval clinical 
programme. 
In chapter 3 we looked at the association between knowledge at time of approval and 
safety issues from a reverse angle compared to chapter 2. We reviewed EPARs of all new 
drugs registered in Europe in an 11 year period and DHPCS in the same period. The aim was 
to determine whether for drugs registered with special procedures (Exceptional 
Circumstances (EC) or Conditional Approval (CA)), allowing for less information to be 
present at approval, are at more risk of having a safety issue identified after marketing. 
Drugs that are registered with these special procedures usually meet an unmet medical 
need or are technically difficult to evaluate in a clinical trial. We found that despite allowing 
less data in the clinical development program, these procedures were not associated with a 
higher probability of DHPCs as 16% of regularly approved drugs and 15% of drugs registered 
with EC or CA received a DHPC. When correcting for time, the difference between the 
registration procedures remained insignificant, suggesting that registration with procedures 
allowing for a smaller clinical data package does not lead to an earlier nor later discovery of 
serious safety issues. We concluded that our results do not support the view that early drug 
approval increases the risk of serious safety issues emerging after market approval for drugs 
meeting the requirements of an exceptional circumstances or conditional approval 
procedure. 
The method used in chapter 3 was repeated in chapter 4, but extended with an analysis of 
innovativeness of drugs. We assessed the innovativeness of drugs using a decision matrix 
that takes into account the seriousness of the disease the drug is intended to treat, whether 
therapy to treat the disease is already available and how much of an improvement the drug 
is from the available therapy and finally how effective the drug is in the treatment of the 
disease. (9) We hypothesized that highly innovative drugs may find their way quickly into 
daily practice as they are considered an important addition to the available therapeutic 
armamentarium. They mays also be used in a more diseased population, where other drugs 
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may have failed but where the drug may have been less researched. This is the so-called 
'channelling' phenomenon. This pattern of use may therefore lead to identifying hitherto 
unknown safety issues. The focus of our study was to compare the frequency and timing of 
serious safety issues identified post-approval for more innovative drugs versus less 
innovative drugs. We found that grading of innovativeness is not significantly associated 
with the likelihood of receiving a DHPC, in contrast with our hypothesis. We concluded that 
more than half of all new drugs approved in Europe can be considered at least modest 
innovations that add value to the available drug armamentarium. In spite of our hypothesis, 
a higher level of innovation was not clearly related to an increased risk of serious safety 
issues that are identified only after the drug being marketed. 
In the second part of this thesis I determined the values stakeholders in drug regulation and 
drug use attach to benefits and risks of drugs. In management of chronic diseases, patient 
self-management and participation in treatment decisions is an integral part. (10) 
Regulators have acknowledged that patients are a valuable source of information and can 
contribute to work within the regulatory agencies. (11,12) However, patient involvement 
has to date been of an advisory nature and not as active participants in the decision making 
before allowing drugs on the market. With increasing patient involvement in the activities of 
the European Medicines Agency, the Agency believes their scientific committees are 
encouraged to reflect about the real-life implications of regulatory decisions. (11) Whether 
that is the case has not yet been established and it is unclear if regulators share the same 
values of benefits and risks as patients. Additionally, formal assessment of patient 
preferences has to date not been a part of the regulatory decision making. 
There are cases where regulatory decisions have been criticised by healthcare professionals, 
patients or society at large. Pressure was put on regulators to approve drugs to treat HIV 
infection when little was known about their mechanism of action, while opposition has been 
voiced against the approval or continued use of human papilloma virus vaccine and the 
combined measles, mumps and rubella vaccine. {13-17) The decision of the FDA to remove 
natalizumab from the market was met with great opposition from patients with multiple 
sclerosis, ultimately resulting in the re-introduction of the drug to the market. (18,19) 
There is an essential difference in perspective between regulators on one hand and doctors 
and patients on the other when they are assessing the benefits and risks of any new drug. 
Regulators base their decision to approve new drugs on an assessment of their benefit risk 
balance at the population level while doctors and patients make their decisions on the 
individual level. Whether this different perspective explains why regulators sometimes 
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make decisions that meet opposition, or whether there is a genuine difference in the values 
regulators attach to drug benefit and risks in comparison to doctors and patients is hitherto 
unexplored. 
To this extent we set up discrete choice surveys studies that consist of providing 
respondents a choice between two or more options. In our studies these options were drugs 
that were described in scenarios with relevant attributes, i.e. drug effects. Every attribute 
(drug effect) is varied at different levels and shown to respondents in a set of different 
scenarios. Respondents are given these scenarios in pairs from which to choose the scenario 
they prefer most. The strength of the method is that it provides information on the relative 
importance of the attributes. It is therefore a valuable approach to understand how trade­
offs are made when weighing benefits and risks of drugs by the different stakeholder 
involved. The relevance of the results of such discrete choice models is determined by the 
relevance of the selection of relevant attributes and the corresponding levels of these 
attributes. These should reflect actual important decision criteria of the respondents. {20,21) 
In Chapter 5 we explained how we selected drug effects to develop the hypothetical drugs 
that were used the discrete choice surveys. To identify drug effect candidates we used a 
combination of methods, comprising a public literature review, a review of regulatory EMA 
guidelines and qualitative interviews with stakeholders in drug regulation and diabetes care. 
These interviews were performed to elicit potentially overlooked and/or possibly non 
rational drug effects that were considered important by these stakeholders. Based on these 
activities we selected the following drug effects; HbAlc control, cardiovascular effects both 
detrimental as well as beneficial, effect on weight, the potential to cause gastrointestinal 
side effects and hypoglycaemia as well as a potential risk to cause bladder cancer. All these 
effects were identified from the three different methods we used. Interestingly during the 
interviews ease of use (once versus multiple times per day, injectables versus oral 
administration) or costs were not spontaneously introduced. A few other issues came up 
during the discussions and from the review, but were not included in the stated choice 
models as they were either considered less relevant (dosing frequency and administration 
schedule, costs) or considered too complex a task (uncertainty at time of approval and 
possibility to postpone further studies till after approval). Finally, we added the risk of 
bladder cancer as at time of designing the study there was a major controversy between 
European regulators whether the benefit/risk of pioglitazone could still be considered 
positive after another the risk of bladder cancer was added to its long list of important 
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safety concerns. In at least two European countries the marketing of the product was 
suspended. 
In Chapter 6 we then evaluated separately the values patients with type 2 diabetes attach 
to these different drug benefits and risks using the discrete choice survey design. The aim of 
this study was to identify what value patients attach to short-term and long-term benefits 
relative to symptomatic adverse drug reactions (ADR) and serious ADRs. In our discrete 
choice survey on the patients were asked to choose between sets of hypothetical oral anti­
diabetes drugs. The drugs in the choice sets were created with varying levels of the drug 
effects described in chapter 5. We found that the long-term efficacy parameter of 
cardiovascular risk was considered more important than the surrogate efficacy parameter of 
changes in HbAlc level. However, the patients did find it more important to avoid persistent 
or frequent symptomatic ADRs than a large increase in the small risk of bladder cancer, 
indicating that patients weigh more heavily ADRs that influence their quality of life on a 
daily basis. Our results further demonstrated that experience with the drug therapy affects 
the preferences of patients, as a large decrease in HbAlc was valued higher by patients that 
had inadequate control of their HbAlc and patients that had experienced ADRs were less 
inclined to choose OADs with persistent GI problems than those who had not. 
In Chapter 7, the discrete choice survey of chapter 6 was extended to regulators working for 
the Dutch Medicines Evaluation Board and doctors treating type 2 diabetes. The aim of this 
study was primarily to compare the values regulators attach to benefits and risks of new 
drugs when compared to doctors and patients, when presented with the same trade-offs 
between short-term and long-term benefits relative to symptomatic ADRs and serious ADRs 
for an individual patient. In the survey, we asked regulators to base their decisions for an 
individual hypothetical patient with type 2 diabetes, in order to put them at par with the 
doctor and patient. Thereby avoiding that the regulators' usual focus on a population level 
would obscure the values they attach to the investigated benefits and risks as presented in 
our scenarios. We found that regulators considered a lowering of CV risk more important 
than lowering of HbAlc and saw persistent GI problems and increase of CV risk as important 
negative drug effects. Regulators also considered weight increase as a negative drug effect, 
but those results were barely significant. Overall, we saw no significant differences between 
regulators and doctors nor regulators and patients. Looking descriptively at the separate 
analyses of each group we did see a difference in the value of frequent hypoglycaemia, 
where regulators did not place a significant value on frequent hypoglycaemia while both 
doctors and patients considered that significantly as a negative drug effect. Slight 
differences were also seen between regulators and doctors regarding a large decrease in 
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HbA1c, where only doctors significantly valued it as a positive drug effect. Patients also 
regarded an increase in weight more strongly as a negative drug effect than both regulators 
and doctors. Based on our results we concluded that regulators value drug effects of oral 
anti-diabetes drugs similar to doctors and patients when a trade-off between benefits and 
risks is made at the patient level. 
METHODOLOGICAL CONSIDERATIONS 
Design 
The studies included in part I in this thesis have a retrospective cohort design, using data 
collected from the websites of the European Medicines Agency (EMA) and the Dutch 
Medicines Evaluation board (MEB). The studies in part II are cross-sectional surveys using 
the discrete choice method, which is a form of conjoint analysis. Subsequently the strengths 
and limitations of the methods used in this thesis are discussed. 
Information reliability in retrospective studies 
Retrospective studies have usually the disadvantage of retrospectively not being able to 
measure some key statistics and biases that may affect the selection of controls. In our case 
we are not measuring disease state or biological changes in living subjects, but procedural 
and technical aspects of drug licensing. Most relevant data was recorded at the time of drug 
licensing and needed to be collected from the websites of the appropriate agencies. 
However, there are issues with reliability as we have had to trust that the information 
currently presented on the websites is as it was at the time of approval of each drug or at 
the time of issuance of the DHPCs. Particularly with regards to the scientific discussion of 
the EPARs this results in some uncertainty, as before 2005 these were regularly updated so 
it proved difficult to define what information was available at time of approval and what 
became known at a later stage. Other aspects of the information we collected are 
susceptible to change. Orphan designation of drugs can also change over time and it is 
possible that some drugs that had an orphan designation at time of marketing are classified 
as non-orphan drugs in our studies. Also the EPARs do not include data that applicant and 
regulator found confidential and we might therefore not be able to detect possible biases 
that could be found in the confidential material. However, one may assume that all relevant 
clinical efficacy and safety data are present in the EPARs; the available data should therefore 
be sufficient to draw conclusions. Data that is considered confidential mostly concerns data 
on the quality of the medicinal product (the drug formulation, manufacturing methods, 
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etcetera). The EMA has taken a turn towards making data of marketing application dossiers 
available to the public. This will greatly facilitate the research presented in the first part of 
the thesis. However, it should be realised that the magnitude of the data, and its granularity 
will need skilled researchers that conscientiously review the available data to be able to 
present a balanced and reliable interpretation. 
In assessing the innovativeness of drugs, we had to look retrospectively and grade according 
to the situation at the time the drug was approved. Most EPARs did have an introduction 
discussing the nature of the disease the drug was intended to treat and the availability of 
treatment. This discussion was usually very short and limited, often requiring us to look up 
other treatment options and assess whether or not they were available at the time of 
licensing of the drug we were assessing. It is possible that we might have missed other 
treatment options or overestimated what was available. Additionally, the criterion for 
assessing innovativeness requires an estimation of whether the drug for assessment is 
better than available treatment, either with regards to efficacy or safety. Most EPARs did 
not include any head-to-head comparison of treatments, but included comparison with 
placebo. This required the assessors to look up the safety and efficacy of the available 
treatments. Therefore, the classification was performed by at least two independent 
reviewers, where all cases of disagreement were resolved by discussing these cases with a 
third reviewer. This was done using the validated scoring method developed by one of the 
co-authors Domenico Motola. (9) 
Complexity of discrete choice studies. 
Discrete choice methods have the distinct advantage that they recognize that people are 
willing to make trade-offs between the different attributes (in our case drug effects) of a 
product. In our studies we measure the importance of a drug effect in relation to other drug 
effects that are presented. Each time the responder is asked to make a choice between two 
drugs he is implicitly asked to make a trade-off between all those drug effects. With enough 
observations and enough different choice sets we can estimate the weight our group of 
responders place on individual drug effects in their trade-offs. However, this method has 
limitations. 
Firstly, we had to make a choice on which drug effects to include in creating our 
hypothetical drugs. We tried to make a list of drug effects that was relevant to today's 
treatment of diabetes, but we had to drop several possible attributes. We could only 
measure what we present to the responders and might therefore miss drug effects that 
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could have been important to some of the responders. However, if we had included more 
drug effects or other drug characteristics we would have run into a power problem or had to 
ask the responders to make too many trade-offs at the same time. More attributes require 
more observations to be able to run the analysis This issue poses a risk of researcher bias 
that we cannot leave without discussion. In our selection criteria, we excluded attributes 
that are not of great consideration in the regulatory setting, such as costs and ease of use. 
These attributes might have been of importance to doctors and patients, which could have 
demonstrated a larger difference in choices made by regulators on one hand and doctors 
and patients on the other. Though in our explorative interviews this was not the case. 
Likewise we excluded attributes that we expected could be difficult to grasp for patients but 
may have be significant to the regulators, e.g. the size of clinical trials and to what extent 
stakeholders accept further evaluation of drug benefits and risks post approval. Our 
selection of attributes, focusing on drug effects, may have caused an underestimation of 
differences between regulators on one hand and doctors and patients on the other. 
However, these issues are difficult to translate to the individual patient level and were 
somewhat aside of our main research question. They would have asked the doctor and 
patient to take the perspective of the regulator, which may be an interesting question for 
further study. 
Secondly, the responses are inherently linked to the levels of the drug effects chosen. When 
larger differences in levels are given, more effect on patient preferences may result and vice 
versa for smaller differences in levels. As with selecting the drug effects to be included, the 
levels were selected by the researchers and are subjective to researcher bias. We tried to 
minimize this effect by selecting levels that are plausible and representative of what is 
known about the OADs already on the market or recently taken off the market. It is 
therefore important to perform these studies with realistic estimation. 
Generalizability 
Generalizability of results is always a potential limitation of any study. The studies in part I 
focused on drugs registered with the European Centralized Procedure. In the early years of 
the Centralized Procedure only drugs that fulfilled certain requirements were allowed to be 
licenced using the procedure. Gradually these requirements have changed and currently the 
procedure is mandatory for drugs to treat HIV/AIDS, cancer, diabetes, neurodegenerative 
diseases, auto-immune and other immune dysfunctions and viral diseases as well as drugs 
derived from biotechnology processes and orphan medicines. Other new active substances 
are allowed to be licensed using the Centralized Procedure, but can go through national 
procedures, mutual recognition procedures or de-centralized procedure. Therefore we 
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cannot claim that our results are generalizable to drugs approved before our study period or 
using other procedures than the Centralized Procedure. Although experience teaches us 
that currently only few new important active substances do not go through the Centralised 
Procedure in Europe. Therefore, the clinical relevance for daily practice will grow over time. 
Chapter 2 particularly focused on HIV drugs, which do have significantly higher likelihood of 
receiving a DHPC than other drug classes, and cannot be extrapolated to other types of 
drugs. However, European regulatory guidelines do acknowledge class-related drug effects 
and similar requirements as those on the guideline for clinical development of HIV drugs 
have been taken up for other disease areas. 
In part II we used the example of type 2 diabetes to examine the values regulators, doctors 
and patients attach to drug benefits and risks and what trade-offs they make. The regulators 
that participated in our study were all working for the Dutch Medicines Evaluation Board 
and might not be representative of regulators working for other competent authorities. 
Particularly when looking at the differences in reactions to the cancer risk linked with 
pioglitazone, we might expect different results should this study be repeated with 
regulators from countries that removed pioglitazone from the market. Similarly, the doctors 
participating in our study were also practising in the Netherlands and might not be 
representative of doctors practicing in other areas in Europe. Although the doctors 
responding to our survey were representative of Dutch doctors in terms of gender and 
location in the Netherlands, we did have a low response rate that may have biased our 
results in a sense that doctors that are especially interested in diabetes treatment may be 
overrepresented. Finally, the patient population resides in the northern part of the 
Netherlands and might not necessarily represent patients from outside the Netherlands. 
The patients selected for the study were ranging from 60 to 75 years of age and might differ 
in their preferences or values from those older or younger. However, this age group is the 
largest users of OADs in the Netherlands (43% of total OAD users in 2009 (22)) and with a 
response rate of more than 70% we may assume that the responders are representative of 
Dutch diabetes type 2 patients. 
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IMPLICATION FOR REGULATORY POLICY AND PRACTICE 
So what are then the implications of the research presented in this thesis, considering our 
findings and the limitations as described. 
limited knowledge at time of approval 
Highly innovative drugs are likely to be registered through EC and CA procedures and are 
often first-in-class drugs. As first-in-class drugs have no class experience to base on, and EC 
and CA approved drugs have limited clinical data, we assume that there is even more limited 
knowledge on these drugs at the time of approval than for 'me-too' drugs registered with 
the regular central procedure. Because of this, regulators usually require even stricter risk 
management plans for EC and CA approved drugs. (6,7) In chapter 3 we demonstrated that 
drugs registered with EC and CA procedures were not more likely to be subject to DHPCs or 
safety related withdrawals, despite the limited clinical data and more rigorous risk 
management plans. Likewise in chapter 4 for the drugs with various levels of innovation we 
found that a higher level of innovation was not clearly related to an increased risk of serious 
safety issues that are identified only after the drug being marketed. It is possible that the 
population exposed to EC and CA drugs and many highly innovative drugs might not be 
sufficiently large to detect less common ADRs. We did try to address the influence of drug 
use in chapter 4, but saw no indication that higher use resulted in more safety alerts. 
Although safety issues of highly innovative drugs might be detected earlier because doctors 
might be more prone to report issues with drugs that are not familiar to them or are first-in­
class drugs, we did not find a correlation. (24) The message is thus that for the specific 
group of drugs meeting the requirements of an exceptional circumstance or conditional 
approval procedure, or are graded important innovations, this can be considered to provide 
an acceptable trade-off between knowledge required at time of approval and long-term safe 
and effective use in clinical practice. For both sets of drugs pro-active pharmacovigilance 
seems indicated and we suggest that the effectiveness of these measures should be 
monitored. Finally, none of both types of drugs were removed from the market because of 
safety concerns, thereby indicating that appropriate monitoring post approval may suffice 




The option of patient registries and adaptive licensing 
In this thesis I have focused on the drug approval process, but before a new drug becomes 
available on the market it has pass another hurdle that of the health technology assessment 
(HTA). The HTA is basis for re-imbursement decisions, that is whether the drug will be paid 
for by the health insurance. These decisions are made on national basis and although 
collaboration has been set up with the European Network of Health Technology Assessment 
(EUnetHTA), HTA must be performed taking into account individual national priorities and 
systems. (25) Payers may not agree with regulators that sufficient demonstration of efficacy 
and safety has been demonstrated with the EC and CA procedures. (26) A recent proposal of 
adaptive licensing procedure (AL) suggests a method of continuous assessment that would 
include a dialogue between study sponsors, regulators and payers. Although for drugs 
registered with EC or CA procedures further data collection is required post marketing to 
maintain the marketing approval, how this should be done is not pre-defined in the 
legislation. The AL procedure would require that a pre-defined protocol should be followed, 
allowing only patients that comply with a "label-scenario" to receive the drug and ensuring 
that prescription controls and support are in place for the prescribing doctors. (26) The 
current requirements of the European Centralized Procedure include a submission of a risk 
management plan that address all known and possible risks associated with the drug. (27) In 
special cases this may include educational material for patients and doctors or the set-up of 
a patient registry, where only those registered can receive or prescribe the drug. 
While conducting our interviews in chapter 5, the topic of patient registries arose. The 
general consensus of the participants was that a patient registry for the first few years after 
market approval would be an attractive strategy in the view of a number of respondents. 
Since patient dossiers are mostly electronic and filled out by the physicians or nurses during 
the consultation, it would not add considerable burden to the healthcare provider. In our 
interviews the patient did not oppose the idea of their dossiers being linked securely to a 
central patient registry for this purpose, provided it would be anonymised. 
In the context of the proposed adaptive licensing procedure, or even the current EC and CA 
procedures, mandatory patient registries seem opportune. Well-designed registries might 
not only detect safety issues sooner, it might also shed light on effectiveness of the drug in 
wider patient groups or where surrogate endpoints were used as determinants for efficacy. 
The collaboration of regulators and payers proposed in the adaptive licensing procedure 
could ensure that the drugs would be paid for by the payers if the patient conforms with the 
"label-scenario" and is registered in the system and only doctors linked to the system would 
be allowed to prescribe the drug. Data handling and analysis would be in the hands of the 
national pharmacovigilance centers and the financing of the system could, at least in part, 
152 
General discussion and summary 
be from fees collected from the pharmaceutical industry. Whether this approach could also 
mean as for the EC and CA approved drugs that some of the establishment of safety 
knowledge can be relegated to post approval is an interesting consideration supported by 
our findings in chapter 3. 
Patient and healthcare professional participation in regulatory decision making 
Although standardization of regulatory decision making has been proposed {28) it still 
remains that the decisions are made by regulators who individually attach values to drug 
effects and other drug characteristics. How these values are attached may differ between 
cultures, countries and individuals, although guidance is provided with guidelines and 
regulations. Personal experience can play a role in attributing these values, as we 
demonstrated in chapter 6, where it seems that patients that have experienced difficulties 
with their diabetes treatment have different preferences relating for the particular drug 
effect, usually adverse drug effect. The regulators take on drug effects is also affected by the, 
national authority's policies, which may vary due to legal, cultural and other differences. {29) 
It is evident that regulators from different national authorities do not always agree on 
decisions to grant or suspend market approval. Some drugs are allowed to the market based 
on a majority vote of the CHMP, not consensus, and different responses have been seen 
with regards to serious safety issues, such as the bladder cancer risk associated with 
pioglitazone. While the FDA and EMA decided that the benefit-risk balance for pioglitazone 
was still positive in a limited population, the French and German authorities suspended its 
use. {30-33) 
In chapter 7 we demonstrated that regulators value drug effects similar to doctors and 
patients when a benefit risk assessment is made at the individual patient level. In cases such 
as that of pioglitazone and bladder cancer risk, the decisions made by regulators are not 
always straightforward and the input of healthcare professionals and patients may be of 
value in the debate. Shared decision making has become an integral part of management of 
chronic diseases, where dialogue between the patient and healthcare provider allows for 
patient participation in decisions made regarding their treatment. (10) A path towards 
patient and healthcare professional participation in regulatory decision making has been 
laid out by including selected individuals in regulatory activities. (11) EMA has formalised 
collaboration with patient organisations in the Patients' and Consumers' Working Party. In 
the USA, the Food and Drug Administration (FDA) did the same in the Patient 
Representative Program. (11,12) However, patients and healthcare professionals have a 
limited contribution to the scientific discussion, as they are not allowed to take part in active 
discussions on the application and can only give their expert opinion. (11) In regulatory 
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policy, the public has the option to comment and give recommendation on guidelines under 
development, although it has been claimed that not enough is done to promote the 
involvement of healthcare professionals and patients.(34) Our studies suggest that 
regulators value major benefits and risks of drugs similar as doctors and patients. As such, 
the input of doctors and patients in the regulatory process can support regulators in making 
decisions which are not that straightforward and may provoke debate, such as regarding the 
impact of small risks of serious adverse effects. Furthermore, we see some slight differences 
in valuing less serious adverse effects, which should be addressed further when involving 
other parties in the regulatory decision process. Steps have been taken in that direction, but 
further strengthening of the patient and healthcare professionals' voice is needed. This 
could in our view comprise the option of mapping the opinion of a larger group of patients 
and healthcare professionals on the benefit risk balance in ambivalent situations related to 
new drugs or new drug information. 
I MPLICATIONS FOR FUTURE RESEARCH 
Regulatory learning 
While we have shown for the class of HIV drugs that regulators had addressed previously 
identified class-related safety issues when assessing new drugs, another study within the 
Escher project has found that this may not always be the case. (5) When reviewing the 
EPARs and SmPC of several pairs of first-in-class and me-too drugs it was noted that safety 
learning occurred for nearly half of the ADRs reported for each drug. Although at first sight 
our results might be at odds, there are methodological differences that explain these 
opposite findings. Firstly, we investigated different drug groups. While the study finding 
regulatory learning lacking investigated drugs from several different drug groups, we look 
closely at the development and registration of HIV drugs only in chapter 2. It is possible that 
HIV drugs are treated differently by regulators, where regulators better responded to 
previous findings, i.e. they showed 'regulatory learning'. Secondly we differed in the proxy 
used for safety issues. In our case we focused on safety issues, resulting in DHPCs or safety 
related withdrawals. These safety issues were generally more serious than the ADRs 
included in the other study, where all ADRs mentioned in the drugs' SmPCs were included. It 
is logical to assume that more serious issues would be more likely to be taken up, thus 
supporting regulatory learning. Without stating which method of assessing is correct, as 
both methods have their merits, it remains clear that further studies on regulatory learning 
are necessary. These studies should include a critical assessment of the validity of 
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recommendations in the many regulatory guidelines on disease specific drug development 
as well as how these recommendations have been followed in new dossiers. These studies 
should expand on the knowledge already acquired by the Esher project. 
Patient and healthcare professional involvement in regulatory decision making 
We have discussed the merits of including healthcare professionals and patients in 
regulatory decision making. Although there are different ways to do so, research in the area 
is still lacking. The feasibility of including discrete choice experiments in the context of 
contentious market approval applications needs to be viewed critically. Such studies should 
when performed be executed by independent researchers that are neither biased towards 
the industry or the regulators position. Direct participation of healthcare professionals and 
patients has already started and the participants experience in the process has been 
researched. (11) More research on that experience is still needed and estimates of how an 
increased involvement would affect the regulatory process need to be made. Other 
methods of patient and healthcare professional involvement need to be proposed and 
discussed. Although from our study there seems to be no major disconnect between 
regulators and these other stakeholders on how to value benefits and risks of new drugs. 
Regulatory science is relatively new and with the Escher project it has reached new heights. 
The experience of the Escher project needs to be built upon, making regulatory science an 
integral part in public health discussions. 
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Regulatory benefit-risk assessment 
De kosten van het ontwikkelen van nieuwe geneesmiddelen nemen toe, mede door de 
toegenomen eisen van de geneesmiddelautoriteiten. Tegelijkertijd neemt het aantal nieuw 
geregistreerde geneesmiddelen af en zien we dat voor al geregistreerde geneesmiddelen 
nieuwe veiligheidsproblemen warden geidentificeerd, die er toe hebben geleid dat 
autoriteiten urgente waarschuwingen naar zorgverleners hebben moeten sturen of zelfs het 
geneesmiddel van de markt hebben moeten halen. Het vinden van veiligheidsproblemen 
nadat een geneesmiddel eenmaal is geregistreerd is overigens niet verwonderlijk, omdat 
preregistratie klinische studies maar een beperkte statistsche power hebben om 
bijwerkingen die niet rechtstreeks gekoppeld zijn aan de farmacologie van een geneesmiddel 
op te sporen. Echter, verschillende belanghebbenden hebben de registratieautoriteiten 
bekritiseerd dat zij niet voldoende gedegen potentieel voorspelbare veiligheidsproblemen al 
voor registratie in kaart hadden gebracht, bijvoorbeeld door de kennis die zij hebben over 
soortgelijke geneesmiddelen voldoende mee te wegen. Het vinden van een goede balans 
tussen aan de ene kant adequate regelgeving, met name wat betreft het vaststellen van 
geneesmiddelrisico's, en aan de andere kant het stimuleren van geneesmiddelinnovatie is 
complex, maar van essentieel belang. Overregulering zou er toe kunnen leiden dat patienten 
belangrijke therapeutische vernieuwingen warden onthouden, terwijl onvoldoende post­
marketing surveillance er toe zou kunnen leiden dat schadelijke effecten van 
geneesmiddelen onopgemerkt blijven. Om de registratie van nieuwe geneesmiddelen te 
faciliteren voor ziekten waar onvoldoende of geen adequate behandelstrategien 
beschikbaar zijn - die voorzien in een ,onvervulde medische behoefte' - hebben de 
registratieautoriteiten specifieke registratie-procedures ingesteld die minder onderzoek 
voor registratie vereisen. 
In het eerste deel van dit proefschrift onderzocht ik het vermogen van het huidige 
registratiesysteem om te waarborgen dat nieuwe geregistreerde geneesmiddelen voldoende 
veilig zijn en of de registratieautoriteiten leren van eerdere ervaringen met verwante 
geneesmiddelen. lk onderzocht daarnaast of de mate van kennis ten tijde van registratie 
geassocieerd is met het optreden van ernstige bijwerkingen na registratie. 
In hoofdstuk 2 hebben we ons gericht op het lerend vermogen van de registratieautoriteiten. 
We evalueerden hoe industrie en registratieautoriteiten het risico van veiligheidsproblemen 
die bekend waren van oudere middelen hebben meegenomen bij het ontwikkelen, 
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respectievelijk beoordelen van nieuwe gerelateerde geneesmiddelen (uit dezelfde 
geneesmiddelklasse). Wij keken specifiek naar HIV-medicijnen, omdat bij deze m iddelen 
vaker dan voor enige andere klasse van geneesmiddelen ernstige nieuwe 
veiligheidsproblemen werden ge'identificeerd na registratie. Veiligheidsproblemen werden 
ge'identificeerd aan de hand van Direct Healthcare Professional Communication (DHPC) 
brieven afgegeven voor HIV medicijnen. Deze DHPCs warden door de industrie na 
afstemming met de registratieautoriteiten naar zorgverleners gestuurd om hen te 
informeren over een nieuw geidentificeerd ernstig geneesmiddelprobleem. We zochten in 
de publiek toegankelijke beoordelingsrapporten, European Public Assessment Reports 
(EPAR's), van geneesmiddelen naar informatie over hoe de veiligheid van het HIV-middel 
was onderzocht en of er aandacht was besteed tijdens de beoordeling door de 
registratieautoriteit aan een al bekend geneesmiddelrisico van gerelateerde 
geneesmiddelen. Daarnaast hebben we beoordeeld of deze kennis heeft geleid tot relevante 
wijzigingen in de samenvatting van de productkenmerken (Summary of Product 
Characteristics SPC). We vonden dat de registratieautoriteiten een adequaat lerend 
vermogen hadden. In de meeste gevallen werden al bekende klasse-gerelateerde 
veiligheidsproblemen in aanmerking genomen tijdens de beoordeling van nieuwe 
geneesmiddelen. Hoe dit gedaan werd varieerde en hing af van de aard van het 
veiligheidsprobleem. Voor geneesmiddelen die al op de markt waren, werd het merendeel 
van de veiligheidsproblemen behandeld in de SPC. 
In hoofdstuk 2 onderzochten we oak of toenemende regelgeving van invloed is op de 
ontwikkelingsduur van nieuwe hiv-medicijnen. Hiervoor hebben we gekeken naar de duur 
van het klinische geneesmiddelonderzoeksprogramma. We gebruikten hiervoor als proxy de 
tijd die verstreken was sinds de eerste octrooiaanvraag tot de datum waarop het 
geneesmiddel werd geregistreerd. We vergeleken de duur van het klinische 
onderzoeksprogramma voor geneesmiddelen, die geregistreerd werden voordat een klasse­
gerelateerd veiligheidsprobleem was ge'identificeerd met die middelen die werden 
geregistreerd nadat een DHPC voor een klasse-gerelateerd geneesmiddel was verzonden. 
We vonden dat, ondanks dat de industrie en registratieautoriteiten aandacht hadden 
besteed aan deze klasse-gerelateerde problemen in het ontwikkelingsprogramma en het 
beoordelingsproces, dit geen invloed lijkt te hebben gehad op de duur van het klinische 
onderzoeksprogramma inclusief de beoordelingstijd. 
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In hoofdstuk 3 keken we naar de relatie tussen kennis over een geneesmiddel op het 
moment van registratie en veiligheid vanuit eentegenovergesteld perspectief ten opzichte 
van hoofdstuk 2. Wij beoordeelden EPAR's van alle nieuwe geneesmiddelen die 
geregistreerd werden gedurende een periode van 11 jaar in Europa en naar de verstuurde 
DHPCs voor deze middelen in dezelfde periode. Het doel was om te bepalen of voor 
geneesmiddelen die geregistreerd werden via speciale procedures; de ,uitzonderlijke 
omstandigheden' (Exceptional Circumstances, EC) of ,voorwaardelijke 
goedkeuring' (Conditional Approval, CA)) procedures. Bij deze EC of CA procedures is het 
mogelijk geneesmiddelen te registreren op basis van minder pre-registratie onderzoek. Deze 
speciale procedures zijn toegankelijk voor geneesmiddelen die in een ,onvervulde medische 
behoefte' voorzien of waar het technisch niet haalbaar is om in klinisch onderzoek 
doorslaggevend de klinische effectiviteit aan te tonen. Het doel van ons onderzoek was om 
te kijken of deze middelen een grater risico !open op het vinden van veiligheidsproblemen 
na registratie. We vonden dat ondanks dat registratie voor deze middelen mogelijk was met 
minder gegevens in de klinische ontwikkelingsprogramma's, deze procedures niet waren 
geassocieerd met een hogere kans op een DHPC na registratie. Uiteindelijk kregen 16% van 
de geneesmiddelen die werden geregistreerd via de reguliere procedure en 15% van de 
geneesmiddelen geregistreerd bij EC of CA ontving een DHPC. Dit verschil bleef niet 
statistisch significant wanneer gecorrigeerd werd voor de follow-up duur, hetgeen 
suggereert dat deze registratieprocedures met kleinere klinische ontwikkelingsprogramma's 
niet tot eerdere (of latere) ontdekking van ernstige veiligheidskwesties leidt. Hieruit 
concludeerden wij dat een eerdere goedkeuring van dit soort geneesmiddelen, die voldoen 
aan de voorwaarden voor een EC of CA procedure, het risico op ernstige bijwerkingen na 
registratie niet verhogen. 
We pasten de methode die in hoofdstuk 3 werd gebruikt opnieuw toe in hoofdstuk 4, 
waarbij we keken naar de relatie tussen post-registratie veiligheidsproblemen en de mate 
van innovativiteit van een geneesmiddel. Wij beoordeelden de mate van innovativiteit van 
nieuwe geneesmiddelen op het moment van registratie, waarbij we gebruik maakten van 
een algorithme dat was ontwikkeld door de groep van Motola in ltalie. Het algorithme houdt 
rekening met de ernst van de ziekte waarvoor het geneesmiddel bedoeld is, of er voor de 
behandeling van de ziekte al effectieve alternatieve therapien zijn en tenslotte hoe groat de 
effectiviteit van het geneesmiddel was voor de behandeling van de ziekte. De hypothese was 
dat innovatievere geneesmiddelen kunnen hun weg snel vinden naar de patient in de 
dagelijkse praktijk, omdat ze warden beschouwd als een belangrijke aanvulling op het 
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beschikbare therapeutische arsenaal. Ze warden mogelijk ook gebruikt in een ziekere 
patientenpopulatie waar andere geneesmiddelen niet effectief waren, maar waar het 
geneesmiddel mogelijk niet specifiek is onderzocht. Dit is het zogenaamde "channeling" 
fenomeen. Dit soort van gebruik kan dus mogelijk leiden tot het identificeren van tot dan toe 
onbekende bijwerkingen. Het doel onze studie was om de frequentie en timing van post­
registratie ernstige veiligheidsproblemen te vergelijken van innovatieve geneesmiddelen 
versus niet innovatieve geneesmiddelen. We vonden dat de mate van innovativiteit niet 
significant geassocieerd was met de kans op een DHPC. We concludeerden dat meer dan de 
helft van alle nieuwe geneesmiddelen die werden goedgekeurd in Europa in onze 
studieperiode op zijn minst konden warden geklassificeerd als bescheiden innovaties, die 
waarde toevoegen aan het beschikbare geneesmiddelarsenaal. Dus in tegenstelling tot onze 
hypothese was een hoger niveau van innovatie niet duidelijk geassocieerd met een 
verhoogd risico op ernstige veiligheidsproblemen, die pas nadat het geneesmiddel op de 
markt werd gebracht werden gevonden. 
In het tweede deel van dit proefschrift onderzocht ik de waarde die belanghebbenden; 
registratieautoriteiten, voorschrijvers en patienten, hechten aan de baten en risico's van 
geneesmiddelen. Participatie van de patient in behandelbeslissingen en het management 
van zijn/haar chronische ziekten, is tegenwoordig steeds meer de norm. De 
registratieautoriteiten erkennen dat patienten een waardevolle bran van informatie kunnen 
zijn en dat zij kunnen bijdragen aan verschillende activiteiten van deze autoriteiten. Echter, 
het betrekken van patienten bij het registratieproces is meer in de vorm van het geven van 
advies, maar gaat niet zover dat zij als actieve deelnemers betrokken zijn in het 
besluitvormingsproces over registratie van een geneesmiddel. Met de toenemende 
betrokkenheid van de patient bij de activiteiten van het Europese geneesmiddelen 
agentschap (European Medicines Agency, EMA), verwacht het agentschap dat haar 
wetenschappelijke comites warden aangespoord om meer rekening te houden met de 
gevolgen van hun regulatoire beslissingen voor de dagelijkse praktijk. Of dit ook werkelijk 
het geval is, is nog niet vastgesteld en het is onduidelijk of geneesmiddelenbeoordelaars 
dezelfde waarden hechten aan baten en risico's (van geneesmiddelen) als patienten. Tot op 
heden is een formele evaluatie van de voorkeuren van patienten, met betrekking tot 
verschillende baten en risico's van geneesmiddelen, geen onderdeel van het 
besluitvormingsproces. 
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Verschillende door de registratieautoriteiten genomen beslissingen zijn bekritiseerd door 
beroepsbeoefenaren in de gezondheidszorg, patienten of de samenleving als geheel. Er is in 
het verleden bijvoorbeeld grate druk uitgeoefend op de registratieautoriteiten om 
geneesmiddelen te registreren voor de behandeling van het humane immunodeficientie 
virus (HIV) terwijl er slechts weinig bekend was over het werkingsmechanisme van deze 
middelen. Daarentegen is er kritiek geuit op de registratie van het humaan papilloma virus 
(HPV) vaccin, of handhaving van de registratie van het gecombineerde mazelen, bof en 
rubella vaccin. De beslissing van de FDA om natalizumab van de markt te halen ontmoette 
veel weerstand van patienten met multiple sclerose, wat er uiteindelijk toe leidde dat het 
geneesmiddel opnieuw werd ge·introduceerd op de markt. 
Er is een essentieel verschil in het perspectief waarmee registratieautoriteiten enerzijds en 
artsen en patienten anderzijds de baten en risico's van een nieuw geneesmiddel wegen. De 
autoriteiten baseren hun beslissing om een nieuw geneesmiddelen geed te keuren op een 
beoordeling van de baten-risicobalans op populatieniveau, terwijl artsen en patienten hun 
afwegingen op een individueel niveau maken. Of dit andere perspectief verklaart waarom 
registratieautoriteiten soms beslissingen nemen die op tegenstand stuiten, of dat 
geneesmiddelbeoordelaars daadwerkelijk een andere waarde hechten aan baten en risico's 
van geneesmiddelen in vergelijking met artsen en patienten is tot nu toe nooit onderzocht. 
Om dit te onderzoeken hebben we een zogenaamd ,discrete choice' experiment opgezet. Dit 
is een vragenlijstonderzoek waarbij respondenten gevraagd wordt een keuze te maken uit 
twee of meer opties. In onze studies waren deze opties geneesmiddelen die werden 
beschreven in scenario's met relevante attributen, dat wil zeggen verschillende 
geneesmiddeleffecten. Elke attribuut (geneesmiddeleffect) varieert dan op verschillende 
niveaus en wordt getoond aan de respondenten in onze studie als een set van telkens zes 
attributen, dus leidend tot verschillende scenario's (= fictieve geneesmiddelen). De 
respondenten kregen deze scenario's telkens in paren gepresenteerd, waaruit ze dan het 
door hen geprefereerde scenario moesten kiezen. De kracht van deze methode is dat hieruit 
informatie verkregen kan warden over het relatieve belang dat de respondenten hechten 
aan individuele geneesmiddeleffecten (attributen) ten opzichte van de andere effecten. 
Deze techniek is dan oak een waardevolle methode om te begrijpen welke onderliggende 
keuzes de verschillende belanghebbende partijen maken bij het wegen van de baten-risico 
balans van een geneesmiddel. De waarde van de gevonden resultaten van 
dergelijke ,discrete choice' modellen wordt sterk bepaald door het kiezen van de meest 
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relevante attributen (geneesmiddeleffecten in ons onderzoek) en de overeenkomstige 
niveaus waarop deze effecten varieren. Deze attributen moeten een afspiegeling zijn van de 
werkelijke criteria waarop respondenten hun beslissingen bepalen. 
In hoofdstuk 5 hebben we uitgelegd waarop de selectie berust van de geneesmiddeleffecten 
die we in de ,discrete choice' studie gebruikt hebben om de fictieve geneesmiddelen 
(scenario's) samen te stellen. Om mogelijk relevante geneesmiddeleffecten te identificeren 
voor onze studie gebruikten we een combinatie van methoden. We kozen voor ons 
experiment geneesmiddelen voor de behandeling van diabetes als casus. We voerden een 
literatuurstudie uit en extraheerden we de belangrijkste criteria uit de EMA richtlijnen 
waarop registratieautoriteiten hun beoordeling van een nieuw geneesmiddel voor de 
behandeling van diabetes baseren. Daarnaast voerden we kwalitatieve interviews met 
betrokkenen partijen in het geneesmiddeltoezicht en de diabeteszorg. Deze interviews 
werden gevoerd om mogelijk over het hoofd geziene en om eventueel niet rationele 
geneesmiddeleffecten die wel als belangrijk werden beschouwd door deze betrokken boven 
tafel te krijgen. Op basis van deze verschillende methoden hebben we de volgende 
geneesmiddeleffecten geselecteerd om de scenario's op te stellen: de mate van HbAlc 
controle, zowel positieve als negatieve cardiovasculaire effecten, toename danwel afname 
van gewicht, het meer of minder frequent optreden van gastro-intestinale bijwerkingen of 
hypoglykemie en een mogelijk verhoogd risico op blaaskanker. lnteressant was dat tijdens 
de interviews gebruiksgemak (eenmaal versus meerdere keren per dag toedienen of 
injecteerbare versus orale toedieningsvormen) of kosten niet spontaan in de gesprekken 
naar voren kwamen als zijnde relevant. Deze en sommige andere mogelijke 
geneesmiddeleffecten kwamen tijdens literatuur/richtlijn studie en of de interviews wel naar 
voren, maar werden niet opgenomen in de uiteindelijke scenario's omdat ze als minder 
relevant (toedieningsfrequentie en toedieningsschema, kosten) of als te complex (de 
onzekerheid op het moment van registratie over de baten-risico balans van een nieuw 
genessmiddel en de mogelijkheid om verdere geneesmiddelonderzoek uit te stellen tot na 
registratie) werden beschouwd. Ten slotte hebben we nog een toegenomen risico op 
blaaskanker als bijwerking van een antidiabetesmiddel opgenomen. Dit effect werd 
geselecteerd omdat ten tijde van het ontwerpen van de ,discrete choice' studie er een grote 
controverse was ontstaan tussen Europese registratieautoriteiten of de baten-risicobalans 
van het betreffende antidiabetes middel, pioglitazon, nog positief was nu het risico op 
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blaaskanker werd toegevoegd aan de al lange lijst van belangrijke bijwerkingen. In ten 
minste twee Europese landen werd het gebruik van pioglitazon opgeschort. 
In hoofdstuk 6 hebben we vervolgens de daadwerkelijk ,discrete choice' studie beschreven 
waarin we evalueerden welke waarde patienten met type 2-diabetes hechten aan de in 
hoofdstuk 5 beschreven afzonderlijke positieve en negatieve geneesmiddeleffecten. Het 
doel van deze studie was om te bepalen hoe patienten de verschillende korte en lange 
termijn baten wegen in vergelijking tot symptomatische en frequente bijwerkingen en/of 
ernstige maar zeldzame bijwerkingen. In onze ,discrete choice' studie werd aan patienten 
gevraagd om telkens te kiezen tussen twee fictieve orale anti-diabetes geneesmiddelen met 
verschillende effecten, de scenario's. De geneesmiddelen beschreven in de scenario's 
werden samengesteld door de zes geneesmiddeleffecten te varieren op verschillende 
niveaus, bijvoorbeeld toe- of afname van het risico op hart- of herseninfarct en 
cardiovasculaire dood, zeals beschreven in hoofdstuk 5. We vonden dat voor patienten de 
werkzaamheid op lange termijn, dat is het verminderen van cardiovasculair voorvallen, 
belangrijker was dan een afname in HbA1C een erkende surrogaat parameter voor 
werkzaamheid van anti-diabetes geneesmiddelen. De patienten vonden het belangrijker om 
persisterende of frequente symptomatische bijwerkingen indien mogelijk te vermijden dan 
dat zij een geneesmiddel vermeden dat een forse relatieve toename gaf van een klein 
absoluut risico op blaaskanker. Deze laatste bevinding geeft aan dat patienten bijwerkingen 
die de kwaliteit van hun !even op een dagelijkse basis negatief be'invloeden zwaar wegen. 
Onze resultaten laten verder zien dat eerdere ervaringen met anti-diabetesmiddelen de 
voorkeuren van een patient be'invloedt. Een groat effect (meer daling) op het HbAlc niveau 
werd meer gewaardeerd door patienten waarbij het werkelijke HbAlc niet voldoende ender 
controle was. Patienten die eerder bijwerkingen hadden ervaren waren minder geneigd om 
orale anti-diabetes middelen met hardnekkige gastro-intestinale problemen te kiezen dan 
degenen die zelf geen bijwerkingen hadden ervaren. 
In Hoofdstuk 7 werd de ,discrete choice' studie uit hoofdstuk 6 uitgebreid door dezelfde 
vragenlijst voor te leggen aan geneesmiddelenbeoordelaars werkzaam bij het College ter 
Beoordeling van Geneesmiddelen en huisartsen en internist-endocrinologen. Het primaire 
doel van deze studie was om de waarde die geneesmiddelbeoordelaren hechten aan baten 
en risico's van nieuwe geneesmiddelen te vergelijken met die van artsen en patienten, 
wanneer zij met dezelfde scenario's te maken krijgen en een afweging gevraagd warden te 
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maken voor de behandeling van een individuele patient. Om de beoordelaars vanuit 
hetzelfde perspectief te laten beslissen, werd aan alle groepen dezelfde hypothetische 
patient met type 2 diabetes gepresenteerd, waarvoor aan alle groepen werd gevraagd om 
hun keuze te baseren met deze patient in gedachten. Op deze wijze wordt voorkomen dat 
de geneesmiddelenbeoordelaars hun keuze zouden baseren vanuit hun gebruikelijke 
perspectief op het populatieniveau, wat mogelijk de waarde die zij hechten aan de 
individuele baten en risico's zoals gepresenteerd in onze scenario's zou vertroebelen. We 
vonden dat oak de beoordelaars een verlaging van het cardiovasculaire risico belangrijker 
beschouwden dan het verlagen van HbA1c en dat zij daarnaast aanhoudende gastro­
intestinale klachten en verhoging van het cardiovasculaire risico als belangrijke negatieve 
geneesmiddeleffecten beschouwden. 
De geneesmiddelenbeoordelaars beschouwden oak een gewichtstoename als een relevant 
negatief effect van het fictieve anti-diabetesmiddel, maar dit resultaat was maar net 
statistisch significant. Over het geheel genomen zagen we geen belangrijke verschillen 
tussen de geneesmiddelenbeoordelaars en artsen, noch tussen de beoordelaars en 
patienten. Wanneer we meer beschrijvend naar de afzonderlijke analyses van de effecten 
binnen elke groep keken zagen we wel een verschil in de waarde die de beoordelaars 
hechtten aan het optreden van frequente hypoglycemie episodes. Bij de 
geneesmiddelenbeoordelaars was de waarde die zij aan dit effect hechtten niet statistisch 
significant, in de context van alle andere geneesmiddeleffecten, terwijl dit bij zowel de 
artsen als patienten als een statistisch significant negatief geneesmiddeleffect naar voren 
kwam. Kleine verschillen werden oak gezien in de waarde die de beoordelaars en artsen 
hechtten aan een door een fictief geneesmiddel veroorzaakte grate afname in HbAlc, dat 
alleen in de analyse in de groep artsen als een statistisch significant positief effect van het 
geneesmiddel naar voren kwam. Wat uiteindelijk nag opviel was dat patienten een meer 
uitgesproken negatieve waarde hechtten aan een toename in gewicht dan zowel de 
geneesmiddelbeoordelaren en artsen. 
Op basis van onze resultaten concluderen wij dat beoordelaren werkzaam bij de 
registratieautoriteiten effecten van orale anti-diabetes geneesmiddelen op een 
vergelijkbare wijze wegen als artsen en patienten wanneer hen gevraagd wordt een keuze te 
maken tussen de verschillende baten en risico's van een middel voor een individuele patient. 
In hoofdstuk 8 bespreken wij een aantal limitaties van dit onderzoek, zoals daar zijn het 
retrospectieve karakter van de studies in deel 1 waardoor niet alle parameters even hard 
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kunnen warden gedefinieerd. In het algemeen zijn de registratiedata die we gebruikt 
hebben in onze studies echter goed gedocumenteerd. Nochtans zijn de wetenschappelijke 
discussies in de EPARs meer gestructureerd na 2005. De beoordeling van de innovativiteit 
heeft ondanks het gebruikte algorithme enige mate van subjectiviteit, en het was soms lastig 
om de waarde op het moment van registratie achteraf te bepalen. We hebben gepoogd dit 
op te lossen door een beoordeling in consensus met minimaal 3 beoordelaren te maken. De 
,discrete choice' studies hebben een complex ontwerp en vragen de doelgroep zich te 
verplaatsen naar het perspectief beschreven in de scenario's. Het aantal 
geneesmiddeleffecten dat kon warden meegenomen was beperkt, vanwege de noodzaak 
om hoe meer effecten te warden meegenomen er oak meer scenario's aan de 
ondervraagden moeten warden voorgelegd. De keuze van de geneesmiddeleffecten is 
daarom oak cruciaal en dit is de reden van ans uitgebreide vooronderzoek om deze te 
selecteren. 
Wat uit dit proefschrift naar voren komt is dat de Europese registratie autoriteiten een 
lerende organisitie lijken te zijn. Het gebruik van de speciale ,exceptional circumstances' en 
,conditional approval' procedures voor geneesmiddelen die in een ,onvervulde medische 
behoefte' voorzien blijkt uit ans onderzoek gerechtvaardigd. Deze procedure leidde niet tot 
meer onverwachte problemen na registratie dan op reguliere wijze geregistreerde middelen 
en dient dus te warden gecontinueerd. Geneesmiddelenbeoordelaars werkzaam bij de 
registratieautoriteiten hechten een vergelijkbare waarde aan baten en risico's van 
geneesmiddelen als artsen en patienten. Het betrekken van deze laatste groepen bij lastige 
beslissingen, bijvoorbeeld waar weinig voorkomende maar ernstige risico's kunnen optreden, 
kan extra draagvlak creeren voor de uiteindelijke beslissing die door de autoriteiten op 
populatieniveau wordt genomen. Doordat op deze wijze oak het individuele perspectief op 
de baten-risico balans wordt meegewogen. 
168 
Samantekt a fslensku 
Samantekt a 1slensku 
169 
Regulatory benefit-risk assessment 
Kostnaour vio pr6un nyrra lyfja eykst og fcerri lyf koma a markao a meoan peer krofur sem 
geroar eru til nyrra lyfja heroast. A sama tfma koma alvarlegar aukaverkanir lyfja sem pegar 
eru a markaoi f lj6s og leioa til pess ao aovorun er gefin ut eoa lyfin jafnvel tekin af markaoi. 
Par sem kif nfskar lyfjaranns6knir eru takmorkunum haoar f mati a oryggi lyfja, cetti ekki ao 
koma a 6vart ao sumar alvarlegar aukaverkanir uppgotvast pegar lyfio er komio a markao. 
Pvf er mikilvcegt ao finna rett jafnvcegi milli peirra skilyroa sem lyf purfa ao uppfylla via 
skraningu, t.d. vio mat a oryggi, og pess ao orva pr6un nyrra lyfja. Of stffar reglur gcetu haldio 
nauosynlegum lyfjum fra sjuklingum sem parfnast peirra, a meoan of slakt eftirlit eftir 
markaosetningu dugar ekki til ao bera kennsl a neikvceoar aukaverkanir lyfja. I sjukd6mum 
par sem meoferoarmoguleika skortir, hafa skraningaryfirvold brugoist vio meo serstokum 
ferlum sem leyfa sofnun minni gagna til ao skra lyf. 
I fyrri hluta pessarar ritgeroar er ahersla logo a getu skraningarkerfisins til ao tryggja oryggi 
nyrra lyfja og athugao hvort skraningaryfirvold lceri af reynslu sinni af eldri lyfjum f sama 
flokki. Eg kanna tengsl peirrar pekkingar sem er til staoar pegar lyf er skrao a markao vio 
ahcettu a aukaverkunum. 
Kafli tvo fjallar um lcerd6m f skraningu lyfja. Vic skooum hvort alvarlegar aukaverkanir HIV 
lyfja hafi ahrif a pr6un og skraningarmat nyrri HIV lyfja af sama flokki. Vici rynum f aovaranir 
(Direct Healthcare Professional Communication, DHPC) sem gefnar hafa verio ut f Hollandi 
fyrir HIV lyf, til ao bera kennsl a aukaverkanir sem aovarirnar fjalla um. Pvf ncest rynum vio f 
opinber skraningarskjol evr6psku lyfjastofnunarinnar (European Public Assessment Report, 
EPAR) fyrir hvert lyf af sama flokki og hafa fengio markaosleyfi eftir ao viovorunin var gefin 
ut. Petta er gert til ao leggja mat a hvort fjallao er um aukaverkunina vio lyfjapr6un og -
skraningu. Vici rynum f samantekt um eiginleika peirra lyfja sem hafa fengio markaosleyfi 
aour en viovorunin var gefin ut (Summary of Product Characteristics, SmPC) og berum saman 
vio pao SmPC sem var f gildi vio frumskraningu. Pao er til ao sannreyna hvort vioeigandi 
breytingar hafi verio geroar. Niourstaoa okkar er ao lyfjafyrirtceki og -yfirvold dragi 
vioeigandi lcerd6m af peim alvarlegu aukaverkunum sem koma upp eftir markaossetningu. 
Mismunandi aoferoir voru notaoar til ao varpa lj6si a aukaverkanirnar og f6ru eftir eoli 
aukaverkunar. P.e. samantektir um eiginleika flestra eldri lyfja a markaoi, voru uppfceroar a 
vioeigandi hatt til ao vara vio aukaverkuninni. 
170 
Samantekt a islensku 
f kafla tvo er einnig kannao hvort auknar skraningarkrofur hafi ahrif a pann tfma sem tekur 
ao pr6a og koma nyju HIV lyfi a markao. Acetlao er ao klfnfsk pr6un hefjist pegar s6tt er um 
einkaleyfi a lyfinu og vari pann tfma sem lfour fra gero einkaleyfaums6knar til utgafu 
markaosleyfis. Tfminn sem klfnfsk pr6un lyfja sem fengu gefnar ut aovaranir er borinn saman 
via tfmann sem klfnfsk pr6un lyfja sem komu seinna a markao t6k. Niourstaoa okkar er ao 
pratt fyrir ao lcerd6mur vceri dreginn af alvarlegum aukaverkunum f pr6un og skraningu nyrri 
lyfja, hafoi hann ekki ahrif a hversu langan tfma pao tekur ao pr6a og skra lyfin. 
f kafla prju skooum via samband pekkingar via skraningu og aukaverkana eftir 
markaosetningu fra ooru sj6narhorni. Via rynum f EPAR allra nyrra lyfja skraora f Evr6pu a 
ellefu ara tfmabili og DHPC aovaranir gefnar ut f Hollandi a sama tfmabili. Markmioio var ao 
akvaroa hvort lyf sem skrao eru meo serstokum ferlum (sampykki meo undantekningum 
(Exceptional Circumstances - EC) eoa skilyrt sampykki (Conditional Approval - CA)) fengju 
frekar DHPC eftir markaossetningu. l:>essir serstoku ferlar gera fyrirtcekjum kleift ao scekja um 
markaosleyfi fyrir lyf sfn meo takmorkuoum upplysingum og fcerri ranns6knum, og eru 
yfirleitt cetlaoir lyfjum til meohondlunar a vanrcektum sjukd6mum eoa peim sem er 
tceknilega erfitt ao rannsaka klfnfskt. f lj6s kom ao pratt fyrir fcerri klfnfskar ranns6knir fyrir 
skraningu, voru lyf skrao meo pessum serstoku skraningarferlum ekki lfklegri til ao fa DHPC 
viovorun, en 16% lyfja skrao meo hefobundnum ferlum og 15% EC eoa CA skraora lyfja fengu 
DHPC. Niourstaoa okkar styour ekki pa hugmynd ao lyf skrao meo takmorkuoum 
upplysingum seu ekki orugg, ao pvf gefnu ao pau uppfylli skilyroi serstakra skraningarferla. 
Aoferoin f kafla prju er notuo aftur f kafla fjogur, auk pess ao meta hversu mikil nyjung lyfio 
er via skraningu. f ranns6kninni er logo ahersla a hvort ao pau lyf, sem metin voru mikils a 
serstokum nyjungarmcelikvaroa, vceru lfklegri til ao fa DHPC aovorun eftir markaossetningu. 
Nyjungarmcelikvaroinn byggir a fylki sem tekur mio af alvarleika sjukd6msins sem lyfinu er 
cetlao ao meohondla, hvort meofero til ao meohondla sjukd6minn er nu pegar f booi og 
hvort lyfio er framfor mioao via pa meofero. Pa er einnig tekio mio af pvf hversu virkt lyfio er 
f meofero sjukd6msins. Tilgata okkar var ao nystarleg lyf fara fyrr f notkun og lceknar avfsa 
peim frekar en oorum lyfjum par sem pau eru alitin mikilvceg viob6t via lyfjaurvalio sem til 
staoar er. Einnig gceti hugsast ao slfkar nyjungar seu frekar notaoar f meofero mjog veikra 
sjuklinga, par sem onnur lyf hafa brugoist, en f slfkum tilfellum gceti lyfio hafa verio 
rannsakao minna. Slfkt notkunarmynstur gceti pvf leitt til pess ao aour 6pekktar aukaverkanir 
uppgotvist. Pvf var borin saman tfoni og tfmasetning tilkynninga um alvarlegar aukaverkanir 
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milli mismunandi lyfja eftir pvf hversu miklar nyjungar lyfin eru. f lj6s kom ad pao hversu 
nystarlegt lyf er tengist ekki lfkindum a ao alvarlegar aukaverkanir komi fram. Niourstoour 
syndu ad a.m.k. helmingur nyrra skraora lyfja f Evr6pu eru ao einhverju leyti nyjungar og 
fjolga meoferoarurr�oum. 
f seinni hluta ritgeroarinnar r�oi eg hversu avinningur og ah�tta lyfja vega pungt hja 
hagsmunaaoilum f lyfjaskraningum og lyfjanotkun. l:>atttaka sjuklinga f meofero og 
akvaroanatoku er mikilv�gur pattur f meofero langvinnra sjukd6ma. Skraningaryfirvold hafa 
einnig viourkennt sjuklinga sem mikilv�gan upplysingabrunn og stoo via starfsemi 
skraningaryfirvalda. Hins vegar hefur patttaka sjuklinga eingongu verio raogefandi, en ekki 
beinn hluti akvaroanatoku aour en lyfi er veitt markaosleyfi. Meo aukinni patttoku sjuklinga f 
starfsemi Lyfjastofnunar Evr6pu, telur stofnunin ad serfr�oinefndir peirra seu meovitaori 
um p�r afleioingar sem akvaroanir peirra hafa a sjuklinga. Hvort su se raunin hefur ekki 
fengist staofest og enn er 61j6st hvort starfsmenn skraningaryfirvalda vegi avinning og 
ah�ttu af lyfjum a svipaoan hatt og sjuklingar. Auk pess hefur formlegt mat a 6skum 
sjuklinga ekki verio hluti af akvaroanatoku skraningaryfirvalda hingao til. 
Upp hafa komio tilfelli par sem akvaroanir skraningaryfirvalda hafa verio gagnryndar af 
heilbrigoisstarfsf61ki, sjuklingum eoa oorum einstaklingum. l:>rystingi var beitt til ad sampykkt 
yrou lyf vio HIV sykingu pegar Htio var vitae um verkunarmata peirra. Pa hefur skraning og 
aframhaldandi notkun Human Papilloma Virus b61uefnisins m�tt andstoou, sem og samsett 
b61uefni gegn mislingum, hettus6tt og rauoum hundum. Akvoroun bandarfsku 
lyfjastofnunarinnar um ad fjarl�gja natalfzumab af markaoi var einnig m6tm�lt af MS 
sjuklingum sem ao lokum leiddi til pess ao lyfinu var aftur veitt markaosleyfi. 
Mikils 6samr�mis g�tir milli sj6narhorns skraningaryfirvalda annars vegar og l�kna og 
sjuklinga hins vegar, pegar pessir 61 fku h6par meta avinning og ah�ttu nyrra lyfja. 
Skraningaryfirvold byggja sampykkt nys lyfs a mati a avinningi og ah�ttu lyfsins f samfelaginu, 
a meoan l�knar og sjuklingar byggja akvaroanir a serh�fou og einstaklingsbundnu 
sj6narmioi. Ekki hefur verio kannao hvort 6 1 fk sj6narmio skyri hvers vegna skraningaryfirvold 
taki stundum akvaroanir sem m�ta andstoou sjuklinga, ne hvort pad se raunverulegur 
munur a v�gi avinnings og ah�ttu ao mati skraningaryfirvalda f samanburoi via l�kna og 
sjuklinga. 
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f pessu samhengi pr6uoum vio spurningalista sem byggir a ,,conjoint analysis" aoferoarfrceoi 
sem nefnist ,,discrete choice". f hverri spurningu er patttakendum boonir a.m.k. tveir 
valkostir og eiga ad velja pann sem peim hugnast best. f okkar konnun voru pessi valkostir 
fmynduo lyf samsett af mismunandi eiginleikum sem lysa mismunandi verkunum eoa 
afleioingum af notkun lyfsins. Hver eiginleiki var breytilegur og syndur f samhengi vio aora 
eiginleika lyfsins. l:>attakendur sau hverja samsetningu vio hlio annarrar sem hafoi a.m.k. tvo 
eiginleika 61fka peim f fyrri samsetningunni og voru beonir um ad merkja vio pa samsetningu 
sem peim lfkaoi betur. Kostur pessarar aoferoar er ad hun veitir upplysingar um hlutfallslegt 
mikilvcegi hvers eiginleika og getur synt peer malamiolanir sem mismunandi hagsmunaaoilar 
eru tilbunir ad gera pegar peir vega og meta avinning og ahcettu lyfja. 
f kafla fimm utskyrum vio hvernig vio voldum eiginleika lyfjanna sem notaoir voru til ad setja 
saman lyfjasamsetninguna fyrir ,,discrete choice" konnunina. Til ad bera kennsl a mogulega 
eiginleika notuoum vio mismunandi aoferoir; vio ryndum frceoigreinar, reglugeroir evr6psku 
lyfjastofnunarinnar og t6kum viotol vio hagsmunaaoila f skraningu lyfja vio sykursyki. 
Markmio viotalanna var ad bera kennsl a eiginleika lyfja sem einstaklingum gcetu p6tt 
mikilvcegir, en vilja gleymast f umrceounni, eoa eiginleika sem einstaklingum pykja mikilvcegir 
en eru 6rceoir. Ao lokum voru eftirtaldir lyfjaeiginleikar valdir til notkunar f konnunina; stj6rn 
HbAlc, aukning eoa lcekkun ahcettu hjarta- og ceoasjukd6ma, ahrif a pyngd, lfkur a 
6pcegindum f meltingafcerum eoa bl6sykursfalli, sem og ahcettu a krabbameini f pvagblooru. 
Athygli vakti ad f viotolunum minntust patttakendur ekki a pad ad fyrra bragoi ad pad skipti 
mali hversu auovelt vceri ad nota lyfio, (p.e. einu sinni a dag eoa oftar og f sprautuformi eoa 
tofluformi) eoa ad kostnaour vio lyfio skipti mali. Fleiri eiginleikar fundust vio ad ryna f 
frceoirit og f viotolin. 1:>eir voru aftur a m6ti utilokaoir fra konnuninni vegna pess ad peir p6ttu 
ekki eins mikilvcegir (t.d. skammtafjoldi a dag eoa kostnaour) eoa p6ttu of fl6knir fyrir 
pattakendur (t.d. 6vissa um eiginleikann vio markaossetningu og moguleikinn a ranns6knum 
eftir markaossetningu). Ao lokum voru lfkur a krabbameini f pvagblooru bcett f h6p 
eiginleikanna par sem lyf var tekio af markaoi f a.m.k. tveimur londum f Evr6pu vegna 
aukinnar ahcettu a krabbameini f pvagblooru. 
f kafla sex logo um vio aherslu a ad kanna hvaoa mat sjuklingar med sykursyki af typu 2 leggja 
a avinning og ahcettu lyfja vio sykursyki. Markmio ranns6knarinnar var ad skilgreina 
mikilvcegi skammtfma og langtfma avinnings f samhengi vio alvarlegar aukaverkanir og 
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lettvcegari en 6pcegilegar aukaverkanir. f konnuninni voru sjuklingar beonir um ao velja a 
milli tveggja fmyndaora lyfja vio sykursyki . l=>essi lyf voru samsett af mismunandi stigum 
peirra lyfjaeiginleika sem lyst er f kafla fimm. Niourstoour okkar benda til pess ao 
langtfmaavinningur meoferoarinnar, p.e. minni lfkur a hjarta- og ceoasjukd6mum, var talinn 
mikilvcegari en skammtfmaavinningurinn sem mceldur er meo stj6rn a bl6osykri. Aftur a m6ti 
p6ttu sjuklingum skammtfma aukaverkanir, sem hafa ahrif a daglegt lff, mikilvcegari en 
aukning a lagri ahcettu a krabbameini f pvagblooru. Niourstoour okkar syndu enn fremur ao 
reynsla sjuklinga af lyfjameofero hefur ahrif a 6skir peirra. Sjuklingum meo 6fullncegjandi 
stj6rn a bl6osykri sfnum p6tti til dcemis mikilvcegara ao stj6rna bl6osykri betur, og peir 
sjuklingar sem hofou reynslu af aukaverkunum voldu sfour lyfjasamsetningar meo viovarandi 
meltingarvandamal. 
f kafla sjo var konnunin ur kafla sex logo fyrir starfsmenn hollensku lyfjastofnunarinnar og 
lcekna sem meohondla sykursyki af typu 2. Markmio pessarar ranns6knar var fyrst og fremst 
ao bera mat starfsmanna skraningaryfirvalda a avinningi og ahcettu nyrra lyfja saman vio mat 
lcekna og sjuklinga. Allir h6parnir gatu valio a milli somu lyfjasamsetninganna og voru beonir 
ao byggja val sitt a dcemi af dcemigeroum sjuklingi meo sykursyki af typu 2 sem pyrfti nytt lyf. 
Meo pvf ao fa starfsmenn skraningaryfirvalda til ao setja sig f spar lcekna og sjuklinga, 
komum vio f veg fyrir ao peir byggou akvaroanir a samfelagsgrundvelli og skekki pannig 
samanburoinn vio lcekna og sjuklinga. Vio komumst ao pvf ao starfsmenn skraningaryfirvalda 
telja lcekkun ahcettu hjarta- og ceoasjukd6ma mikilvcegari en lcekkun bl6osykurs. Einnig p6ttu 
starfsmonnum skraningaryfirvalda aukin ahcetta hjarta-og ceoasjukd6ma, og langvarandi 
6pcegindi f meltingarvegi vera ahrifamiklar neikvceoar aukaverkanir. l=>yngdaraukning p6tti 
einnig neikvceo aukaverkun en peer niourstoour voru a morkum pess ao vera marktcekar. A 
heildina litio var hvorki marktcekur munur a milli starfsmanna skraningaryfirvalda og lcekna, 
ne peirra og sjuklinga. Ef litio er a aoskilda greiningu hvers hops fyrir sig, getum vio seo mun 
a mati h6panna hvao varoar lfkur a bl6dsykurfalli. Starfsmenn skraningaryfirvalda gafu 
auknum lfkum a bl6osykurfalli lftio vcegi a medan lceknar og sjuklingar matu auknar lfkur a 
bl6osykurfalli sem verulega neikvceda aukaverkun. Utilshattar munur sast einnig a 
starfsmonnum skraningaryfirvalda og lceknum varoandi mikla lcekkun a bl6osykri, par sem 
eingongu lceknar matu hana sem mikilvcega virkni lyfsins. Sjuklingar telja einnig 
pyngdaraukningu neikvceoa aukaverkun, en hvorki starfsmenn skraningaryfirvalda ne lceknar 
deila peirri skooun. Af pessu drogum vio pa alyktun ao starfsmenn skraningaryfirvalda leggi 
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svipao mat a avinning og ahcEttu lyfja vie sykursyki af typu 2 og lcEknar og sjuklingar pegar lyf 
er valid fyrir dcEmigeroan sjukling. 
f kafla atta eru teknar saman helstu takmarkanir ranns6knanna. Til dcEmis eru ranns6knirnar 
r fyrri hluta pessarar ritgeroar afturvirkar. Par sem gognum er safnao afturvirkt er ekki vrst ad 
hcEgt se ao akvaroa allar breytur a oruggan hatt. f okkar tilfelli voru breyturnar sem notaoar 
voru vel skraoar a peim t1ma sem pcEr komu fram. Einnig var uppbyggingu v1sindalegrar 
umrcEou I opinberum skraningarognum breytt arid 2005 og er nu mun aogengilegri. 
Akvoroun nyjungar nyrra lyfja er einnig mjog huglcEg, pratt fyrir notkun a fyrirfram 
skilgreindu fylki vie pa vinnu, og erfitt var ao meta breyturnar r fylkinu aftur r trmann. Pao 
vandamal var leyst med pvr ad a.m.k. pdr mismunandi serfrcEoingar matu nyjung hvers lyfs. 
Aoferoin notuo r koflum sex og sjo er mjog fl6kin og krefst pess ao patttakendur setji sig r 
spor einhvers annars. Einnig varo ad takmarka hversu marga eiginleika lyfs var hcEgt ad setja 
fram r lysingu lyfjanna, par sem fleiri svarendur hefoi purft til ad na marktcEkri niourstoou og 
fleiri eiginleikar hefou gert verkefnio erfioara fyrir patttakendurna. 1:>vr varo ad vanda valid a 
peim eiginleikum sem notaoir voru og pvr var nauosynlegt ad fara r pcEr forranns6knir sem 
lyst er r kafla fimm. 
Niourstaoa pessarar ritgeroar er ad vioeigandi lcErd6mur er dreginn af alvarlegum 
aukaverkunum lyfja r evr6pska skraningarkerfinu, vioeigandi notkun EC og CA skraningarferla 
nytist afram og ad sj6narmio og alit lcEkna og sjuklinga sem og starfsmanna 
skraningaryfirvalda geta verio gagnleg r matsferli avinnings og ahcEttu lyfja. 
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